US20210261635A1 - Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens - Google Patents
Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens Download PDFInfo
- Publication number
- US20210261635A1 US20210261635A1 US17/317,803 US202117317803A US2021261635A1 US 20210261635 A1 US20210261635 A1 US 20210261635A1 US 202117317803 A US202117317803 A US 202117317803A US 2021261635 A1 US2021261635 A1 US 2021261635A1
- Authority
- US
- United States
- Prior art keywords
- seq
- actin
- cell
- cells
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000007469 Actins Human genes 0.000 title claims abstract description 279
- 108010085238 Actins Proteins 0.000 title claims abstract description 277
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 110
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 54
- 238000000034 method Methods 0.000 title abstract description 40
- 230000001413 cellular effect Effects 0.000 title abstract description 29
- 230000003834 intracellular effect Effects 0.000 title abstract description 25
- 239000000203 mixture Substances 0.000 title abstract description 10
- 244000052769 pathogen Species 0.000 title abstract description 6
- 230000035515 penetration Effects 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 241000700605 Viruses Species 0.000 abstract description 41
- 241000894006 Bacteria Species 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 140
- 230000003612 virological effect Effects 0.000 description 48
- 102000005962 receptors Human genes 0.000 description 39
- 108020003175 receptors Proteins 0.000 description 39
- 208000031886 HIV Infections Diseases 0.000 description 31
- 210000001744 T-lymphocyte Anatomy 0.000 description 29
- 210000004292 cytoskeleton Anatomy 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 230000008569 process Effects 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 238000006116 polymerization reaction Methods 0.000 description 22
- 241000725303 Human immunodeficiency virus Species 0.000 description 21
- 102000002151 Microfilament Proteins Human genes 0.000 description 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 19
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 19
- 208000036142 Viral infection Diseases 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000019491 signal transduction Effects 0.000 description 17
- 208000037357 HIV infectious disease Diseases 0.000 description 16
- 108091000387 actin binding proteins Proteins 0.000 description 16
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 16
- 230000009385 viral infection Effects 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 210000003632 microfilament Anatomy 0.000 description 15
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 14
- 230000000284 resting effect Effects 0.000 description 14
- 210000000170 cell membrane Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 102000004373 Actin-related protein 2 Human genes 0.000 description 11
- 108090000963 Actin-related protein 2 Proteins 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000001054 cortical effect Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000017111 nuclear migration Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 210000002845 virion Anatomy 0.000 description 10
- 230000006044 T cell activation Effects 0.000 description 9
- 230000005540 biological transmission Effects 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 8
- 241000712431 Influenza A virus Species 0.000 description 8
- 108070000030 Viral receptors Proteins 0.000 description 8
- 230000012292 cell migration Effects 0.000 description 8
- 230000004899 motility Effects 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 102000000844 Cell Surface Receptors Human genes 0.000 description 7
- 108010001857 Cell Surface Receptors Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004688 microtubule Anatomy 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 6
- 102000004878 Gelsolin Human genes 0.000 description 6
- 108090001064 Gelsolin Proteins 0.000 description 6
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- 102000011195 Profilin Human genes 0.000 description 6
- 108050001408 Profilin Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 230000032823 cell division Effects 0.000 description 6
- 230000033077 cellular process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000007502 viral entry Effects 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 102000003505 Myosin Human genes 0.000 description 5
- 108060008487 Myosin Proteins 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 101150058540 RAC1 gene Proteins 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001268 conjugating effect Effects 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000007442 viral DNA synthesis Effects 0.000 description 5
- BLRBOMBBUUGKFU-SREVYHEPSA-N (z)-4-[[4-(4-chlorophenyl)-5-(2-methoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino]-4-oxobut-2-enoic acid Chemical compound S1C(NC(=O)\C=C/C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1CC(=O)OC BLRBOMBBUUGKFU-SREVYHEPSA-N 0.000 description 4
- 108050005951 ADF/Cofilin Proteins 0.000 description 4
- 102000017734 ADF/Cofilin Human genes 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 4
- -1 L-2 Chemical compound 0.000 description 4
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 108010040897 Microfilament Proteins Proteins 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 4
- DEFBCZWQLILOJF-UHFFFAOYSA-N NSC 23766 Chemical compound CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 DEFBCZWQLILOJF-UHFFFAOYSA-N 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 241000709992 Potato virus X Species 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000005056 cell body Anatomy 0.000 description 4
- 230000034303 cell budding Effects 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 230000030648 nucleus localization Effects 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000003518 stress fiber Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000713826 Avian leukosis virus Species 0.000 description 3
- 102000013366 Filamin Human genes 0.000 description 3
- 108060002900 Filamin Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000005640 Myosin Type II Human genes 0.000 description 3
- 108010045128 Myosin Type II Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 102000018265 Virus Receptors Human genes 0.000 description 3
- 102000035181 adaptor proteins Human genes 0.000 description 3
- 108091005764 adaptor proteins Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- GQWYWHOHRVVHAP-UHFFFAOYSA-N jasplakinolide Natural products C1C(=O)OC(C)CC(C)C=C(C)CC(C)C(=O)NC(C)C(=O)N(C)C(CC=2C3=CC=CC=C3NC=2Br)C(=O)NC1C1=CC=C(O)C=C1 GQWYWHOHRVVHAP-UHFFFAOYSA-N 0.000 description 3
- DDVBPZROPPMBLW-ZJBINBEQSA-N latrunculin a Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](/C=C\C=C/CC\C(C)=C/C(=O)O3)C)SC(=O)N1 DDVBPZROPPMBLW-ZJBINBEQSA-N 0.000 description 3
- DDVBPZROPPMBLW-UHFFFAOYSA-N latrunculin-A Natural products O1C(=O)C=C(C)CCC=CC=CC(C)CCC(O2)CC1CC2(O)C1CSC(=O)N1 DDVBPZROPPMBLW-UHFFFAOYSA-N 0.000 description 3
- 230000034701 macropinocytosis Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000701386 African swine fever virus Species 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- 102000019198 CapZ Actin Capping Protein Human genes 0.000 description 2
- 108010012892 CapZ Actin Capping Protein Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 102100027869 Moesin Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102100035181 Plastin-1 Human genes 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000269319 Squalius cephalus Species 0.000 description 2
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 2
- 102100035000 Thymosin beta-4 Human genes 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 241000710145 Tomato bushy stunt virus Species 0.000 description 2
- 108010066342 Virus Receptors Proteins 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 230000010189 intracellular transport Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 108010071525 moesin Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000003449 plasmodesmata Anatomy 0.000 description 2
- 108010049148 plastin Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010079996 thymosin beta(4) Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108010007486 ADP-G-actin Proteins 0.000 description 1
- 108010019781 ATP-G-actin Proteins 0.000 description 1
- 108010017189 Actin Capping Proteins Proteins 0.000 description 1
- 102000004365 Actin Capping Proteins Human genes 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 101000854353 Agrocybe aegerita Ribonuclease ageritin Proteins 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 101100181041 Arabidopsis thaliana KINUA gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010007337 Azurin Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000709700 Coxsackievirus A9 Species 0.000 description 1
- 101710200374 Crotamine Proteins 0.000 description 1
- 241000484025 Cuniculus Species 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 102100040130 FH1/FH2 domain-containing protein 1 Human genes 0.000 description 1
- 108090000786 Fascin Proteins 0.000 description 1
- 102000004204 Fascin Human genes 0.000 description 1
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241001559662 Glabratella milletti Species 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010083930 HIV Receptors Proteins 0.000 description 1
- 102000006481 HIV Receptors Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100215371 Homo sapiens ACTB gene Proteins 0.000 description 1
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 1
- 101000834207 Homo sapiens Actin, alpha skeletal muscle Proteins 0.000 description 1
- 101000773237 Homo sapiens Actin, cytoplasmic 2 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000890761 Homo sapiens FH1/FH2 domain-containing protein 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 101710173261 Kelch-like protein 17 Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024639 Listeria infections Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100215374 Mus musculus Actb gene Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 101100163944 Necator americanus apr-2 gene Proteins 0.000 description 1
- 102100023031 Neural Wiskott-Aldrich syndrome protein Human genes 0.000 description 1
- 108010009519 Neuronal Wiskott-Aldrich Syndrome Protein Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 229940123026 Rac1 inhibitor Drugs 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000002154 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Human genes 0.000 description 1
- 108010001288 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000003672 Tropomodulin Human genes 0.000 description 1
- 108090000089 Tropomodulin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100021164 Vasodilator-stimulated phosphoprotein Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 108010045606 actin kinase Proteins 0.000 description 1
- 230000003887 actin polymerization or depolymerization Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- KFVBMBOOLFSJHV-UHFFFAOYSA-K aluminum;sodium;hexane-1,2,3,4,5,6-hexol;carbonate;hydroxide Chemical compound [OH-].[Na+].[Al+3].[O-]C([O-])=O.OCC(O)C(O)C(O)C(O)CO KFVBMBOOLFSJHV-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008758 canonical signaling Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 101150055276 ced-3 gene Proteins 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006895 clathrin independent endocytosis Effects 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- PEFQQQGFYPMQLH-WFQFKEFWSA-N crotamin Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CC=4NC=NC=4)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C=CC(O)=CC=4)CSSC[C@@H](C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=CC=C1 PEFQQQGFYPMQLH-WFQFKEFWSA-N 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012691 depolymerization reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 102000013035 dynein heavy chain Human genes 0.000 description 1
- 108060002430 dynein heavy chain Proteins 0.000 description 1
- PAGGRBGJJBTXFJ-IWFDUIHDSA-N eapl Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=C(O)C=C1 PAGGRBGJJBTXFJ-IWFDUIHDSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000031857 establishment of mitochondrion localization Effects 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 230000002374 filopodial effect Effects 0.000 description 1
- 239000013305 flexible fiber Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 description 1
- 108091012216 heparin binding proteins Proteins 0.000 description 1
- 102000022382 heparin binding proteins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010021685 homeobox protein HOXA13 Proteins 0.000 description 1
- 102000054053 human ACTA1 Human genes 0.000 description 1
- 102000051310 human ACTC1 Human genes 0.000 description 1
- 102000052391 human ACTG1 Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000002420 macropinocytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000020470 microtubule-based transport Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 125000001554 selenocysteine group Chemical group [H][Se]C([H])([H])C(N([H])[H])C(=O)O* 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004991 spatiotemporal regulation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000007482 viral spreading Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 230000010463 virion release Effects 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1719—Muscle proteins, e.g. myosin or actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Definitions
- the present disclosure relates to modulating cellular bioactivity and cell susceptibility to viral infection through modulating actin dynamics.
- Actin-related Cellular Bioactivity The cytoskeleton of a cell consists of three main filaments: actin filaments (also called microfilaments), intermediate filaments, and microtubules.
- actin filaments also called microfilaments
- intermediate filaments also called microtubules.
- microtubules The cytoskeleton provides a cell with shape, structure, and an anchorage for various organelles. It also provides driving forces for cell migration and intracellular transport of macromolecules.
- actin regulates many key functions in cells, including:
- Actin Filaments The major cytoskeletal protein of cells is actin, a 43-kd protein that polymerizes to form actin filaments-thin, flexible fibers approximately 7 nm in diameter and up to several micrometers in length. Within the cell, actin filaments are organized into higher-order structures, forming bundles or three-dimensional networks with the properties of semisolid gels. The assembly and disassembly of actin filaments, their crosslinking into bundles and networks, and their association with other cell structures such as the plasma membrane are regulated by a variety of actin-binding proteins which are critical components of the actin cytoskeleton.
- Actin filaments are particularly abundant beneath the plasma membrane, where they form a network that provides mechanical support, determines cell shape, and allows movement of the cell surface, thereby enabling cells to migrate, engulf particles, and divide.
- Cooper, G. M. The Cell: A Molecular Approach, 2 nd Ed., Sinauer Associates, Sunderland, Mass. (2000). ncbi.nlm.nih.gov Actin structure, function and sequences are described by Otterbein, L R, The Crystal Structure of Uncomplexed Actin in the ADP State, Science , Vol. 293, 27 Jul. 2001; Kabsch, W., The Actin Fold, FASEB J. 9, 167-174 (1995); Homes, K. C.
- Actins exist either as a monomeric form (G-actin) or as assembled, double helical, filamentous polymers (filamentous actin, F-actin, or microfilaments).
- actin cytoskeleton provides mechanical support and is a major driving force for cell motility. Actin also participates in many cellular processes such as cell division, surface receptor cycling, vesicle and organelle movement, and signal transduction. In immune cells, actin is also involved in cell adhesion, cell migration, chemotaxis, and T cell activation (Wulfing and Davis, 1998).
- Intracellular actin activity is regulated through actin polymerization and depolymerization, which are regulated by multiple actin modulators in cells.
- G-actin can automatically polymerize at high salt concentration.
- Polymerized actin filaments (F-actin) can also dissociate into G-actin.
- polymerized actin filaments have polarity, with (+) and ( ⁇ ) ends (or barbed and pointed ends).
- actin polymerization and depolymerization reactions reach a steady-state, G-actin is added to the (+) end and dissociated from the ( ⁇ ) end at equal rates, so the length of the actin filaments remains constant. This process is called actin treadmilling, which resembles a process of actin subunits “walking” from the (+) end to the ( ⁇ ) end (Pollard and Borisy, 2003).
- G-actin In cells, actin dynamics are tightly regulated to ensure proper and speedy response to stimuli.
- G-actin is normally associated with cellular regulators such as profilin and thymosin ⁇ 4.
- Profilin acts as a nucleotide-exchange factor, which allows the switch from ADP-actin to ATP-actin ready for actin polymerization.
- Thymosin ⁇ 4 is an actin-sequestering protein, which serves as a buffering protein for the maintenance of the monomeric actin pool.
- F-actin is also associated with multiple cellular regulators such as ADF/cofilin and the Apr2/3 complex.
- ADF/Cofilin is a family of actin-severing proteins which depolymerize F-actin mainly at the ( ⁇ ) end.
- the Arp2/3 complex is a seven-subunit protein that promotes the growth of new actin filaments.
- actin capping proteins such as CapZ and gelsolin can cap the ends of actin filaments, preventing actin polymerization or depolymerization (Pollard and Borisy, 2003).
- actin and microtubule cytoskeleton gives mechanical support and control of cell shape.
- the actin and microtubule cytoskeleton networks also provide trafficking routes through cytoplasm for intracellular macromolecules and, sometimes, invading bacteria and viruses.
- actin polymerization and depolymerization provide a major driving force for cell migration through treadmilling
- muscle cells actin fiber is the scaffold on which myosin proteins generate force to produce muscle contraction.
- actin has a wide range of roles, including regulation of cell surface receptors, cell division, cell adhesion and differentiation, T cell/B cell activation, and gene expression.
- Actin is also involved in the process of apoptosis, in which cellular stress induces the reorganization of the actin cytoskeleton, giving rise to actin stress fiber.
- actin is fragmented into two fragments of 15 kD and 31 kD by the ICE/ced-3 family of proteases, which is one of the major characteristics of apoptotic cells.
- microtubule network also plays important roles in many cellular processes. Microtubules provide means of intracellular transport of organelles and secretory vesicles. They are also involved in the formation of mitotic spindles during cell division (mitosis and meiosis). Drugs targeting microtubules are known to induce apoptosis of cancer cells.
- Actin and microtubule dynamics are also important for intracellular bacterial and viral infection of cells. Actin polymerization and depolymerization can modulate receptor dynamics, facilitating the entry of bacteria and viruses. Actin polymerization can produce essential driving forces and scaffolds for bacterial and viral intracellular migration, nucleic acid synthesis and transcription, or virion assembly and budding (Spear et al. 2012; Spear et al. 2013; Taylor et al 2011). The microtubule network is frequently used by intracellular bacteria and viruses for migrations inside and between cells (Kotsakis et al. 2001).
- the actin-derived peptides of the invention are modified in order to penetrate cells, e.g., by addition of an N-terminal polyarginine segment.
- Relevant reviews of cell-penetrating peptides are: C. Bechara et al., Cell-penetrating peptides: 20 years later, where do we stand?, FEBS Letters 587 (2013) 1693-1702; B. Gupta, et al., Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides, Advanced Drug Delivery Reviews 57 (2005) 637-651; M. Lindgren, et al., cell-penetrating peptides, TiPS—March 2000 (Vol. 21) 99-103; M.
- Actin is involved in: 1) supporting cell shape and cell growth; 2) driving cells to migrate; 3) cell signal transduction; 4) cell surface receptor cycling between the surface and the cytoplasm; 5) cell-cell junction and cell adhesion; 6) muscle cell contraction; 7) in the cardiovascular system, actin activity affects heart beat and blood vessel elasticity and capacitance; 8) the process of viral and bacterial infection.
- Actin can function as a barrier to block viral infection, while viruses and bacteria may also use actin polymerization to promote inter- and intracellular migration; 9) the intracellular delivery of chemical compounds (e.g. small-molecule drugs) and biological substances (e.g. DNA, peptides, and proteins et al).
- the cortical actin in a cell structure can also block the intracellular delivery of compounds and substances, affecting the delivery efficiency; 10) the process of cell growth, differentiation and apoptosis.
- ⁇ -actin structure showing subdomains 1 to 4 and the hydrophobic cleft between subdomains 1 and 3 (red circle).
- This hydrophobic cleft is a common binding pocket of most actin binding proteins (ABPs) such as gelsolin, profilin, and ADF/cofilin as shown.
- ABSPs most actin binding proteins
- Two diametrically opposed clefts separate the two large domains of actin.
- the larger cleft, between subdomains 2 and 4 constitutes the nucleotide-binding site, whereas the smaller cleft, between subdomains 1 and 3, mediates the interactions of actin with most actin binding proteins (ABPs) ( FIG. 2D ).
- ABPs are extremely diverse, both structurally and functionally, but for some reason related to the filament structure, most ABPs seem to share a common binding area on the actin surface, which is the hydrophobic pocket between actin subdomains 1 and 3. Both gelsolin and cofilin bind to this cleft, and profilin also interacts with the back of this cleft. It is possible that our peptides interface with the binding of some ABPs, thereby disturbing actin dynamics, and indirectly the dynamics of surface receptors.
- an actin-based peptide comprising an actin core domain and a cell penetration domain, operably linked together by a spacer domain,
- N-terminus or C-terminus may have either the actin core domain or the cell penetration domain.
- the actin core domain is selected from the group consisting of NB5 (SEQ ID NO: 1, 7, 15-138), NB7 (SEQ ID NO: 2, 8, 9, 139-290), NB9 (SEQ ID NO: 3, 9, 10, 11, 291-470), NB10 (SEQ ID NO: 4, 12, 471-601), B11 (SEQ ID NO: 5, 13, 602-723), and B17 (SEQ ID NO: 6, 14, 724-845).
- the actin core domain is labeled with a traceable dye or marker.
- an actin-based peptide comprising a B11 core selected from the sequences set forth in SEQ ID NO: 5, 13, and 602-723.
- a method for controlling viral or bacterial infection comprising administering an actin-based peptide to a cell, virus, or bacteria, in an amount sufficient to inhibit or enhance infection of said virus or bacteria.
- HIV infection is increased by administering said actin-based peptide to a cell.
- the actin-based peptide comprises an actin core domain selected from NB7 (SEQ ID NO: 2, 8, 9, 139-290), and NB9 (SEQ ID NO: 3, 9, 10, 11, 291-470).
- a method for inhibiting or enhancing viral or bacterial infection comprising: administering an agent to a cell or a virus or bacteria, with an amount of one or more peptide sequences selected from SEQ ID NOs: 1-845 effective to inhibit or enhance infection of said virus or bacteria.
- a method for inhibiting or enhancing viral or bacterial vector delivery into a cell comprising: administering an agent to a cell or a viral or bacterial vector, with an amount of one or more peptide sequences selected from SEQ ID NOs: 1-845 effective to inhibit or enhance vector delivery to said virus or bacteria.
- a method for modulating actin dynamics in a cell comprising: delivering into a cell one or more actin peptides selected from SEQ ID NOs: 1-845, in an amount effective to modulate actin dynamics.
- a method for modulating cellular bioactivity comprising: delivering into a cell one or more actin-based peptides selected from SEQ ID NOs: 1-845, in an amount effective to modulate cellular bioactivity.
- the cellular bioactivity is: cytoplasmic and nuclear actin dynamics, cell morphology, cell motility and mobility, cell surface receptor density, cell adhesion processes, gene expression, cell division, growth, differentiation, and apoptosis, the processes of endocytosis and exocytosis, smooth and heart muscle cell contraction and relaxation, blood vessel elasticity and capacitance, a process of inflammation, cellular susceptibility to intracellular pathogens, or cellular uptake of chemical compounds, including small and macro molecules, medical drugs, nucleic acids, and proteins.
- an actin-based peptide conjugated to a cell-penetration peptide or membrane-permeable molecule is provided.
- the peptide fragment is selected from SEQ ID NO: 1-845.
- the peptide fragment is labeled with a traceable dye or marker.
- a peptide composition comprising:
- a peptide composition comprising:
- a method for intracellular delivery of an actin peptide fragment comprising: conjugating said actin peptide fragment with a cell-penetration peptide or membrane-permeable molecule.
- a peptide having a formula set forth in SEQ ID NOs: 1-845 is provided.
- the peptide is a cyclic peptide.
- kits comprising one or more peptides having a formula set forth in SEQ ID NOs: 1-845, and an effective amount of a therapeutic compound, a diagnostic compound, or a compound for modulating cellular activity.
- actin-based peptide can be used to trigger actin dynamics to modulate pathogen infection.
- Another object is to provide actin-based peptides which can be used to enhance viral vector entry into cells such as cancer cells, stem cells, or terminally-differentiated cells for gene delivery or gene therapy.
- actin-based peptides can be used to enhance viral amplification in primary culture of cells from biological samples, such as blood samples or tissue samples.
- biological samples such as blood samples or tissue samples.
- the use of these peptides can facilitate the isolation and recovery of viruses from biological samples such as the recovery of HIV from blood CD4 T cells.
- the subject peptides can be used to trigger cell death for therapy, such as killing cancer cells.
- Another object is to provide peptides and methods of modulating actin activity, to either inhibit or enhance cell migration and cell mobility.
- Such peptides can be used to inhibit or enhance cell migration in the body. They can be used to slow down cancer cell migration, or used as anti-inflammatory drugs, or used to modulate the movement of stem cells in the body, or used to attract progenitor cells for tissue damage repairs.
- actin-based peptides can be used to up-regulate or down-regulate cell surface receptors, change cellular behaviors or responses to receptor-mediated signal transduction. This property can be used to facilitate the study of receptor dynamics and cell signaling, or to facilitate the efficacy of medical drugs targeting cell receptors and signaling pathways.
- actin-based peptides can be labeled with a traceable dye or marker and be used to monitor intracellular actin and microtubule dynamics, and the behaviors of actin-binding proteins.
- FIG. 1 (A) Schematic representation of the design and discovery of the actin-based peptides.
- the actin-based peptides also contain an additional domain which allows them to penetrate cell membrane to enter cells.
- the actin-based peptides also contain a spacer domain which links the actin core domain with the cell penetration domain.
- B Screening of an actin-based peptide library for bioactivities in enhancing HIV infection.
- HIV reporter T cells Rev-CEM-GFP
- Rev-CEM-GFP An HIV reporter T cells, Rev-CEM-GFP, were treated with each actin-based peptide, and then infected with HIV-1. Enhancement of HIV infection was quantified.
- HIV replication in peptide-untreated cells was quantified, and plotted as 100%.
- peptide N5, N7, and N9 were found to enhance HIV replication from 350% to 400%.
- FIG. 2 (A) Schematic representation of the actin-core domains discovered from screening. (B) The amino acid sequences of the core domains. (C) The location and AA position of the actin-core domains within the human ⁇ -actin protein (SEQ ID NO: 848). (D) ⁇ -actin structure, showing subdomains 1 to 4 and the hydrophobic cleft between subdomains 1 and 3 (red circle). This hydrophobic cleft is a common binding pocket of most actin binding proteins (ABPs) such as gelsolin, profilin, and ADF/cofilin as shown.
- ABSPs actin binding proteins
- FIG. 3 Enhancement of HIV infection by actin-based peptides N7 and N9.
- the HIV Rev-dependent indicator cell, Rev-CEM-GFP was not infected (+Cell) or infected with HIV-1 (+HIV), or pre-treated with peptide N7, and then infected with HIV-1 (N7+HIV). Following infection for 2 hours, cells were washed to remove the virus and the_peptide. Viral replication was measured at 2 days post infection by flow cytometry. N7 enhances HIV infection from 0.79% to 15.5%, as measured by the percentage of GFP+ cells. PI,_propidium iodide, was added before flow cytometry for cytotoxicity control. GFP+ cells were counted only when the cells are viable (low PI staining).
- B Effects of peptide N9 were similarly measured. It enhanced HIV infection from 1.95% to 14.07%
- FIG. 4 Up-regulation of cell surface receptors by N7.
- CEM-SS T cells or blood resting CD4 T cells were stimulated with peptide N7 for a time course. Effects on surface CD4, CXCR4 density were measured by anti-CD4 or anti-CXCR4, followed by flow cytometry.
- FIG. 5 Peptide N7 and N9 modulate cell signal transduction and chemotactic cofilin and actin activity.
- A Resting memory CD4 T cells were treated with N7 for a time course, cofilin phosphorylation was measured by Western Blot. Total cofilin and GAPDH was also measured for loading control.
- B Resting CD4 T cells were treated with N9, and actin polmerization and depolymerization were measured by FITC-phalloidin staining.
- FIG. 6 Peptide N7 and N9 enhance HIV DNA synthesis, nuclear migration, and integration.
- A CEM-SS T cells were treated with N7 during HV infection for 2 hours, washed, and then analyzed for viral DNA synthesis and 2-LTR circles, a marker for HIV nuclear migration.
- B Blood resting CD4 T cells were similar infected, washed, and cultured without T cell activation. Viral DNA synthesis and DNA integration were analyzed.
- FIG. 7 Peptide N9 promotes HIV infection of resting CD4 T cells. Resting CD4 T cells were treated with N9, and then infected with HIV for 2 hours. Following infection, cells were washed, and culture in the absence of T cell activation and N9. Viral p24 release was measured. As controls, cells were culture with the addition of IL-7 (daily addition), or with a scrambled peptide, or only in the culture medium.
- FIG. 8 Human T lymphoblast cell A3.01 was treated with N10 (10 uM). N10-mediated cell killing was monitored by staining of dead cells with Propidium iodide and FITC-labelled Annexin V. Cells were analyzed by flow cytometry.
- the present disclosure relates to composition and methodology for using actin-based peptide fragments to modulate cellular bioactivity, including but not limited to modulating cytoplasmic and nuclear actin dynamics, cell morphology, modulating cell motility and mobility, cell receptor dynamics, cell adhesion processes, gene expression, cell division, growth, differentiation, and apoptosis, the processes of endocytosis and exocytosis, the process of inflammation, and cellular susceptibility to intracellular pathogens such as viruses.
- actin dynamics can be modulated by using actin-based peptides that are delivered intra-cellularly.
- actin-based peptides either in the L- or D-forms, can trigger or modulate actin dynamics, which lead to the modulation of cellular bioactivity such as modulation of cell surface receptors, inhibiting or promoting cell migration, increasing or decreasing cell death, or altering cellular susceptibility to intracellular bacterial or viral pathogens.
- CPPs cell-penetration peptide
- membrane-permeable molecule a cell-penetration peptide
- CPPs cell-penetration peptide
- cationic, amphipathic, and hydrophobic Table 1-3, Milletti F.
- Cationic CPPs are mostly derived from heparin-, RNA-, and DNA-binding proteins, such as the HIV Tat peptide, arginine-based peptides, FHV coat peptide, Yeast PrP6, Penetratin, HoxA-13, PDX-1 et al.
- Many amphipathic CPPs are derived from antimicrobial peptides, such as LL-37, L-2, Crotamine, Buforin2, or from viral proteins, such as Ribotoxin 2 L3 loop, PreS2-TLM, VP22 et al.
- Many amphipathic CPPs are also derived from signal peptides [e.g.
- K-FGF+NLS, MPrPp(1-30)], or various natural proteins pVEC, Azurin p18, hT18-32).
- hydrophobic CPPs are derived from signal peptide, such as K-FGF, or from various nature proteins, such as Bip, C105Y, FGF12 et al.
- an actin-based peptide comprises an actin core domain and a cell penetration domain, operably linked together by a spacer domain. Unless indicated otherwise, the actin-based peptide N-terminus or C-terminus may have either the actin core domain or the cell penetration domain.
- Exemplary actin-based peptides include but are not limited to the peptides set forth in SEQ ID NOs: 1-845.
- Actin core domain refers to a highly conserved domain from the actin protein sequences of human, mouse, rabbit, fly, etc.
- Exemplary actin core domains include NB5 (YNELRVAPEE) SEQ ID NO: 853, NB7 (QIMFETFNTP) SEQ ID NO: 854, NB9 (LPHAILRLDL) SEQ ID NO: 855, NB10 (AGRDLTDYLM) SEQ ID NO: 856, Bi (LCYVALDFEQ) SEQ ID NO: 857, and B17 (KYSVWIGGSI) SEQ ID NO: 858.
- NB5 YNELRVAPEE
- QIMFETFNTP QIMFETFNTP
- NB9 LPHAILRLDL
- NB10 AGRDLTDYLM
- Bi LCYVALDFEQ
- B17 KYSVWIGGSI
- Cell penetration domain derive from cell-penetration peptide (CPPs) or membrane-permeable molecules.
- CPPs cell-penetration peptide
- Spacer domain refers to an amino acid sequence that links an actin core domain to a cell penetration domain.
- Exemplary spacer domain sequences include but are not limited to poly glycine or poly alanine.
- a composition can be delivered into a cell in any form by any effective route, including but not limited to oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosol, spray, inhalation, percutaneous (epidermal), subcutaneous, intravenous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, mucosal, and intrathecal.
- a composition can be administered alone, or in combination with any ingredient(s), active or inactive.
- actin-based peptides of the invention are likely to act through three different mechanisms: 1) the peptides disturb actin polymerization and actin depolymerization at the plus and minus ends. Thus, disturbing the process of actin treadmilling; 2) these peptides may compete directly with actin binding proteins such as cofilin, Arp2/3, thus, affecting actin dynamics; 3) these peptides may compete with actin binding adaptor proteins or actin binding motifs present on the intracellular domains of receptors.
- Actin-peptides can inhibit or enhance viral infection processes at multiple steps, such as: 1) enhance or inhibit of viral entry; 2) enhance or inhibit viral intracellular migration, 3) enhance or inhibit viral nuclear migration, 4) enhance or inhibit viral assembly and budding; 5) enhance or inhibit viral cell-cell transmission.
- the actin cytoskeleton exists as a polarized array of filaments, termed F-actin, in dynamic equilibrium with a globular actin, or G-actin, pool. Polymerization of the F-actin filament occurs predominately at the barbed end (also known as the plus end), while depolymerization occurs predominantly at the pointed end (also known as the minus end).
- actin-binding proteins ABSPs
- ABPs actin-binding proteins
- actin-modulating ABPs which exhibit various activities towards F-actin, including bundling and crosslinking (Fimbrin, Fascin, Filamin A, etc.), membrane and receptor association (ERM proteins, among others), capping (CapZ, tropomodulin, etc.), anti-capping (Ena/VASP proteins), nucleating and branching (the Arp2/3 complex), nucleation and polymerizing (Spirel/2 and formins), actin-associated motor activity (Myosins), and severing functions (cofilin, gelsolin, etc.).
- Rho-family monomeric GTPases which are activated by nucleotide exchange of bound GDP to GTP.
- the Rho GTPases which include 20 members, are divided into canonical signaling motifs that mediate particular cellular processes ( FIG. 1 ).
- RhoA-ROCK-LIMK-Cofilin and RhoA-ROCK-MLC pathways which are partially responsible for the assembly of the contractile uropod, stress fibers, and focal adhesions.
- actin As a fundamental component of the host cellular cytoskeleton, actin is routinely engaged by infecting bacterial and viruses. Bacteria and Viruses from diverse groups, and infecting diverse hosts, have convergently evolved an array of mechanisms for manipulating the actin cytoskeleton for efficacious infection.
- the actin cytoskeleton is critical for viral infection at many stages of the life cycle, including binding, cell entry, nuclear localization, genomic transcription and reverse transcription, assembly, and egress/dissemination. Specifically, viruses subvert the force-generating and macromolecular scaffolding properties of the actin cytoskeleton to propel viral surfing, internalization, and migration within the cell. Additionally, viruses utilize the actin cytoskeleton to support and organize assembly sites, and eject budding virions for cell-to-cell transmission.
- Actin and Viral Entry After engagement of the extracellular matrix (ECM) and the viral receptor, viruses must migrate to sites favorable for their particular mode of entry, whether it is direct plasma membrane fusion, or routes as divergent as macropinocytosis, phagocytosis, and the various forms of clathrin-mediated and clathrin-independent endocytosis. During this process, viruses frequently encounter actin-based processes, such as filopodia and microvilli, and utilize these structures to efficiently migrate to the cell membrane for entry.
- virus surfing in which engagement of the receptor or ECM promotes movement of the attached virion towards the cell body in an actin-dependent mechanism.
- MLV Murine leukemia virus
- ABV Avian leukosis virus
- HAV Human immunodeficiency virus
- MLV particles in particular, migrated to the base of the filopodia and fused with the membrane, indicating that this was the active, and perhaps predominant, entry location (Lehmann M J, et al., 2005).
- this viral surfing was energy-dependent, being inhibited by sodium azide, and was dependent on functional myosin II and F-actin: treatment of cells with the myosin II inhibitor, blebbistatin, or cytochalasin D, which blocks F-actin barbed ends from polymerization, eliminated virus surfing and promoted random motility at the plasma membrane (Lehmann M J, et al., 2005).
- myosin II inhibitor blebbistatin
- cytochalasin D which blocks F-actin barbed ends from polymerization
- the model developed around this process is centered around actin retrograde flow in which myosin II generates forces that pull the filopodia-associated actin filaments towards the cell body, which is commensurate with viral receptor-actin association and filopodial tip actin polymerization.
- the net result is that the virus-receptor complex is processively pushed and dragged towards the cell body where entry occurs.
- HSV-1 Herpes simplex virus type 1
- HSV-16 Human papilloma virus 16
- HCV Hepatitis C virus
- HSV-1 HSV-1 not only migrated upon filopodia, but dramatically induced their formation in P19 neuron-like cells (Dixit R, et al., 2008). This indicates that HSV-1 engagement of the viral receptor specifically introduces signaling events to mediate filopodia formation, implicating that Rho and PI3K-dependent pathways are critical for mediating cytoskeletal structures essential for viral infection (Clement C, et al., 2006; Zheng K, et al., 2014b).
- HSV-1 virus-receptor engagements can actively signal to the actin cytoskeleton.
- This receptor-mediated signaling can dramatically affect entry events, promoting receptor clustering, receptor endocytosis, and fusion complex stabilization. Additionally, these signal transduction events often have important impacts on subsequent events in the viral life cycle. For instance, binding of HIV-1 to the chemokine coreceptor CXCR4/CCR5 triggers the activation of Rac1-PAK1/2-LIMK-cofilin (Yoder A, et al., 2008; Vorster P J, et al., 2011).
- This signaling pathway regulates actin dynamics and the surface cycling of CXCR4, facilitating viral entry and post entry DNA synthesis and nuclear migration (Vorster P J, et al., 2011).
- Clustering of HIV-1 viral receptor and coreceptor CD4 and either CCR5 or CXCR4 has also been suggested to be dependent on viral receptor signaling: specifically, engagement of both CD4 and CXCR4 activates Filamin A (Jimenez-Baranda S, et al., 2007), which promots receptor motility and clustering.
- the ERM protein, Moesin was also found to play a similar role in HIV-1 receptor clustering, in which the membrane receptor-actin crosslinking activity and receptor clustering occur after a viral receptor-mediated Moesin phosphorylation event (Barrero-Villar M, et al., 2009). It is probable that many other viruses utilize the actin cytoskeleton to induce receptor clustering and promote viral entry.
- viral entry occurs either at the plasma membrane directly, or during/after internalization by one of the endocytic routes.
- Many, and perhaps all, of these routes depend on actin to one extent or another, particularly in primary, differentiated cells.
- macropinocytosis which involves the Rac1-PAK-LIMK-Cofilin and, possibly, Rac1-WAVE-Arp2/3 pathways, has been shown to be required for HIV-1 entry into macrophages (Carter G C, et al., 2011).
- Macropinocytosis is also required for the entry of African swinefever virus (ASFV) (Sinchez E G, et al., 2012) and HPV-16 (Schelhaas M, et al., 2012). It also serves as an alternate entry route for Influenza A virus (IAV) (de Vries E, et al., 2011).
- IAV Influenza A virus
- An interesting twist on this is found in vaccinia virus entry, where viral envelope-associated phosphatidylserine induces an apoptotic body-mimicking signaling pathway, inducing a Rac1, PAK, tyrosine kinase, and actin-dependent macropinocytic entry route.
- Poliovirus also utilizes an actin and tyrosine-kinase dependent route for entry, wherein genomic RNA release occurs in vesicles or membrane invaginations within 100-200 nm of the plasma membrane (Brandenburg B, et al., 2007). These examples, including many viruses from divergent groups, illuminate the need to co-opt the force generating and scaffolding functions of the cortical actin cytoskeleton, and the signaling pathways that modulate these functions, during viral entry.
- Actin and nuclear migration After accessing the cortisol, most viruses must traverse the gap between the entry site and the nucleus for expression, genome replication, and, for some viruses, assembly. It is to this end that viruses utilize cellular force-generating apparatuses, which, along with dynein and kinesin for microtubule-based transport, include the motor and polymerizing proteins for the actin cytoskeleton; specifically, spire, formins, Arp2/3, and myosins.
- HIV-1 migrates to the nucleus utilizing two downstream components of Rac signaling, the Rac1-PAK1/2-LIMK-Cofiln pathway (Yoder A, et al., 2008; Vorster P J, et al., 2011), and the Rac1-WAVE2-Arp2/3 signaling pathway (Spear M, et al., 2014).
- the initial stimulus for Rac activation was also shown to require coreceptor—CCR5 or CXCR4—engagement and signal transduction (Yoder A, et al., 2008; Vorster P J, et al., 2011; Spear M, et al., 2014).
- NPFs Nuclear Promoting Factors
- WASP/WAVE family of proteins nuclear Promoting Factors
- Arp2/3 complex for actin polymerization Higgs H N, et al., 1999, 2001; Pollard T D, et al., 2003.
- the viral WCA domain activates Arp2/3 at the viral core surface, generating forces and an actin comet tail that propel the core to the nucleus for expression and replication (Goley E D, et al., 2006; Ohkawa T, et al., 2010).
- HSV-1 has also been shown to utilize actin for intracellular motility and nuclear localization in a process involving the cofilin phosphatase and activator, slingshot, and calcium-regulated protease, calpain (Zheng K, et al., 2014a).
- HSV-1 promotes ubiquitin/proteasome-dependent degradation of slingshot, leading to cofilin activation and promoting viral replication (Xiang Y, et al., 2014).
- Actin in assembly Once localized to the nucleus, or cytoplasm for large dsDNA viruses, viruses must concentrate, organize, and assemble their structural proteins, early-acting accessory and catalytic proteins, and genomic nucleic acids prior to egress of the viral particle. Needless to say, this requirement for colocalization of viral proteins, viral nucleic acids, and cellular factors requires scaffolding functions, and filamentous actin is often subverted for this purpose.
- PVX Potato virus X
- TGB1, 2, and 3 triple-gene block proteins
- actin is required for intercellular transfer of PVX, in addition to Tobacco mosaic virus (TMV) and Tomato bushy stunt virus (TBSV), through plasmodesmata (Harries P A, et al., 2009).
- TMV Tobacco mosaic virus
- TBSV Tomato bushy stunt virus
- Measles virus has also been shown to utilize actin during assembly. For instance, disruption of the actin cytoskeleton rapidly reduced MeV particle release from the plasma membrane (Stallcup K C, et al., 1983). Furthermore, actin has been observed to colocalize with budding MeV, with meromyosin-labeled actin barbed ends protruding into the nascent virions in close juxtaposition with the viral nucleocapsid (Bohn W, et al., 1986).
- M viral Matrix protein
- H viral hemagglutinin
- ROCK, LIMK, and cofilin have also been implicated in HIV-1 and Mason-Pfizer monkey virus assembly, release, and cell-cell transmission (Wen X, et al., 2014). Knockdown of LIMK did not inhibit HIV-1 maturation, yet, fully enveloped particles remained associated with the plasma membrane as mature virion aggregates (Wen X, et al., 2014). LIMK was also shown to be recruited to assembly sites (Wen X, et al., 2014). Although the exact mechanism for ROCK-LIMK-Cofilin contribution to virion release remains incompletely resolved, the authors suggested a factor retains the viral particles when normal cytoskeletal dynamics are disrupted (Wen X, et al., 2014).
- Actin and cell-cell transmission Cell-to-cell transmission of animal viruses is a highly efficacious route of dissemination that minimizes interactions with the innate and adaptive immune system. Additionally, this process can render certain antivirals less effective, giving the issue increasing prominence in therapeutic research (Agosto L M, et al., 2014). It constitutes the infection of neighboring cells by an infected cell, typically mediated by the fusogenic surface protein or envelope glycoprotein. Perhaps the best-studied example of this is Vaccinia virus cell-cell transmission (reviewed in (Welch M D, et al., 2013)).
- Vaccinia virions were found to project from CCB-sensitive microvilli-like structures (Stokes G V, 1976); later, it was discovered that these virus-associated projections contained, in addition to actin, ⁇ -actinin (Hiller G, et al., 1979), fimbrin, and filamin (Hiller G, et al., 1981; Krempien U, et al., 1981). Additionally, Intracellular Enveloped Virions (IEVs) were shown to induce CCD-sensitive actin comet tails, reminiscent of Listeria, Shigella and Rickettsia infections (Cudmore S, et al., 1995).
- IEVs Intracellular Enveloped Virions
- the actin comet-inducing factor as identified by phenotypic characterization of deletion mutant viruses, was viral A36, a type 1b membrane protein (Röttger S, et al., 1999) that becomes tyrosine phosphorylated (Frischknecht F, et al., 1999a) at Y112 and Y132 (Frischknecht F, et al., 1999b).
- Y112 phosphorylation recruits the adaptor protein, Nck, via its SH2 domain (Frischknecht F, et al., 1999b), while Y132 was shown to recruit another adaptor protein, Grb2 (Scaplehorn N, et al., 2002).
- HIV has also been shown to utilize an actin-dependent (Jolly C, et al., 2004, 2007) mode of transmission between T cells, in which viral Env glycoprotein on the donor cell organizes a polarized Virological Synapse (VS) that mediates highly efficient cell-cell transmission. This process may be up to 18,000 times more efficacious that free viral infection (Chen P, et al., 2007).
- the VS and associated signaling complex which contains the viral receptor, CD4, and viral coreceptor, CXCR4 or CCR5, resembles the Supramolecular Activation Complex (SMAC) observed in T cell activation (Vasiliver-Shamis G, et al., 2008), including the incorporation of the T cell Receptor (TCR) (Vasiliver-Shamis G, et al., 2009).
- SMAC Supramolecular Activation Complex
- TCR T cell Receptor
- the derived signals are insufficient to promote T cell activation, they do create an actin-depleted zone, which may facilitate viral infection at its earliest stages (Vasiliver-Shamis G, et al., 2009).
- HIV has been shown to transfer between T cells using cellular nanotube processes, which may mimic aspects of the VS (Sowinski S, et al., 2008).
- DCs dendritic cells
- These viral filopodia were found to be quite dynamic, allowing up to 800 CD4 T cell contacts per hour (Aggarwal A, et al., 2012). Additionally, these viral filopodia partially required the formin, Diaphanous-2 (Diaph2), and the viral Nef accessory protein (Aggarwal A, et al., 2012).
- actin In addition to the more canonical modes of viral cooption of the actin cytoskeleton thus described, there is accumulating evidence that cytosolic and nuclear actin may play important roles in viral transcription, translation, and genome replication though somewhat unique modalities.
- the viral core is deposited on a dense meshwork of cortical actin that undergoes dynamics related to signal transduction mediated by the viral Env-CD4 and Env-CXCR4/CCR5 interactions (Jimenez-Baranda S, et al., 2007; Harmon B, et al., 2008, 2010; Yoder A, et al., 2008; Barrero-Villar M, et al., 2009; Vorster P J, et al., 2011; Spear M, et al., 2014).
- RTC Reverse Transcriptase Complex
- Nuclear actin bundles have also been implicated in late gene (gag) mRNA nuclear export and expression (Kimura T, et al., 2000): specifically, treatment with LatA, which disrupted viral Rev-RNP-induced nuclear actin bundles, caused retention of gag mRNA in the nucleus, decreasing cytosolic gag mRNA and, presumably, reducing Gag and Gag-Pol protein expression (Kimura T, et al., 2000).
- Rh1 has also been shown to be important for Influenza A virus (IAV) polymerase complex activity (Dierkes R, et al., 2014).
- IAV Influenza A virus
- NSC23766 Treatment of cells with a Rac1 inhibitor, NSC23766 (Gao Y, et al., 2004), reduced viral replication in A549 cells with an IC 50 of 22 ⁇ M (Dierkes R, et al., 2014).
- knockdown of TIAM1, the Rac1-activating GEF, or Rac1 itself also reduced viral replication (Dierkes R, et al., 2014).
- NSC23766 reduced viral protein expression, which was later linked to inhibition of the viral polymerase complex (Dierkes R, et al., 2014).
- mice infected with IAV and treated with NSC23766 showed reduce titer of IAV in lung tissue, increased body weights, and a higher survivability than solvent-treated control mice (Dierkes R, et al., 2014). Although there was no specific study of whether NSC23766-mediated inhibition of the viral polymerase complex required actin, it is likely that actin played some role.
- Actin-Based Peptides can Inhibit or Enhance Bacterial Infection Through Inhibiting Bacterial Motility and Mobility
- the cytoskeleton is a dynamic structure composed of microfilaments (filamentous actin or F-actin), intermediate filaments, and microtubules that are mainly responsible for defining cell shape, mediating motility, and transporting macromolecules and organelles.
- the actin cytoskeleton in particular, has been shown to be the driving force for cell motility and migration [1].
- the actin cytoskeleton is also a target for pathogens. It has been known that the human bacterial pathogens Listeria monocytogenes [2, 3] effectively uses the driving force generated from actin polymerization for mobility.
- Actin cytoskeleton is also a point of integration for receptor cross talk through modulation of protein dynamics and clustering.
- Gowriskankar and coauthors [5] have also proposed a model in which active remodeling of cortical actin regulates spatiotemporal organization of cell surface molecules such as surface receptors.
- the authors classify surface molecules into 3 classes based on their relationship with the cortical actin—namely, inert surface molecules, passive surface molecules, and active surface molecules.
- the inert (e.g. short-chain lipids) and passive (e. g. transmembrane proteins with actin-binding domains) molecules on the cell surface can be driven to form transient nanoclusters by actin dynamics and local actin architecture.
- integrin and T cell receptors can directly connect to the cytoplasmic actin using actin-binding motifs such as PDZ, SH3 (Src-or PRD (proline-rich domain).
- Active cell surface molecules e.g. integrin and T cell receptors
- integrin and T cell receptors are capable of interacting with actin and modifying its dynamics. These molecules can recruit molecules involved in actin remodulation. They can also be organized in microclusters by actin-dependent processes.
- the instant actin-based peptides can modulate cell surface molecules and receptors through promoting or inhibiting actin dynamics.
- the instant actin-based peptides can modulate cancer receptors.
- a review article describing the most important cancer receptors is A. M. Scott et al., Antibody therapy of cancer, Nature Reviews Cancer , Vol. 12, APRIL 2012, 278-287.
- Table 2 in the article lists important receptors that can be targeted for therapy (e.g, CD20, CD30, CD33, CD52, EpCAM, CEA, gpA33, Mucins, TAG-72, CAIX, PSMA, VEGF, VEGFR, EGFR, Integrin ⁇ V ⁇ 3, Integrin ⁇ 5 ⁇ 3, ERBB2, ERBB3, EPHA3, TRAILR1, RANKL, FAP, Tenascin)
- the instant actin-based peptides provide anti-inflammatory/inhibit cheomotaxis: Actin polymerization is the major driving force for the chemotaxis of immune cells. It is known that inhibiting actin polymerization inhibits chemotaxis, which is required for the inflammatory responses of immune cells. The instant actin-based peptides can interfere with actin polymerization process, and may possess anti-inflammatory properties.
- P the number of amino acids in an actin peptide, P can be from 2 amino acids to (L-1) amino acids.
- FIG. 1C In screening a peptide library ( FIG. 1C ), multiple peptides including Peptide N7 and N9 were identified that can drastically enhance HIV infection of human T cells ( FIG. 1C ). As shown in FIG. 3 , the actin-based peptides N7 and N9 enhance HIV infection.
- the HIV Rev-dependent indicator cell, Rev-CEM-GFP was not infected (+Cell) or infected with HIV-1 (+HIV), or pre-treated with peptide N7, and then infected with HIV-1 (N7+HIV). Following infection for 2 hours, cells were washed to remove the virus and the peptide. Viral replication was measured at 2 days post infection by flow cytometry.
- N7 enhances HIV infection from 0.79% to 15.5%, as measured by the percentage of GFP+ cells.
- PI propidium iodide, was added before flow cytometry for cytotoxicity control. GFP+ cells were counted only when the cells are viable (low PI staining).
- N9 enhanced HIV infection from 1.95% to 14.07%.
- Resting memory CD4 T cells were treated with N7 for a time course, and cofilin phosphorylation was measured by Western Blot. Total cofilin and GAPDH was also measured for loading control ( FIG. 5A ). Resting CD4 T cells were treated with N9, and actin polymerization and depolymerization were measured by FITC-phalloidin staining ( FIG. 5B ). See FIG. 5 .
- peptide N7 and N9 enhance HIV DNA synthesis, nuclear migration, and integration.
- CEM-SS T cells were treated with N7 during HV infection for 2 hours, washed, and then analyzed for viral DNA synthesis and 2-LTR circles, a marker for HIV nuclear migration. See FIG. 6(A) .
- Blood resting CD4 T cells were similar infected, washed, and cultured without T cell activation. Viral DNA synthesis and DNA integration were analyzed. See FIG. 6(B) .
- N9 The ability of N9 to stimulate HIV infection of blood resting CD4 T cells was also tested. Resting CD4 T cells are relatively resistant to HIV infection. The lack of activity in the cortical actin limits viral early steps in the infection of resting T cells (Yoder et al., 2008). As shown in FIG. 7 , a single-dosage N9 treatment prior to HIV infection drastically stimulated HIV infection of resting T cells. Importantly, this enhancement occurs in the absence of T cell activation or cytokine stimulation, and N9 is more potent at early time in stimulating viral infection than certain cytokines such as IL-7 (administered daily).
- Example 7 Protocol for Using Actin-Based Peptides to Block Cell Migration (Chemotaxis)
- Example 8 Results and Protocol for Using Peptide N10 to Kill Cancer Cells
- FIG. 8 shows human T lymphoblast cell A3.01 was treated with N10 (10 uM). N10-mediated cell killing was monitored by staining of dead cells with Propidium iodide and FITC-labelled Annexin V. Cells were analyzed by flow cytometry.
- NB5 SEQ ID NO: 853
- NB7 SEQ ID NO: 854
- NB9 SEQ ID NO: 855
- NB10 SEQ ID NO: 856
- B11 SEQ ID NO: 857
- B17 SEQ ID NO: 858
- 40 AA centered around each core domain, also all the possible 20 AA that can be derived around the core domain, and all the possible 10 AA that can be derived around the core domain. Also listed are multiple mutations on the 40AA, 20 AA, and 10 AA (X, X0 equal all possible AA).
- a Peptide Sequence of the Invention includes One or More of the following:
- a peptide according to formula SEQ ID No:1 to SEQ ID No:845 is a cyclic peptide.
- a cyclic peptide can be made by covalently crosslinking amino acid residues together via a disulfide bond (e.g., thiol group of cysteine) or a side chain of amino acid residues (e.g., Lye, Arg, Ser, Tyr).
- a functionalized linker e.g., polyethylene glycol or PEG
- PEG polyethylene glycol or PEG
- sequences enumerated here comprise 40 AA, 20 AA, and 10 AA, it is to be understood that peptides of the invention may include any length from 5 to 40 AA.
- SEQ ID NO: 846 Human ACTAl: Human ACTA1 (alpha skeletal muscle actin)
- SEQ ID NO: 848 Human ACTAB: Human ACTB (cytoplasmic 1 actin)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.
Description
- This application claims priority to U.S. Provisional Application No. 62/357,991, filed Jul. 2, 2016, which application is incorporated by reference herein in its entirety.
- The present disclosure relates to modulating cellular bioactivity and cell susceptibility to viral infection through modulating actin dynamics. Provided herein are methodology, compositions, and the like for modulating actin-related cellular bioactivity and cellular susceptibility to viral infection.
- Actin-related Cellular Bioactivity: The cytoskeleton of a cell consists of three main filaments: actin filaments (also called microfilaments), intermediate filaments, and microtubules. The cytoskeleton provides a cell with shape, structure, and an anchorage for various organelles. It also provides driving forces for cell migration and intracellular transport of macromolecules. In addition, actin regulates many key functions in cells, including:
-
- The formation of various of actin networks in cells for providing cellular trafficking routes.
- Modulation of cell surface receptors. Actin is heavily involved in receptor clustering and cycling.
- Cytokinesis. Cell division involves a contracting ring that is composed of actin, myosin, and a-actinin.
- Apoptosis. Actin is degraded into two fragments during apoptosis. Stress can induces the formation of stress fibers that is involved in apoptosis. The mitochondrial migration of the actin binding protein cofilin is also involved in triggering cell apopotosis.
- Cell adhesion and development. Adhesion of epithelial cells with extracellular matrix or with adjacent cells involves the actin cytoskeleton as well as cadherins and catenins.
- Gene expression modulation. Actin's state of polymerization can affect the pattern of gene expression.
- Smooth and hear muscle contraction: both actin and myosin are involved in muscle contraction and relaxation, and they make up 90% of muscle protein. The interaction of actin-myosin results in the movement of the two proteins that produces contractions.
- Nuclear actin function: actin can also enter the nucleus, and is involved in the architectural integrity of the nucleus, gene transcription, and translocation of the activated chromosome fragment from under membrane to euchromatin.
- Actin Filaments: The major cytoskeletal protein of cells is actin, a 43-kd protein that polymerizes to form actin filaments-thin, flexible fibers approximately 7 nm in diameter and up to several micrometers in length. Within the cell, actin filaments are organized into higher-order structures, forming bundles or three-dimensional networks with the properties of semisolid gels. The assembly and disassembly of actin filaments, their crosslinking into bundles and networks, and their association with other cell structures such as the plasma membrane are regulated by a variety of actin-binding proteins which are critical components of the actin cytoskeleton. Actin filaments are particularly abundant beneath the plasma membrane, where they form a network that provides mechanical support, determines cell shape, and allows movement of the cell surface, thereby enabling cells to migrate, engulf particles, and divide. Cooper, G. M., The Cell: A Molecular Approach, 2nd Ed., Sinauer Associates, Sunderland, Mass. (2000). ncbi.nlm.nih.gov Actin structure, function and sequences are described by Otterbein, L R, The Crystal Structure of Uncomplexed Actin in the ADP State, Science, Vol. 293, 27 Jul. 2001; Kabsch, W., The Actin Fold, FASEB J. 9, 167-174 (1995); Homes, K. C. et al., Atomic model of the actin filament, Nature, Vol. 347, 6 Sep. 1990; Mattila, P. K. et al., Dynamics of the actin cytoskeleton mediates receptor cross talk: An emerging concept in tuning receptor signaling, J. Cell Biol. Vol. 212 No. 3, 267-280 (2016); Sandiford, S. L. et al. (2015), Cytoplasmic Actin Is an Extracellular Insect, PLoS Pathog 11(2): e1004631. doi:10.1371/journal.ppat.1004631; Hardin, J., Regulating cell-cell junctions from A to Z, J. Cell Biol. Vol. 213 No. 2 151-153 (2016); and Yoder, A. et al., HIV Envelope-CXCR4 Signaling Activates Cofilin to Overcome Cortical Actin Restriction in Resting CD4 T Cells, Cell 134, 782792, Sep. 5, 2008.
- There are three actin isoforms, alpha, beta, and gamma. Alpha actin is mainly found in contractile structures such as those of muscle cells. Beta actin is found at the leading edge of migrating cells to drive cell mobility. Gamma actin is found in the filaments of stress fibers. Actins exist either as a monomeric form (G-actin) or as assembled, double helical, filamentous polymers (filamentous actin, F-actin, or microfilaments).
- In cells, the actin cytoskeleton provides mechanical support and is a major driving force for cell motility. Actin also participates in many cellular processes such as cell division, surface receptor cycling, vesicle and organelle movement, and signal transduction. In immune cells, actin is also involved in cell adhesion, cell migration, chemotaxis, and T cell activation (Wulfing and Davis, 1998).
- Intracellular actin activity is regulated through actin polymerization and depolymerization, which are regulated by multiple actin modulators in cells. In test tubes, in the absence of other actin regulators, G-actin can automatically polymerize at high salt concentration. Polymerized actin filaments (F-actin) can also dissociate into G-actin. Structurally, polymerized actin filaments have polarity, with (+) and (−) ends (or barbed and pointed ends). When actin polymerization and depolymerization reactions reach a steady-state, G-actin is added to the (+) end and dissociated from the (−) end at equal rates, so the length of the actin filaments remains constant. This process is called actin treadmilling, which resembles a process of actin subunits “walking” from the (+) end to the (−) end (Pollard and Borisy, 2003).
- In cells, actin dynamics are tightly regulated to ensure proper and speedy response to stimuli. G-actin is normally associated with cellular regulators such as profilin and thymosin β4. Profilin acts as a nucleotide-exchange factor, which allows the switch from ADP-actin to ATP-actin ready for actin polymerization. Thymosin β4 is an actin-sequestering protein, which serves as a buffering protein for the maintenance of the monomeric actin pool. F-actin is also associated with multiple cellular regulators such as ADF/cofilin and the Apr2/3 complex. ADF/Cofilin is a family of actin-severing proteins which depolymerize F-actin mainly at the (−) end. The Arp2/3 complex is a seven-subunit protein that promotes the growth of new actin filaments. In addition, actin capping proteins such as CapZ and gelsolin can cap the ends of actin filaments, preventing actin polymerization or depolymerization (Pollard and Borisy, 2003).
- In cells, actin and microtubule cytoskeleton gives mechanical support and control of cell shape. The actin and microtubule cytoskeleton networks also provide trafficking routes through cytoplasm for intracellular macromolecules and, sometimes, invading bacteria and viruses. In non-muscle cells, actin polymerization and depolymerization provide a major driving force for cell migration through treadmilling, whereas in muscle cells, actin fiber is the scaffold on which myosin proteins generate force to produce muscle contraction. In addition, actin has a wide range of roles, including regulation of cell surface receptors, cell division, cell adhesion and differentiation, T cell/B cell activation, and gene expression.
- Actin is also involved in the process of apoptosis, in which cellular stress induces the reorganization of the actin cytoskeleton, giving rise to actin stress fiber. During apoptosis, actin is fragmented into two fragments of 15 kD and 31 kD by the ICE/ced-3 family of proteases, which is one of the major characteristics of apoptotic cells.
- The microtubule network also plays important roles in many cellular processes. Microtubules provide means of intracellular transport of organelles and secretory vesicles. They are also involved in the formation of mitotic spindles during cell division (mitosis and meiosis). Drugs targeting microtubules are known to induce apoptosis of cancer cells.
- Actin and microtubule dynamics are also important for intracellular bacterial and viral infection of cells. Actin polymerization and depolymerization can modulate receptor dynamics, facilitating the entry of bacteria and viruses. Actin polymerization can produce essential driving forces and scaffolds for bacterial and viral intracellular migration, nucleic acid synthesis and transcription, or virion assembly and budding (Spear et al. 2012; Spear et al. 2013; Taylor et al 2011). The microtubule network is frequently used by intracellular bacteria and viruses for migrations inside and between cells (Kotsakis et al. 2001).
- In general, the actin-derived peptides of the invention are modified in order to penetrate cells, e.g., by addition of an N-terminal polyarginine segment. Relevant reviews of cell-penetrating peptides are: C. Bechara et al., Cell-penetrating peptides: 20 years later, where do we stand?, FEBS Letters 587 (2013) 1693-1702; B. Gupta, et al., Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides, Advanced Drug Delivery Reviews 57 (2005) 637-651; M. Lindgren, et al., cell-penetrating peptides, TiPS—March 2000 (Vol. 21) 99-103; M. Kristensen, et al., Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, Int. J. Mol. Sci. 2016, 17, 185; and F. Milletti, Cell-penetrating peptides: classes, origin, and current landscape, Drug Discovery Today, Vol. 17, No 15-16, August 2012.
- Actin is involved in: 1) supporting cell shape and cell growth; 2) driving cells to migrate; 3) cell signal transduction; 4) cell surface receptor cycling between the surface and the cytoplasm; 5) cell-cell junction and cell adhesion; 6) muscle cell contraction; 7) in the cardiovascular system, actin activity affects heart beat and blood vessel elasticity and capacitance; 8) the process of viral and bacterial infection. Actin can function as a barrier to block viral infection, while viruses and bacteria may also use actin polymerization to promote inter- and intracellular migration; 9) the intracellular delivery of chemical compounds (e.g. small-molecule drugs) and biological substances (e.g. DNA, peptides, and proteins et al). The cortical actin in a cell structure can also block the intracellular delivery of compounds and substances, affecting the delivery efficiency; 10) the process of cell growth, differentiation and apoptosis.
- The crystal structure of G-actin coupled with DNase I was solved in 1990 by Kabsch and colleagues [5]. The crystal structure of uncomplexed actin was also solved by Otterbein and coauthors [2]. The near-atomic resolution structure of F-actin was deduced by Holmes and colleagues using a combination of the crystal structure of G-actin and X-ray fiber diffraction data [3]. Currently, there are also over 80 structures of actin in complex with various actin binding proteins such as gelsolin, cofilin, and profilin [4]. Structurally, actin is organized into two related domains, which can be further subdivided into 4 subdomains numbered 1 to 4 (
FIG. 2D ). - β-actin structure, showing
subdomains 1 to 4 and the hydrophobic cleft betweensubdomains 1 and 3 (red circle). This hydrophobic cleft is a common binding pocket of most actin binding proteins (ABPs) such as gelsolin, profilin, and ADF/cofilin as shown. Two diametrically opposed clefts separate the two large domains of actin. The larger cleft, betweensubdomains subdomains FIG. 2D ). ABPs are extremely diverse, both structurally and functionally, but for some reason related to the filament structure, most ABPs seem to share a common binding area on the actin surface, which is the hydrophobic pocket betweenactin subdomains - In one aspect, provided is an actin-based peptide, comprising an actin core domain and a cell penetration domain, operably linked together by a spacer domain,
- wherein an N-terminus or C-terminus may have either the actin core domain or the cell penetration domain.
- In one embodiment, the actin core domain is selected from the group consisting of NB5 (SEQ ID NO: 1, 7, 15-138), NB7 (SEQ ID NO: 2, 8, 9, 139-290), NB9 (SEQ ID NO: 3, 9, 10, 11, 291-470), NB10 (SEQ ID NO: 4, 12, 471-601), B11 (SEQ ID NO: 5, 13, 602-723), and B17 (SEQ ID NO: 6, 14, 724-845).
- In another embodiment, the actin core domain is labeled with a traceable dye or marker.
- In another aspect, provided is an actin-based peptide, comprising a B11 core selected from the sequences set forth in SEQ ID NO: 5, 13, and 602-723.
- In another aspect, provided is a method for controlling viral or bacterial infection, comprising administering an actin-based peptide to a cell, virus, or bacteria, in an amount sufficient to inhibit or enhance infection of said virus or bacteria. In one embodiment, HIV infection is increased by administering said actin-based peptide to a cell. In another embodiment, the actin-based peptide comprises an actin core domain selected from NB7 (SEQ ID NO: 2, 8, 9, 139-290), and NB9 (SEQ ID NO: 3, 9, 10, 11, 291-470).
- In another aspect, provided is a method for inhibiting or enhancing viral or bacterial infection, comprising: administering an agent to a cell or a virus or bacteria, with an amount of one or more peptide sequences selected from SEQ ID NOs: 1-845 effective to inhibit or enhance infection of said virus or bacteria.
- In another aspect, provided is a method for inhibiting or enhancing viral or bacterial vector delivery into a cell, comprising: administering an agent to a cell or a viral or bacterial vector, with an amount of one or more peptide sequences selected from SEQ ID NOs: 1-845 effective to inhibit or enhance vector delivery to said virus or bacteria.
- In another aspect, provided is a method for modulating actin dynamics in a cell, comprising: delivering into a cell one or more actin peptides selected from SEQ ID NOs: 1-845, in an amount effective to modulate actin dynamics.
- In another aspect, provided is a method for modulating cellular bioactivity, comprising: delivering into a cell one or more actin-based peptides selected from SEQ ID NOs: 1-845, in an amount effective to modulate cellular bioactivity. In one embodiment, the cellular bioactivity is: cytoplasmic and nuclear actin dynamics, cell morphology, cell motility and mobility, cell surface receptor density, cell adhesion processes, gene expression, cell division, growth, differentiation, and apoptosis, the processes of endocytosis and exocytosis, smooth and heart muscle cell contraction and relaxation, blood vessel elasticity and capacitance, a process of inflammation, cellular susceptibility to intracellular pathogens, or cellular uptake of chemical compounds, including small and macro molecules, medical drugs, nucleic acids, and proteins.
- In another embodiment, provided is an actin-based peptide conjugated to a cell-penetration peptide or membrane-permeable molecule. In one embodiment, the peptide fragment is selected from SEQ ID NO: 1-845. In another embodiment, the peptide fragment is labeled with a traceable dye or marker.
- In another aspect, provided is a method of making a peptide composition, comprising:
-
- a) synthesizing one or more actin-based peptides; and
- b) covalently conjugating or non-covalently conjugating said actin-based peptide with a traceable dye, a small molecule, nucleic acid, peptide, or protein.
- In another aspect, provided is a method of making a peptide composition, comprising:
-
- a) synthesizing one or more actin-based peptides selected from SEQ ID NOs: 1-845; and
- b) covalently conjugating or non-covalently conjugating said actin-based peptide with a traceable dye, a small molecule, nucleic acid, peptide, or protein.
- In another aspect, provided is a method for intracellular delivery of an actin peptide fragment, comprising: conjugating said actin peptide fragment with a cell-penetration peptide or membrane-permeable molecule.
- In another aspect, provided is a peptide having a formula set forth in SEQ ID NOs: 1-845. In one embodiment, the peptide is a cyclic peptide.
- In another aspect, provide is a kit comprising one or more peptides having a formula set forth in SEQ ID NOs: 1-845, and an effective amount of a therapeutic compound, a diagnostic compound, or a compound for modulating cellular activity.
- Objects of the instant actin-derived peptides:
- 1) To enhance or inhibit cell signal transduction; enhance or block the activation of signaling pathways related to regulating actin dynamics.
- 2) To up-regulate or down-regulate receptor density on the cell surface such as up-regulate the chemokine receptors, adhesion molecules, cancer related surface receptors on the cell surface.
- 3) To enhance or inhibit viral infection or viral vector transduction of cells; promote or inhibit viral spreading.
- 4) To affect the process of cell growth, differentiation and apoptosis.
- Other objects include providing compositions and methods for enhancing or inhibiting viral infections. In one embodiment, actin-based peptide can be used to trigger actin dynamics to modulate pathogen infection.
- Another object is to provide actin-based peptides which can be used to enhance viral vector entry into cells such as cancer cells, stem cells, or terminally-differentiated cells for gene delivery or gene therapy.
- In another aspect, the actin-based peptides can be used to enhance viral amplification in primary culture of cells from biological samples, such as blood samples or tissue samples. The use of these peptides can facilitate the isolation and recovery of viruses from biological samples such as the recovery of HIV from blood CD4 T cells.
- In another aspect, because modulating actin and cofilin activity can lead to apoptosis, the subject peptides can be used to trigger cell death for therapy, such as killing cancer cells.
- Another object is to provide peptides and methods of modulating actin activity, to either inhibit or enhance cell migration and cell mobility. Such peptides can be used to inhibit or enhance cell migration in the body. They can be used to slow down cancer cell migration, or used as anti-inflammatory drugs, or used to modulate the movement of stem cells in the body, or used to attract progenitor cells for tissue damage repairs.
- In another aspect, actin-based peptides can be used to up-regulate or down-regulate cell surface receptors, change cellular behaviors or responses to receptor-mediated signal transduction. This property can be used to facilitate the study of receptor dynamics and cell signaling, or to facilitate the efficacy of medical drugs targeting cell receptors and signaling pathways.
- In another aspect, actin-based peptides can be labeled with a traceable dye or marker and be used to monitor intracellular actin and microtubule dynamics, and the behaviors of actin-binding proteins.
-
FIG. 1 : (A) Schematic representation of the design and discovery of the actin-based peptides. The whole amino acid (AA) sequence of β-actin (L=375 AA) can be divided into a library of overlapping peptides with defined amino acid length (e.g. 10 to 40 AA), which is defined as the actin core domain. The actin-based peptides also contain an additional domain which allows them to penetrate cell membrane to enter cells. In addition, the actin-based peptides also contain a spacer domain which links the actin core domain with the cell penetration domain. (B) Screening of an actin-based peptide library for bioactivities in enhancing HIV infection. An HIV reporter T cells, Rev-CEM-GFP, were treated with each actin-based peptide, and then infected with HIV-1. Enhancement of HIV infection was quantified. For controls, HIV replication in peptide-untreated cells was quantified, and plotted as 100%. In this screening, peptide N5, N7, and N9 were found to enhance HIV replication from 350% to 400%. -
FIG. 2 : (A) Schematic representation of the actin-core domains discovered from screening. (B) The amino acid sequences of the core domains. (C) The location and AA position of the actin-core domains within the human β-actin protein (SEQ ID NO: 848). (D) β-actin structure, showingsubdomains 1 to 4 and the hydrophobic cleft betweensubdomains 1 and 3 (red circle). This hydrophobic cleft is a common binding pocket of most actin binding proteins (ABPs) such as gelsolin, profilin, and ADF/cofilin as shown. -
FIG. 3 : Enhancement of HIV infection by actin-based peptides N7 and N9. (A) The HIV Rev-dependent indicator cell, Rev-CEM-GFP, was not infected (+Cell) or infected with HIV-1 (+HIV), or pre-treated with peptide N7, and then infected with HIV-1 (N7+HIV). Following infection for 2 hours, cells were washed to remove the virus and the_peptide. Viral replication was measured at 2 days post infection by flow cytometry. N7 enhances HIV infection from 0.79% to 15.5%, as measured by the percentage of GFP+ cells. PI,_propidium iodide, was added before flow cytometry for cytotoxicity control. GFP+ cells were counted only when the cells are viable (low PI staining). (B) Effects of peptide N9 were similarly measured. It enhanced HIV infection from 1.95% to 14.07% -
FIG. 4 : Up-regulation of cell surface receptors by N7. CEM-SS T cells or blood resting CD4 T cells were stimulated with peptide N7 for a time course. Effects on surface CD4, CXCR4 density were measured by anti-CD4 or anti-CXCR4, followed by flow cytometry. -
FIG. 5 : Peptide N7 and N9 modulate cell signal transduction and chemotactic cofilin and actin activity. (A) Resting memory CD4 T cells were treated with N7 for a time course, cofilin phosphorylation was measured by Western Blot. Total cofilin and GAPDH was also measured for loading control. (B) Resting CD4 T cells were treated with N9, and actin polmerization and depolymerization were measured by FITC-phalloidin staining. -
FIG. 6 : Peptide N7 and N9 enhance HIV DNA synthesis, nuclear migration, and integration. (A) CEM-SS T cells were treated with N7 during HV infection for 2 hours, washed, and then analyzed for viral DNA synthesis and 2-LTR circles, a marker for HIV nuclear migration. (B) Blood resting CD4 T cells were similar infected, washed, and cultured without T cell activation. Viral DNA synthesis and DNA integration were analyzed. -
FIG. 7 : Peptide N9 promotes HIV infection of resting CD4 T cells. Resting CD4 T cells were treated with N9, and then infected with HIV for 2 hours. Following infection, cells were washed, and culture in the absence of T cell activation and N9. Viral p24 release was measured. As controls, cells were culture with the addition of IL-7 (daily addition), or with a scrambled peptide, or only in the culture medium. -
FIG. 8 : Human T lymphoblast cell A3.01 was treated with N10 (10 uM). N10-mediated cell killing was monitored by staining of dead cells with Propidium iodide and FITC-labelled Annexin V. Cells were analyzed by flow cytometry. - The present disclosure relates to composition and methodology for using actin-based peptide fragments to modulate cellular bioactivity, including but not limited to modulating cytoplasmic and nuclear actin dynamics, cell morphology, modulating cell motility and mobility, cell receptor dynamics, cell adhesion processes, gene expression, cell division, growth, differentiation, and apoptosis, the processes of endocytosis and exocytosis, the process of inflammation, and cellular susceptibility to intracellular pathogens such as viruses.
- In one embodiment, and as described below, actin dynamics can be modulated by using actin-based peptides that are delivered intra-cellularly. These actin-based peptides, either in the L- or D-forms, can trigger or modulate actin dynamics, which lead to the modulation of cellular bioactivity such as modulation of cell surface receptors, inhibiting or promoting cell migration, increasing or decreasing cell death, or altering cellular susceptibility to intracellular bacterial or viral pathogens.
- The intracellular delivery of actin-based peptides can be achieved through conjugation with cell-penetration peptide (CPPs) or membrane-permeable molecule. Currently, there are many documented CPPs that are derived from various sources (e. g. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discovery Today, Vol. 17, Numbers 15/16, August 2012:). CPPs are groups of diverse peptides around 5-30 amino acids. CPPs can cross the cellular membrane and act as vehicles for the intracellular delivery of proteins, peptides, small molecules, and nucleic acids. Currently, CPPs can be classified into 3 major classes: cationic, amphipathic, and hydrophobic (Table 1-3, Milletti F. Drug Discovery Today, Vol. 17, Numbers 15/16, August 2012). Cationic CPPs are mostly derived from heparin-, RNA-, and DNA-binding proteins, such as the HIV Tat peptide, arginine-based peptides, FHV coat peptide, Yeast PrP6, Penetratin, HoxA-13, PDX-1 et al. Many amphipathic CPPs are derived from antimicrobial peptides, such as LL-37, L-2, Crotamine, Buforin2, or from viral proteins, such as
Ribotoxin 2 L3 loop, PreS2-TLM, VP22 et al. Many amphipathic CPPs are also derived from signal peptides [e.g. K-FGF+NLS, MPrPp(1-30)], or various natural proteins (pVEC, Azurin p18, hT18-32). There are only a few hydrophobic CPPs, compared with cathion and amphipathic peptides. Some of the hydrophobic CPPs are derived from signal peptide, such as K-FGF, or from various nature proteins, such as Bip, C105Y, FGF12 et al. - All technical terms in this description are commonly used in biochemistry, molecular biology and immunology, respectively, and can be understood by those skilled in the field of this invention. Those technical terms can be found in: MOLECULAR CLONING: A LABORATORY MANUAL, 3rd ed., vol. 1-3, ed. Sambrook and Russel, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, ed. Ausubel et al., Greene Publishing Associates and WileyInterscience, New York, 1988 (with periodic updates); SHORT PROTOCOLS IN MOLECULAR BIOLOGY: A COMPENDIUM OF METHODS FROM CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 5.sup.th ed., vol. 1-2, ed. Ausubel et aI., John Wiley & Sons, Inc., 2002; GENOME ANALYSIS: A LABORATORY MANUAL, vol. 1-2, ed. Green et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1997; CELLULAR AND MOLECULAR IMMUNOLOGY, 4.sup.th ed. Abbas et al., WB Saunders, 1994.
- As used herein, an actin-based peptide comprises an actin core domain and a cell penetration domain, operably linked together by a spacer domain. Unless indicated otherwise, the actin-based peptide N-terminus or C-terminus may have either the actin core domain or the cell penetration domain. Exemplary actin-based peptides include but are not limited to the peptides set forth in SEQ ID NOs: 1-845.
- Actin core domain refers to a highly conserved domain from the actin protein sequences of human, mouse, rabbit, fly, etc. Exemplary actin core domains include NB5 (YNELRVAPEE) SEQ ID NO: 853, NB7 (QIMFETFNTP) SEQ ID NO: 854, NB9 (LPHAILRLDL) SEQ ID NO: 855, NB10 (AGRDLTDYLM) SEQ ID NO: 856, Bi (LCYVALDFEQ) SEQ ID NO: 857, and B17 (KYSVWIGGSI) SEQ ID NO: 858. Using these core domains, the present inventor developed the instant actin-based peptides set forth in SEQ ID NOs 1-845.
- Cell penetration domain derive from cell-penetration peptide (CPPs) or membrane-permeable molecules.
- Spacer domain refers to an amino acid sequence that links an actin core domain to a cell penetration domain. Exemplary spacer domain sequences include but are not limited to poly glycine or poly alanine.
- As contemplated herein, a composition can be delivered into a cell in any form by any effective route, including but not limited to oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosol, spray, inhalation, percutaneous (epidermal), subcutaneous, intravenous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, mucosal, and intrathecal. A composition can be administered alone, or in combination with any ingredient(s), active or inactive.
- Without being bound by theory, it is thought that the actin-based peptides of the invention are likely to act through three different mechanisms: 1) the peptides disturb actin polymerization and actin depolymerization at the plus and minus ends. Thus, disturbing the process of actin treadmilling; 2) these peptides may compete directly with actin binding proteins such as cofilin, Arp2/3, thus, affecting actin dynamics; 3) these peptides may compete with actin binding adaptor proteins or actin binding motifs present on the intracellular domains of receptors.
- Actin-peptides can inhibit or enhance viral infection processes at multiple steps, such as: 1) enhance or inhibit of viral entry; 2) enhance or inhibit viral intracellular migration, 3) enhance or inhibit viral nuclear migration, 4) enhance or inhibit viral assembly and budding; 5) enhance or inhibit viral cell-cell transmission.
- Interaction of viruses with actin cytoskeleton: The actin cytoskeleton exists as a polarized array of filaments, termed F-actin, in dynamic equilibrium with a globular actin, or G-actin, pool. Polymerization of the F-actin filament occurs predominately at the barbed end (also known as the plus end), while depolymerization occurs predominantly at the pointed end (also known as the minus end). The precise spatiotemporal regulation of actin polymerization, mediated by actin-binding proteins (ABPs) and their upstream regulators, coordinates the force-generating and scaffolding properties of actin. These, in turn, regulate complex cellular processes including chemotaxis, cell adhesion, cytokinesis, the formation of cellular processes (microvilli, filopodia, lamellipodia, invadopodia, etc.), organelle movement, endocytosis, and the assembly of macromolecular domains during signal transduction and receptor internalization.
- These primary functions of the actin cytoskeleton are themselves regulated by the actin-modulating ABPs, which exhibit various activities towards F-actin, including bundling and crosslinking (Fimbrin, Fascin, Filamin A, etc.), membrane and receptor association (ERM proteins, among others), capping (CapZ, tropomodulin, etc.), anti-capping (Ena/VASP proteins), nucleating and branching (the Arp2/3 complex), nucleation and polymerizing (Spirel/2 and formins), actin-associated motor activity (Myosins), and severing functions (cofilin, gelsolin, etc.). Directly upstream of these factors and their associated activities are the Rho-family monomeric GTPases, which are activated by nucleotide exchange of bound GDP to GTP. The Rho GTPases, which include 20 members, are divided into canonical signaling motifs that mediate particular cellular processes (
FIG. 1 ). Among these are the Rac1-PAK-LIMK-Cofilin pathway, which terminates with LIMK phosphorylating and inactivating cofilin; the Rac1-WAVE-Arp2/3 pathway, which promotes actin nucleation and branching, and lamellipodium generation; the Cdc42-WASP-Arp2/3 and Cdc42-mDia pathways, which activate Arp2/3 and the formin, mDia, respectively, and promote actin nucleation, branching, polymerization, and the formation of filopodia; and the RhoA-ROCK-LIMK-Cofilin and RhoA-ROCK-MLC pathways, which are partially responsible for the assembly of the contractile uropod, stress fibers, and focal adhesions. - It is these force-generating and scaffolding properties exhibited by the actin cytoskeleton and its effectors that frequently become targets of necessity for viral replication, which also require these activities. As discussed in details below, functions such as Arp2/3 nucleation and branching and formin-mediated actin polymerization are co-opted to produce force for viral motility. Similarly, the normal mechanisms of actin rearrangement, such as cofilin activation and inactivation cycling, are dysregulated to create favorable microcompartments for genome replication and nuclear localization. As such, each stage in the viral life cycle, from entry to egress and dissemination, will be considered in turn, explicating the various motifs of viral subversion of normal cellular actin signaling functions.
- As a fundamental component of the host cellular cytoskeleton, actin is routinely engaged by infecting bacterial and viruses. Bacteria and Viruses from diverse groups, and infecting diverse hosts, have convergently evolved an array of mechanisms for manipulating the actin cytoskeleton for efficacious infection. The actin cytoskeleton is critical for viral infection at many stages of the life cycle, including binding, cell entry, nuclear localization, genomic transcription and reverse transcription, assembly, and egress/dissemination. Specifically, viruses subvert the force-generating and macromolecular scaffolding properties of the actin cytoskeleton to propel viral surfing, internalization, and migration within the cell. Additionally, viruses utilize the actin cytoskeleton to support and organize assembly sites, and eject budding virions for cell-to-cell transmission.
- Actin and Viral Entry: After engagement of the extracellular matrix (ECM) and the viral receptor, viruses must migrate to sites favorable for their particular mode of entry, whether it is direct plasma membrane fusion, or routes as divergent as macropinocytosis, phagocytosis, and the various forms of clathrin-mediated and clathrin-independent endocytosis. During this process, viruses frequently encounter actin-based processes, such as filopodia and microvilli, and utilize these structures to efficiently migrate to the cell membrane for entry.
- Among the most common forms of this process is virus surfing, in which engagement of the receptor or ECM promotes movement of the attached virion towards the cell body in an actin-dependent mechanism. For instance, Lehmann et al. exhibited Murine leukemia virus (MLV), Avian leukosis virus (ALV), and Human immunodeficiency virus (HIV) surfing along filopodia in HEK293T cells transfected with their respective receptors (Lehmann M J, et al., 2005). MLV particles, in particular, migrated to the base of the filopodia and fused with the membrane, indicating that this was the active, and perhaps predominant, entry location (Lehmann M J, et al., 2005). Furthermore, this viral surfing was energy-dependent, being inhibited by sodium azide, and was dependent on functional myosin II and F-actin: treatment of cells with the myosin II inhibitor, blebbistatin, or cytochalasin D, which blocks F-actin barbed ends from polymerization, eliminated virus surfing and promoted random motility at the plasma membrane (Lehmann M J, et al., 2005). These treatments additionally inhibited MLV and ALV viral infection in rat XC cells, indicating that the viral surfing route contributed to productive infection (Lehmann M J, et al., 2005). The model developed around this process is centered around actin retrograde flow in which myosin II generates forces that pull the filopodia-associated actin filaments towards the cell body, which is commensurate with viral receptor-actin association and filopodial tip actin polymerization. The net result is that the virus-receptor complex is processively pushed and dragged towards the cell body where entry occurs.
- Viral surfing on filopodia has also been described for Herpes simplex virus type 1 (HSV-1) (Clement C, et al., 2006; Dixit R, et al., 2008), vaccinia virus (Mercer J, et al., 2008), Human papilloma virus 16 (HPV-16) (Schelhaas M, et al., 2008), Hepatitis C virus (HCV) (Coller K E, et al., 2009), and HIV-1 (Lehmann M J, et al., 2005), indicating that utilization of actin retrograde flow in cellular processes, particularly filopodia, may be a general mechanism for extracellular viral migration towards the cell body. To some extent, the intracellular migration of viruses is a virus-dependent active process, requiring signal transduction from or clustering of the viral receptor. For instance, HSV-1 not only migrated upon filopodia, but dramatically induced their formation in P19 neuron-like cells (Dixit R, et al., 2008). This indicats that HSV-1 engagement of the viral receptor specifically introduces signaling events to mediate filopodia formation, implicating that Rho and PI3K-dependent pathways are critical for mediating cytoskeletal structures essential for viral infection (Clement C, et al., 2006; Zheng K, et al., 2014b).
- As indicated above for HSV-1, another common theme preceding cell entry is that virus-receptor engagements can actively signal to the actin cytoskeleton. This receptor-mediated signaling can dramatically affect entry events, promoting receptor clustering, receptor endocytosis, and fusion complex stabilization. Additionally, these signal transduction events often have important impacts on subsequent events in the viral life cycle. For instance, binding of HIV-1 to the chemokine coreceptor CXCR4/CCR5 triggers the activation of Rac1-PAK1/2-LIMK-cofilin (Yoder A, et al., 2008; Vorster P J, et al., 2011). This signaling pathway regulates actin dynamics and the surface cycling of CXCR4, facilitating viral entry and post entry DNA synthesis and nuclear migration (Vorster P J, et al., 2011). Clustering of HIV-1 viral receptor and coreceptor (CD4 and either CCR5 or CXCR4) has also been suggested to be dependent on viral receptor signaling: specifically, engagement of both CD4 and CXCR4 activates Filamin A (Jimenez-Baranda S, et al., 2007), which promots receptor motility and clustering. The ERM protein, Moesin, was also found to play a similar role in HIV-1 receptor clustering, in which the membrane receptor-actin crosslinking activity and receptor clustering occur after a viral receptor-mediated Moesin phosphorylation event (Barrero-Villar M, et al., 2009). It is probable that many other viruses utilize the actin cytoskeleton to induce receptor clustering and promote viral entry.
- After engagement with the viral receptor, viral entry occurs either at the plasma membrane directly, or during/after internalization by one of the endocytic routes. Many, and perhaps all, of these routes depend on actin to one extent or another, particularly in primary, differentiated cells. For instance, macropinocytosis, which involves the Rac1-PAK-LIMK-Cofilin and, possibly, Rac1-WAVE-Arp2/3 pathways, has been shown to be required for HIV-1 entry into macrophages (Carter G C, et al., 2011). Macropinocytosis is also required for the entry of African swinefever virus (ASFV) (Sinchez E G, et al., 2012) and HPV-16 (Schelhaas M, et al., 2012). It also serves as an alternate entry route for Influenza A virus (IAV) (de Vries E, et al., 2011). An interesting twist on this is found in vaccinia virus entry, where viral envelope-associated phosphatidylserine induces an apoptotic body-mimicking signaling pathway, inducing a Rac1, PAK, tyrosine kinase, and actin-dependent macropinocytic entry route. Although, as reviewed by Moss (Moss B, 2012), the poxvirus entry fusion complex-composed of 11-12 glycosylated proteins—is abnormally complex, and other entry routes exist. Huttunem et al. (2014) also implicate a Rac1-dependent entry mechanism, involving neutral multivesicular bodies, in Coxsackievirus A9 entry (Huttunen M, et al., 2014). Similarly, HSV-1 has been shown to utilize a RhoA, tyrosine kinase, and actin-dependent phagocytosis-like route for entry (Clement C, et al., 2006; Zheng K, et al., 2014b). Poliovirus also utilizes an actin and tyrosine-kinase dependent route for entry, wherein genomic RNA release occurs in vesicles or membrane invaginations within 100-200 nm of the plasma membrane (Brandenburg B, et al., 2007). These examples, including many viruses from divergent groups, illuminate the need to co-opt the force generating and scaffolding functions of the cortical actin cytoskeleton, and the signaling pathways that modulate these functions, during viral entry.
- Actin and nuclear migration: After accessing the cortisol, most viruses must traverse the gap between the entry site and the nucleus for expression, genome replication, and, for some viruses, assembly. It is to this end that viruses utilize cellular force-generating apparatuses, which, along with dynein and kinesin for microtubule-based transport, include the motor and polymerizing proteins for the actin cytoskeleton; specifically, spire, formins, Arp2/3, and myosins. For instance, HIV-1 migrates to the nucleus utilizing two downstream components of Rac signaling, the Rac1-PAK1/2-LIMK-Cofiln pathway (Yoder A, et al., 2008; Vorster P J, et al., 2011), and the Rac1-WAVE2-Arp2/3 signaling pathway (Spear M, et al., 2014). The initial stimulus for Rac activation was also shown to require coreceptor—CCR5 or CXCR4—engagement and signal transduction (Yoder A, et al., 2008; Vorster P J, et al., 2011; Spear M, et al., 2014). Interestingly, from a potential therapeutic standpoint, treatment of CD4 T lymphocytes with the Arp2/3 inhibitor, CK-548 (Nolen B J, et al., 2009), dramatically reduced HIV-1 replication at dosages that did not affect CD4 T cell activation or induce cytotoxicity (Spear M, et al., 2014). For viruses with larger genomes, more elaborate mechanisms for mediating nuclear localization exist. This is the case with baculovirus, where the p78/83 capsid encodes a WASP/WAVE homology domain, the WASP homology-Cofilin homology/Connector-Acidic domain (WCA) (Machesky L M, et al., 2001). This domain is normally found in the Nuclear Promoting Factors (NPFs) of the WASP/WAVE family of proteins, whereupon NPF activation leads to WCA exposure and activation of the Arp2/3 complex for actin polymerization (Higgs H N, et al., 1999, 2001; Pollard T D, et al., 2003). However, in the presence of baculovirus p78/83, the viral WCA domain activates Arp2/3 at the viral core surface, generating forces and an actin comet tail that propel the core to the nucleus for expression and replication (Goley E D, et al., 2006; Ohkawa T, et al., 2010). As will be discussed later, nuclear translocation of the Arp2/3 complex, nuclear F-actin polymerization, and the resultant perturbation of nuclear structure also play a critical role during viral assembly and egress (Ohkawa T, et al., 1999; Goley E D, et al., 2006). HSV-1 has also been shown to utilize actin for intracellular motility and nuclear localization in a process involving the cofilin phosphatase and activator, slingshot, and calcium-regulated protease, calpain (Zheng K, et al., 2014a). The siRNA knockdown of slingshot and calpain reduced viral infection and led to a perinuclear localization of the viral cores, whereas wild-type virus localized to the nucleus efficaciously. In a somewhat stunning display of the requirements for specificity in actin signaling at distinct stages of viral replication, at later time points (8 hours post-infection and beyond), HSV-1 promotes ubiquitin/proteasome-dependent degradation of slingshot, leading to cofilin activation and promoting viral replication (Xiang Y, et al., 2014).
- Actin in assembly: Once localized to the nucleus, or cytoplasm for large dsDNA viruses, viruses must concentrate, organize, and assemble their structural proteins, early-acting accessory and catalytic proteins, and genomic nucleic acids prior to egress of the viral particle. Needless to say, this requirement for colocalization of viral proteins, viral nucleic acids, and cellular factors requires scaffolding functions, and filamentous actin is often subverted for this purpose. This was shown for baculovirus: specifically, that mutation of the baculoviral CA domain dramatically abrogated nuclear F-actin accumulation and viral replication; furthermore, that viral progeny produced by one such mutant were distorted, either lacking an envelope altogether or having capsids that did not align with their envelope (Goley E D, et al., 2006).
- In a similar fashion, Potato virus X (PVX), radically rearranges the ER and Golgi membranes and host actin into enormous assembly sites called the X-body (Tilsner J, et al., 2012). This process is mediated by the triple-gene block proteins (TGB1, 2, and 3), which are involved in cell-to-cell transfer through plasmodesmata, with PVX TGB1 being able to produce X-like-bodies when expressed alone (Tilsner J, et al., 2012). Although the role of actin in the X-body, and its relation to assembly was not specifically addressed, it has been shown that actin is required for intercellular transfer of PVX, in addition to Tobacco mosaic virus (TMV) and Tomato bushy stunt virus (TBSV), through plasmodesmata (Harries P A, et al., 2009). Thus, it is tempting to speculate that, even for certain plant viruses, actin may contribute to both assembly and cell-to-cell transfer.
- Assembly of Influenza A virus (IAV) filamentous particles has also been shown to partially require an intact cortical actin cytoskeleton, as disruption with cytochalasin D (CCD) dramatically abrogated the titers of the filamentous, but not spherical, virions (Roberts P C, et al., 1998). This was later corroborated by Simpson-Holley et al. (2002), showing that treatment of MDCK cells with CCD, jasplakinolide (Jas), or latrunculin A (LatA) dramatically redistributed plasma membrane hemagglutinin (HA), lipid rafts, and actin into annular structures; there was also a commensurate loss of cell surface HA-containing filamentous projections and filamentous virus production (Simpson-Holley M, et al., 2002a). The authors attributed the loss of filamentous viral assembly not to actin playing a specific role in assembly, per se, but rather mobilizing and recruiting lipid rafts to the assembly sites of filamentous particles, which, given their size, require a much larger pool of lipids than their spherical particle counterparts. As such, with lipid rafts, actin, and HA reorganized into small annuli, only spherical particle production occurs owing to the lack of sufficient lipid raft material for the larger filamentous particles (Simpson-Holley M, et al., 2002b).
- Measles virus (MeV) has also been shown to utilize actin during assembly. For instance, disruption of the actin cytoskeleton rapidly reduced MeV particle release from the plasma membrane (Stallcup K C, et al., 1983). Furthermore, actin has been observed to colocalize with budding MeV, with meromyosin-labeled actin barbed ends protruding into the nascent virions in close juxtaposition with the viral nucleocapsid (Bohn W, et al., 1986). Additionally, the viral Matrix protein (M) was found to associate with F-actin, and this was shown to reduce the interaction with viral hemagglutinin (H) protein, as CCD treatment dramatically reduced actin co-immunoprecipitating with M, while enhancing H co-immunoprecipitation (Wakimoto H, et al., 2013). This study also indicated that there is a tradeoff between M-actin affinity and viral infectivity, wherein a higher affinity between M and H increases the amount of H, and hence the infectivity, of cell-free virus at the expense of cell-cell fusion. Furthermore, mutations in the M protein affecting M-actin affinity may arise in cell types where cell-cell fusion is more productive than free viral infection (Wakimoto H, et al., 2013). In another study, Dietzel et al. (2013) exhibited that, while CCD treatment enhanced the rate of cell-cell fusion, it also reduces co-transport of M-RNP to the cell surface (Dietzel E, et al., 2013). Additionally, Jas treatment blocked free-virus production, while not affecting M-RNP co-transport, indicating that a dynamic actin cytoskeleton is required for cell-free virus maturation and release (Dietzel E, et al., 2013).
- ROCK, LIMK, and cofilin have also been implicated in HIV-1 and Mason-Pfizer monkey virus assembly, release, and cell-cell transmission (Wen X, et al., 2014). Knockdown of LIMK did not inhibit HIV-1 maturation, yet, fully enveloped particles remained associated with the plasma membrane as mature virion aggregates (Wen X, et al., 2014). LIMK was also shown to be recruited to assembly sites (Wen X, et al., 2014). Although the exact mechanism for ROCK-LIMK-Cofilin contribution to virion release remains incompletely resolved, the authors suggested a factor retains the viral particles when normal cytoskeletal dynamics are disrupted (Wen X, et al., 2014).
- Actin and cell-cell transmission: Cell-to-cell transmission of animal viruses is a highly efficacious route of dissemination that minimizes interactions with the innate and adaptive immune system. Additionally, this process can render certain antivirals less effective, giving the issue increasing prominence in therapeutic research (Agosto L M, et al., 2014). It constitutes the infection of neighboring cells by an infected cell, typically mediated by the fusogenic surface protein or envelope glycoprotein. Perhaps the best-studied example of this is Vaccinia virus cell-cell transmission (reviewed in (Welch M D, et al., 2013)). In 1976, Vaccinia virions were found to project from CCB-sensitive microvilli-like structures (Stokes G V, 1976); later, it was discovered that these virus-associated projections contained, in addition to actin, α-actinin (Hiller G, et al., 1979), fimbrin, and filamin (Hiller G, et al., 1981; Krempien U, et al., 1981). Additionally, Intracellular Enveloped Virions (IEVs) were shown to induce CCD-sensitive actin comet tails, reminiscent of Listeria, Shigella and Rickettsia infections (Cudmore S, et al., 1995). The actin comet-inducing factor, as identified by phenotypic characterization of deletion mutant viruses, was viral A36, a type 1b membrane protein (Röttger S, et al., 1999) that becomes tyrosine phosphorylated (Frischknecht F, et al., 1999a) at Y112 and Y132 (Frischknecht F, et al., 1999b). Y112 phosphorylation recruits the adaptor protein, Nck, via its SH2 domain (Frischknecht F, et al., 1999b), while Y132 was shown to recruit another adaptor protein, Grb2 (Scaplehorn N, et al., 2002). These proteins, in turn, help to recruit the N-WASP NPF complex (Frischknecht F, et al., 1999b; Moreau V, et al., 2000), which mediates Arp2/3 activation via its WCA domain. The result of this signaling cascade is the production of actin comet tails. When IEVs fuse with the plasma membrane, becoming Cell-associated Enveloped Virions (CEVs), viral A36 remains in the plasma membrane below the virion, promoting the production of the long, microvilli-like structures identified in 1976, and promoting viral dissemination (Welch M D, et al., 2013). Other factors that promote and regulate vaccinia virus motility are continually being discovered, including the formin, FHOD1, its upstream regulator, Rac1 (Alvarez D E, et al., 2013), and casein kinase 2 (Alvarez D E, et al., 2012).
- HIV has also been shown to utilize an actin-dependent (Jolly C, et al., 2004, 2007) mode of transmission between T cells, in which viral Env glycoprotein on the donor cell organizes a polarized Virological Synapse (VS) that mediates highly efficient cell-cell transmission. This process may be up to 18,000 times more efficacious that free viral infection (Chen P, et al., 2007). Morphologically, the VS and associated signaling complex, which contains the viral receptor, CD4, and viral coreceptor, CXCR4 or CCR5, resembles the Supramolecular Activation Complex (SMAC) observed in T cell activation (Vasiliver-Shamis G, et al., 2008), including the incorporation of the T cell Receptor (TCR) (Vasiliver-Shamis G, et al., 2009). Although the derived signals are insufficient to promote T cell activation, they do create an actin-depleted zone, which may facilitate viral infection at its earliest stages (Vasiliver-Shamis G, et al., 2009). Additionally, HIV has been shown to transfer between T cells using cellular nanotube processes, which may mimic aspects of the VS (Sowinski S, et al., 2008). An interesting twist on these forms of cell-to-cell transmission can be found in infected dendritic cells (DCs), wherein viral filopodia, containing immature virions at their tips, were observed (Aggarwal A, et al., 2012). These viral filopodia were found to be quite dynamic, allowing up to 800 CD4 T cell contacts per hour (Aggarwal A, et al., 2012). Additionally, these viral filopodia partially required the formin, Diaphanous-2 (Diaph2), and the viral Nef accessory protein (Aggarwal A, et al., 2012).
- Other roles of actin: In addition to the more canonical modes of viral cooption of the actin cytoskeleton thus described, there is accumulating evidence that cytosolic and nuclear actin may play important roles in viral transcription, translation, and genome replication though somewhat unique modalities.
- For instance, in HIV-1 infection, after entry into the host cell, the viral core is deposited on a dense meshwork of cortical actin that undergoes dynamics related to signal transduction mediated by the viral Env-CD4 and Env-CXCR4/CCR5 interactions (Jimenez-Baranda S, et al., 2007; Harmon B, et al., 2008, 2010; Yoder A, et al., 2008; Barrero-Villar M, et al., 2009; Vorster P J, et al., 2011; Spear M, et al., 2014). It is in this submembranous, dynamic actin cortex that the Reverse Transcriptase Complex (RTC) must convert the ssRNA genome into dsDNA. The first indication that the RTC may utilize the actin cytoskeleton came in 1995, when Hottiger et al. exhibited an interaction between beta-actin and the large subunit of Reverse Transcriptase (RT), or the Pol polyprotein precursor (Hottiger M, et al., 1995). Later, Bukrinskaya et al. (1998) corroborated these findings, showing that the RTC does indeed associate with the actin cytoskeleton in infected cells, and that pretreating cells with CCD, but not
treatment 2 hours post-infection, reduced the accumulation of early and late reverse transcription products, with a more severe phenotype for late products (Bukrinskaya A, et al., 1998). These results indicated that actin disruption may directly impact the function of RT (Bukrinskaya A, et al., 1998). As was corroborated by later studies, CCD pretreatment reduced the nuclear accumulation of late RT products by 25-fold (Bukrinskaya A, et al., 1998). This process is presumably related to both the reliance on F-actin for both reverse transcription and nuclear migration of the Pre-Integration Complex (PIC) (Yoder A, et al., 2008; Cameron P U, et al., 2010; Vorster P J, et al., 2011; Spear M, et al., 2014). Although, the exact mechanism by which F-actin contributes to RTC activity remain unresolved. Nuclear actin bundles have also been implicated in late gene (gag) mRNA nuclear export and expression (Kimura T, et al., 2000): specifically, treatment with LatA, which disrupted viral Rev-RNP-induced nuclear actin bundles, caused retention of gag mRNA in the nucleus, decreasing cytosolic gag mRNA and, presumably, reducing Gag and Gag-Pol protein expression (Kimura T, et al., 2000). - Rac1 has also been shown to be important for Influenza A virus (IAV) polymerase complex activity (Dierkes R, et al., 2014). Treatment of cells with a Rac1 inhibitor, NSC23766 (Gao Y, et al., 2004), reduced viral replication in A549 cells with an IC50 of 22 μM (Dierkes R, et al., 2014). Furthermore, knockdown of TIAM1, the Rac1-activating GEF, or Rac1 itself also reduced viral replication (Dierkes R, et al., 2014). Additionally, NSC23766 reduced viral protein expression, which was later linked to inhibition of the viral polymerase complex (Dierkes R, et al., 2014). Fascinatingly, mice infected with IAV and treated with NSC23766 showed reduce titer of IAV in lung tissue, increased body weights, and a higher survivability than solvent-treated control mice (Dierkes R, et al., 2014). Although there was no specific study of whether NSC23766-mediated inhibition of the viral polymerase complex required actin, it is likely that actin played some role.
-
- Aggarwal A, lemma T L, Shih I, Newsome T P, McAllery S, Cunningham A L, Turville S G. 2012. Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells. PLoS Pathog, 8: e1002762.
- Agosto L M, Zhong P, Munro J, Mothes W. 2014. Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission. PLoS Pathog, 10: e1003982.
- Alvarez D E, Agaisse H. 2012.
Casein kinase 2 regulates vaccinia virus actin tail formation. Virology, 423: 143-151. - Alvarez D E, Agaisse H. 2013. The formin FHOD1 and the small GTPase Rac1 promote vaccinia virus actin-based motility. J Cell Biol, 202: 1075-1090.
- Barrero-Villar M, Cabrero J R, Gordón-Alonso M, Barroso-González J, Alvarez-Losada S, Muñoz-Fernández M A, Sánchez-Madrid F, Valenzuela-Fernandez A. 2009. Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes. J Cell Sci, 122: 103-113.
- Bohn W, Rutter G, Hohenberg H, Mannweiler K, Nobis P. 1986. Involvement of actin filaments in budding of measles virus: studies on cytoskeletons of infected cells. Virology, 149: 91-106.
- Brandenburg B, Lee L Y, Lakadamyali M, Rust M J, Zhuang X, Hogle J M. 2007. Imaging poliovirus entry in live cells. PLoS Biol, 5: e183.
- Bukrinskaya A, Brichacek B, Mann A, Stevenson M. 1998. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med, 188: 2113-2125.
- Cameron P U, Saleh S, Sallmann G, Solomon A, Wightman F, Evans V A, Boucher G, Haddad E K, Sekaly R-P, Harman A N, Anderson J L, Jones K L, Mak J, Cunningham A L, Jaworowski A, Lewin S R. 2010. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci USA, 107: 16934-16939.
- Carter G C, Bernstone L, Baskaran D, James W. 2011. HIV-1 infects macrophages by exploiting an endocytic route dependent on dynamin, Rac1 and Pak1. Virology, 409: 234-250.
- Chen P, Hibner W, Spinelli M A, Chen B K. 2007. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol, 81: 12582-12595.
- Clement C, Tiwari V, Scanlan P M, Valyi-Nagy T, Yue B Y J T, Shukla D. 2006. A novel role for phagocytosis-like uptake in herpes simplex virus entry. J Cell Biol, 174: 1009-1021.
- Coller K E, Berger K L, Heaton N S, Cooper J D, Yoon R, Randall G. 2009. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog, 5: e1000702.
- Cudmore S, Cossart P, Griffiths G, Way M. 1995. Actin-based motility of vaccinia virus. Nature, 378: 636-638.
- Dierkes R, Warnking K, Liedmann S, Seyer R, Ludwig S, Ehrhardt C. 2014. The Rac1 inhibitor NSC23766 exerts anti-influenza virus properties by affecting the viral polymerase complex activity. PloS One, 9: e88520.
- Dietzel E, Kolesnikova L, Maisner A. 2013. Actin filaments disruption and stabilization affect measles virus maturation by different mechanisms. Virol J, 10: 249.
- Dixit R, Tiwari V, Shukla D. 2008. Herpes
simplex virus type 1 induces filopodia in differentiated P19 neural cells to facilitate viral spread. Neurosci Lett, 440: 113-118. - Frischknecht F, Cudmore S, Moreau V, Reckmann I, Röttger S, Way M. 1999a. Tyrosine phosphorylation is required for actin-based motility of vaccinia but not Listeria or Shigella. Curr Biol CB, 9: 89-92.
- Frischknecht F, Moreau V, Röttger S, Gonfloni S, Reckmann I, Superti-Furga G, Way M. 1999b. Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature, 401: 926-929.
- Gao Y, Dickerson J B, Guo F, Zheng J, Zheng Y. 2004. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA, 101: 7618-7623.
- Goley E D, Ohkawa T, Mancuso J, Woodruff J B, D'Alessio J A, Cande W Z, Volkman L E, Welch M D. 2006. Dynamic Nuclear Actin Assembly by Arp2/3 Complex and a Baculovirus WASP-Like Protein. Science, 314: 464-467.
- Harmon B, Campbell N, Ratner L. 2010. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog, 6: e1000956.
- Harmon B, Ratner L. 2008. Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. J Virol, 82: 9191-9205.
- Harries P A, Park J-W, Sasaki N, Ballard K D, Maule A J, Nelson R S. 2009. Differing requirements for actin and myosin by plant viruses for sustained intercellular movement. Proc Natl Acad Sci USA, 106: 17594-17599.
- Higgs H N, Pollard T D. 1999. Regulation of actin polymerization by Arp2/3 complex and WASp/Scar proteins. J Biol Chem, 274: 32531-32534.
- Higgs H N, Pollard T D. 2001. Regulation of actin filament network formation through ARP2/3 complex: activation by a diverse array of proteins. Annu Rev Biochem, 70: 649-676.
- Hiller G, Jungwirth C, Weber K. 1981. Fluorescence microscopical analysis of the life cycle of vaccinia virus in chick embryo fibroblasts. Virus-cytoskeleton interactions. Exp Cell Res, 132: 81-87.
- Hiller G, Weber K, Schneider L, Parajsz C, Jungwirth C. 1979. Interaction of assembled progeny pox viruses with the cellular cytoskeleton. Virology, 98: 142-153.
- Hottiger M, Gramatikoff K, Georgiev O, Chaponnier C, Schaffner W, Hubscher U. 1995. The large subunit of HIV-1 reverse transcriptase interacts with beta-actin. Nucleic Acids Res, 23: 736-741.
- Huttunen M, Waris M, Kajander R, Hyypia T, Marjomaki V. 2014. Coxsackievirus A9 infects cells via nonacidic multivesicular bodies. J Virol, 88: 5138-5151.
- Jimenez-Baranda S, Gómez-Moutón C, Rojas A, Martinez-Prats L, Mira E, Ana Lacalle R, Valencia A, Dimitrov D S, Viola A, Delgado R, Martinez-A C, Manes S. 2007. Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol, 9: 838-846.
- Jolly C, Kashefi K, Hollinshead M, Sattentau Q J. 2004. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med, 199: 283-293.
- Jolly C, Mitar I, Sattentau Q J. 2007. Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human
immunodeficiency virus type 1. J Virol, 81: 5547-5560. - Kimura T, Hashimoto I, Yamamoto A, Nishikawa M, Fujisawa J I. 2000. Rev-dependent association of the intron-containing HIV-1 gag mRNA with the nuclear actin bundles and the inhibition of its nucleocytoplasmic transport by latrunculin-B. Genes Cells Devoted Mol Cell Mech, 5: 289-307.
- Krempien U, Schneider L, Hiller G, Weber K, Katz E, Jungwirth C. 1981. Conditions for pox virus-specific microvilli formation studied during synchronized virus assembly. Virology, 113: 556-564.
- Lehmann M J, Sherer N M, Marks C B, Pypaert M, Mothes W. 2005. Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells. J Cell Biol, 170: 317-325.
- Machesky L M, Insall R H. 2001. WASP homology sequences in baculoviruses. Trends Cell Biol, 11: 286-287.
- Mercer J, Helenius A. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science, 320: 531-535.
- Moss B. 2012. Poxvirus cell entry: how many proteins does it take? Viruses, 4: 688-707.
- Moreau V, Frischknecht F, Reckmann I, Vincentelli R, Rabut G, Stewart D, Way M. 2000. A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization. Nat Cell Biol, 2: 441-448.
- Nolen B J, Tomasevic N, Russell A, Pierce D W, Jia Z, McCormick C D, Hartman J, Sakowicz R, Pollard T D. 2009. Characterization of two classes of small molecule inhibitors of Arp2/3 complex. Nature, 460: 1031-1034.
- Ohkawa T, Volkman L E, Welch M D. 2010. Actin-based motility drives baculovirus transit to the nucleus and cell surface. J Cell Biol, 190: 187-195.
- Ohkawa T, Volkman L E. 1999. Nuclear F-Actin Is Required for AcMNPV Nucleocapsid Morphogenesis. Virology, 264: 1-4.
- Pollard T D, Borisy G G. 2003. Cellular motility driven by assembly and disassembly of actin filaments. Cell, 112: 453-465.
- Roberts P C, Compans R W. 1998. Host cell dependence of viral morphology. Proc Natl Acad Sci USA, 95: 5746-5751.
- Röttger S, Frischknecht F, Reckmann I, Smith G L, Way M. 1999. Interactions between vaccinia virus IEV membrane proteins and their roles in IEV assembly and actin tail formation. J Virol, 73: 2863-2875.
- Sánchez E G, Quintas A, Pérez-Núñez D, Nogal M, Barroso S, Carrascosa Á L, Revilla Y. 2012. African swine fever virus uses macropinocytosis to enter host cells. PLoS Pathog, 8: e1002754.
- Scaplehorn N, Holmström A, Moreau V, Frischknecht F, Reckmann I, Way M. 2002. Grb2 and Nck act cooperatively to promote actin-based motility of vaccinia virus. Curr Biol CB, 12: 740-745.
- Schelhaas M, Ewers H, Rajamaki M-L, Day P M, Schiller J T, Helenius A. 2008. Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog, 4: e1000148.
- Schelhaas M, Shah B, Holzer M, Blattmann P, Kühling L, Day P M, Schiller J T, Helenius A. 2012. Entry of Human Papillomavirus Type 16 by Actin-Dependent, Clathrin- and Lipid Raft-Independent Endocytosis. PLoS Pathog, 8: e1002657.
- Simpson-Holley M, Ellis D, Fisher D, Elton D, McCauley J, Digard P. 2002a. A functional link between the actin cytoskeleton and lipid rafts during budding of filamentous influenza virions. Virology, 301: 212-225.
- Simpson-Holley M, Ellis D, Fisher D, Elton D, McCauley J, Digard P. 2002b. A Functional Link between the Actin Cytoskeleton and Lipid Rafts during Budding of Filamentous Influenza Virions. Virology, 301: 212-225.
- Sowinski S, Jolly C, Berninghausen O, Purbhoo M A, Chauveau A, Köhler K, Oddos S, Eissmann P, Brodsky F M, Hopkins C, Onfelt B, Sattentau Q, Davis D M. 2008. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol, 10: 211-219.
- Spear M, Guo J, Turner A, Yu D, Wang W, Meltzer B, He S, Hu X, Shang H, Kuhn J, Wu Y. 2014. HIV-1 Triggers WAVE2 Phosphorylation in Primary CD4 T Cells and Macrophages, Mediating Arp2/3-dependent Nuclear Migration. J Biol Chem, 289: 6949-6959.
- Stallcup K C, Raine C S, Fields B N. 1983. Cytochalasin B inhibits the maturation of measles virus. Virology, 124: 59-74.
- Stokes G V. 1976. High-voltage electron microscope study of the release of vaccinia virus from whole cells. J Virol, 18: 636-643.
- Tilsner J, Linnik O, Wright K M, Bell K, Roberts A G, Lacomme C, Santa Cruz S, Oparka K J. 2012. The TGB1 movement protein of Potato virus X reorganizes actin and endomembranes into the X-body, a viral replication factory. Plant Physiol, 158: 1359-1370.
- Vasiliver-Shamis G, Cho M W, Hioe C E, Dustin M L. 2009. Human
Immunodeficiency Virus Type 1 Envelope gp120-Induced Partial T-Cell Receptor Signaling Creates an F-Actin-Depleted Zone in the Virological Synapse. J Virol, 83: 11341-11355. - Vasiliver-Shamis G, Tuen M, Wu T W, Starr T, Cameron T O, Thomson R, Kaur G, Liu J, Visciano M L, Li H, Kumar R, Ansari R, Han D P, Cho M W, Dustin M L, Hioe C E. 2008. Human
immunodeficiency virus type 1 envelope gp120 induces a stop signal and virological synapse formation in noninfected CD4+ T cells. J Virol, 82: 9445-9457. - Vorster P J, Guo J, Yoder A, Wang W, Zheng Y, Xu X, Yu D, Spear M, Wu Y. 2011.
LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection. J Biol Chem, 286: 12554-12564. - De Vries E, Tscherne D M, Wienholts M J, Cobos-Jimenez V, Scholte F, Garcia-Sastre A, Rottier PJM, de Haan CAM. 2011. Dissection of the Influenza A Virus Endocytic Routes Reveals Macropinocytosis as an Alternative Entry Pathway. PLoS Pathog, 7: e1001329.
- Wakimoto H, Shimodo M, Satoh Y, Kitagawa Y, Takeuchi K, Gotoh B, Itoh M. 2013. F-Actin Modulates Measles Virus Cell-Cell Fusion and Assembly by Altering the Interaction between the Matrix Protein and the Cytoplasmic Tail of Hemagglutinin. J Virol, 87: 1974-1984.
- Welch M D, Way M. 2013. Arp2/3-Mediated Actin-Based Motility: A Tail of Pathogen Abuse. Cell Host Microbe, 14: 242-255.
- Wen X, Ding L, Wang J-J, Qi M, Hammonds J, Chu H, Chen X, Hunter E, Spearman P. 2014. ROCK1 and LIM Kinase Modulate Retrovirus Particle Release and Cell-Cell Transmission Events. J Virol,; DOI: 10.1128/JVI.00023-14.
- Xiang Y, Zheng K, Zhong M, Chen J, Wang X, Wang Q, Wang S, Ren Z, Fan J, Wang Y. 2014. Ubiquitin-proteasome-
dependent slingshot 1 downregulation in neuronal cells inactivates cofilin to facilitate HSV-1 replication. Virology, 449: 88-95. - Yoder A, Yu D, Dong L, Iyer S R, Xu X, Kelly J, Liu J, Wang W, Vorster P J, Agulto L, Stephany D A, Cooper I N, Marsh J W, Wu Y. 2008. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell, 134: 782-792.
- Zheng K, Xiang Y, Wang Q, Jin F, Chen M, Ma K, Ren Z, Wang Y. 2014a. Calcium-signal facilitates herpes
simplex virus type 1 nuclear transport throughslingshot 1 and calpain-1 activation. Virus Res, 188C: 32-37. - Zheng K, Xiang Y, Wang X, Wang Q, Zhong M, Wang S, Wang X, Fan J, Kitazato K, Wang Y. 2014b. Epidermal growth factor receptor-PI3K signaling controls cofilin activity to facilitate
herpes simplex virus 1 entry into neuronal cells. mBio, 5: e00958-00913. - Actin and bacterial mobility: The cytoskeleton is a dynamic structure composed of microfilaments (filamentous actin or F-actin), intermediate filaments, and microtubules that are mainly responsible for defining cell shape, mediating motility, and transporting macromolecules and organelles. The actin cytoskeleton, in particular, has been shown to be the driving force for cell motility and migration [1]. As an integral component of intracellular molecular networks, the actin cytoskeleton is also a target for pathogens. It has been known that the human bacterial pathogens Listeria monocytogenes [2, 3] effectively uses the driving force generated from actin polymerization for mobility.
- Mattila and co-authors have suggested that actin regulates receptors through controlling receptor compartmentalization, receptor dynamics, and receptor clustering [4]. Actin cytoskeleton is also a point of integration for receptor cross talk through modulation of protein dynamics and clustering.
- Gowriskankar and coauthors [5] have also proposed a model in which active remodeling of cortical actin regulates spatiotemporal organization of cell surface molecules such as surface receptors. The authors classify surface molecules into 3 classes based on their relationship with the cortical actin—namely, inert surface molecules, passive surface molecules, and active surface molecules. The inert (e.g. short-chain lipids) and passive (e. g. transmembrane proteins with actin-binding domains) molecules on the cell surface can be driven to form transient nanoclusters by actin dynamics and local actin architecture. Many cell surface proteins can directly connect to the cytoplasmic actin using actin-binding motifs such as PDZ, SH3 (Src-or PRD (proline-rich domain). Active cell surface molecules (e.g. integrin and T cell receptors) are capable of interacting with actin and modifying its dynamics. These molecules can recruit molecules involved in actin remodulation. They can also be organized in microclusters by actin-dependent processes.
- The instant actin-based peptides can modulate cell surface molecules and receptors through promoting or inhibiting actin dynamics.
- For example, and in no way limiting, the instant actin-based peptides can modulate cancer receptors. A review article describing the most important cancer receptors is A. M. Scott et al., Antibody therapy of cancer, Nature Reviews Cancer, Vol. 12, APRIL 2012, 278-287. Table 2 in the article lists important receptors that can be targeted for therapy (e.g, CD20, CD30, CD33, CD52, EpCAM, CEA, gpA33, Mucins, TAG-72, CAIX, PSMA, VEGF, VEGFR, EGFR, Integrin αVβ3, Integrin α5β3, ERBB2, ERBB3, EPHA3, TRAILR1, RANKL, FAP, Tenascin)
-
- [1]. Pollard T D, Borisy G G. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003; 112(4):453-65. PubMed PMID: 12600310.
- [2]. Loisel T P, Boujemaa R, Pantaloni D, Carlier M E. Reconstitution of actin-based motility of Listeria and Shigella using pure proteins. Nature. 1999; 401(6753):613-6. PubMed PMID: 10524632.
- [3]. Cameron L A, Giardini P A, Soo F S, Theriot J A. Secrets of actin-based motility revealed by a bacterial pathogen. Nat Rev Mol Cell Biol. 2000; 1(2):110-9. PubMed PMID: 11253363.
- [4]. Mattila P K, Batista F D, Treanor B. Dynamics of the actin cytoskeleton mediates receptor cross talk: An emerging concept in tuning receptor signaling. J Cell Biol. 2016; 212(3):267-80. doi: 10.1083/jcb.201504137. PubMed PMID: 26833785; PMCID: PMC4748574.
- [5]. Gowrishankar K, Ghosh S, Saha S, C R, Mayor S, Rao M. Active remodeling of cortical actin regulates spatiotemporal organization of cell surface molecules. Cell. 2012; 149(6):1353-67. doi: 10.1016/j.cell.2012.05.008. PubMed PMID: 22682254.
- The instant actin-based peptides provide anti-inflammatory/inhibit cheomotaxis: Actin polymerization is the major driving force for the chemotaxis of immune cells. It is known that inhibiting actin polymerization inhibits chemotaxis, which is required for the inflammatory responses of immune cells. The instant actin-based peptides can interfere with actin polymerization process, and may possess anti-inflammatory properties.
-
- 1. Felgner P L, Gadek T R, Holm M, Roman R, Chan H W, Wenz M, Northrop J P, Ringold G M, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987; 84(21):7413-7. PubMed PMID: 2823261; PMCID: PMC299306.
- Illustrative Examples are presented below. They are exemplary and non-limiting.
- As exemplified in
FIG. 1 andFIG. 2 , the amino acid (AA) sequence of human beta-actin, which has 375 amino acids (L=375), can be divided into multiple overlapping fragments (in L- or D-form peptides) with various lengths (P). The total number of peptides (N) can be generated will be: N=L-P, where N=total number of peptides that could be generated, L=the number of amino acids in an actin protein isoform. P=the number of amino acids in an actin peptide, P can be from 2 amino acids to (L-1) amino acids. As exemplified inFIG. 1A , human beta-actin can be divided into multiple peptides (N=375-20=350) of 20 AA in length. These peptides can be chemically conjugated to a cell penetration peptide or member-permeable molecules (either in the N terminus or the C terminus) for intracellular delivery (FIG. 1B ). Conjugation is well known in the chemical arts, and can occur by any art-accepted method. - In screening a peptide library (
FIG. 1C ), multiple peptides including Peptide N7 and N9 were identified that can drastically enhance HIV infection of human T cells (FIG. 1C ). As shown inFIG. 3 , the actin-based peptides N7 and N9 enhance HIV infection. The HIV Rev-dependent indicator cell, Rev-CEM-GFP, was not infected (+Cell) or infected with HIV-1 (+HIV), or pre-treated with peptide N7, and then infected with HIV-1 (N7+HIV). Following infection for 2 hours, cells were washed to remove the virus and the peptide. Viral replication was measured at 2 days post infection by flow cytometry. - N7 enhances HIV infection from 0.79% to 15.5%, as measured by the percentage of GFP+ cells. PI, propidium iodide, was added before flow cytometry for cytotoxicity control. GFP+ cells were counted only when the cells are viable (low PI staining).
- Similar effects were observed and measured for peptide N9. N9 enhanced HIV infection from 1.95% to 14.07%.
- As shown in
FIG. 4 , exposure of T cells to Peptide N7 was also found to drastically up-regulate the surface CXCR4 receptors, while there were a moderate up-regulation of the surface CD4 receptor (FIG. 4 ). Mechanistic studies revealed that Peptide N7 briefly triggers cofilin activation and actin depolymerization (FIG. 5 ), likely causing a transient breakage of the cortical actin layer, leading to higher levels of surface receptors, HIV viral entry, viral DNA synthesis, and nuclear migration (FIG. 6 ). -
-
- 1) Culture human CEM-SS T cells at 5×105 cells/ml
- 2) Add peptide N7 to the cell to a final concentration of 10 uM at various times from 5 min to 120 min (e. g. 5, 10, 15, 30, 45, 60, 120 min).
- 3) Take out 1-2×105 cells, put on ice, perform routine surface staining using FITC-, PE- or PE-cy5-labelled specific antibodies against cell receptors as recommended by the reagent manufacturer for cell surface staining.
- 4) Analyzed the staining by flow cytometer.
- Resting memory CD4 T cells were treated with N7 for a time course, and cofilin phosphorylation was measured by Western Blot. Total cofilin and GAPDH was also measured for loading control (
FIG. 5A ). Resting CD4 T cells were treated with N9, and actin polymerization and depolymerization were measured by FITC-phalloidin staining (FIG. 5B ). SeeFIG. 5 . - As shown in
FIG. 6 , peptide N7 and N9 enhance HIV DNA synthesis, nuclear migration, and integration. CEM-SS T cells were treated with N7 during HV infection for 2 hours, washed, and then analyzed for viral DNA synthesis and 2-LTR circles, a marker for HIV nuclear migration. SeeFIG. 6(A) . Blood resting CD4 T cells were similar infected, washed, and cultured without T cell activation. Viral DNA synthesis and DNA integration were analyzed. SeeFIG. 6(B) . - The ability of N9 to stimulate HIV infection of blood resting CD4 T cells was also tested. Resting CD4 T cells are relatively resistant to HIV infection. The lack of activity in the cortical actin limits viral early steps in the infection of resting T cells (Yoder et al., 2008). As shown in
FIG. 7 , a single-dosage N9 treatment prior to HIV infection drastically stimulated HIV infection of resting T cells. Importantly, this enhancement occurs in the absence of T cell activation or cytokine stimulation, and N9 is more potent at early time in stimulating viral infection than certain cytokines such as IL-7 (administered daily). - Assay Protocols for Using Peptides of the Invention
-
-
- 1) Culture human T cell in growth medium
- 2) Take 1-2×106 cells, resuspend into 2×106 per ml
- 3) Add actin-peptides to cell to a final concentration of 10 uM
- 4) Incubate for 1-2 hours
- 5) Add viruses (e. g. 100-500 ul), and then add additional amount of actin-peptide to maintain the final concentration to 10 uM
- 6) Infect cells for 1-4 hours
- 7) Wash cells to remove the virus and the peptide
- 8) Culture for 1-7 days post infection to monitor viral replication.
-
-
- 1) Take 0.5×105 cells, resuspend into 100 ul medium
- 2) Treat cells with actin-peptide for 1-2 hours
- 3) Add cells to the upper chamber of a 24-well transwell plate (coming)
- 4) The lower chamber is filled with 600 ul medium premixed with SDF-1 (40 ng/ml).
- 5) Incubate the plate at 37° C. for 2 hours
- 6) The upper chamber was removed, and cells in the lower chamber was counted.
- We found that treatment of human T lymphoma cells with N10 led to the killing of T cells (
FIG. 8 ).FIG. 8 shows human T lymphoblast cell A3.01 was treated with N10 (10 uM). N10-mediated cell killing was monitored by staining of dead cells with Propidium iodide and FITC-labelled Annexin V. Cells were analyzed by flow cytometry. -
-
- 5) Culture human A3.01 cells at 5×105 cells/ml
- 6) Add peptide N10 to the cell to a final concentration of 10 uM
- 7) Continue to culture cell at 37° C., maintain cell density below 1×106 cells/ml
- 8) Take out 1-2×105 cells, put on ice, add P.I., and FITC-Annexin V as recommended by the reagent manufacturer for dead/apoptotic cell staining.
- 9) Analyzed the staining by flow cytometer.
-
- Kotsakis, A., Pomeranz, L. E., Blouin, A., and Blaho, J. A. (2001). Microtubule reorganization during herpes
simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein. J Virol 75, 8697-8711. - Pollard, T. D., and Borisy, G. G. (2003). Cellular motility driven by assembly and disassembly of actin filaments. Cell 112, 453-465.
- Spear, M., Guo, J., and Wu, Y. (2012). The trinity of the cortical actin in the initiation of HIV-1 infection.
Retrovirology - Spear, M., Guo, J., and Wu, Y. (2013). Novel anti-HIV therapeutics targeting chemokine receptors and actin regulatory pathways. Immunological Reviews DOl: 10.11llimr.12106.
- Taylor, M. P., Koyuncu, 0.0., and Enquist, L. W. (2011). Subversion of the actin cytoskeleton during viral infection.
Nat Rev Microbiol 9, 427-439. - Wulfing, C., and Davis, M. M. (1998). A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science 282, 2266-2269.
- Yoder, A., Yu, D., Dong, L., Iyer, S. R., Xu, X., Kelly, J., Liu, J., Wang, W., Vorster, P. J., Agulto, L., et al. (2008). HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134, 782-792.
- The following sequences are essentially derived from the core domains of the actin-based bioactive peptides: NB5 (SEQ ID NO: 853), NB7 (SEQ ID NO: 854), NB9 (SEQ ID NO: 855), NB10 (SEQ ID NO: 856), B11 (SEQ ID NO: 857), B17 (SEQ ID NO: 858) (
FIG. 2 ). These include 40 AA centered around each core domain, also all the possible 20 AA that can be derived around the core domain, and all the possible 10 AA that can be derived around the core domain. Also listed are multiple mutations on the 40AA, 20 AA, and 10 AA (X, X0 equal all possible AA). - (G/A)0-20=0 to 20 amino acids of either G or A in each position.
-
- X0=any one of the natural and un-natural amino acids.
- X=any one of the natural and un-natural amino acids.
The amino acid in any of the position in all of the sequences can be replaced by an amino acid that belongs to the same amino acid group as listed in Table 1. (Table 1,Group 1=R, H, K;Group 2=D, E;Group 3=S, T, N, Q;Group 4=A, I, L, M, F, W, Y, V;Group 5=C, U, G, P)
-
TABLE 1 Twenty-One Amino Acids Group 1 Amino acids with positively R = Arginine (Arg) charged side chain H = Histidine (His) K = Lysine (Lys) Group 2Amino acids with negatively D = Aspartic acid (Asp) charged side chain E = Glutamic acid (Glu) Group 3Amino acids with polar S = Serine (Ser) uncharged side chain T = Threonine (Thr) N = Asparagine (Asn) Q = Glutamine (Gln) Group 4Amino acids with hydrophobic A = Alanine (Ala) side chain I = Isoleucine (Ile) L = Leucine (Leu) M = Methionine (Met) F = Phenylalanine (Phe) W = Tryptophan (Trp) Y = Tyrosine (Tyr) V = Valine (Val) Group 5Amino acids with special cases C = Cysteine (Cys) U = Selenocysteine (Sec) G = Glycine (Gly) P = Proline (Pro) -
-
ID (Name) Peptide sequence (N to C) SEQ ID NO: 1 (NB5-core): RRRRRRRR(G/A)0-20YNELRVAPEE SEQ ID NO: 2 (NB7-core): RRRRRRRR(G/A)0-20QIMFETFNTP SEQ ID NO: 3 (NB9-core): RRRRRRRR(G/A)0-20LPHAILRLDL SEQ ID NO: 4 (NB10-core): RRRRRRRR(G/A)0-20AGRDLTDYLM SEQ ID NO: 5 (B11-core): RRRRRRRR(G/A)0-20LCYVALDFEQ SEQ ID NO: 6 (B17-core): RRRRRRRR(G/A)0-20KYSVWIGGSI SEQ ID NO: 7 (B5-20AA): RRRRRRRR(G/A)0-20YNELRVAPEEHPVLLTEAPL SEQ ID NO: 8 (B6-20AA): RRRRRRRR(G/A)0-20NPKANREKMTQIMFETFNTP SEQ ID NO: 9 (N7-20AA): RRRRRRRR(G/A)0-20QIMFETFNTPAMYVAIQAVL SEQ ID NO: 10 (N9-20AA): RRRRRRRR(G/A)0-20HTVPIYEGYALPHAILRLDL SEQ ID NO: 11 (B9-20AA): RRRRRRRR(G/A)0-20LPHAILRLDLAGRDLTDYLM SEQ ID NO: 12 (N10-20AA): RRRRRRRR(G/A)0-20AGRDLTDYLMKILTERGYSF SEQ ID NO: 13 (B11-20AA): RRRRRRRR(G/A)0-20DIKEKLCYVALDFEQEMATA SEQ ID NO: 14 (B17-20AA): RRRRRRRR(G/A)0-20APPERKYSVWIGGSILASLS SEQ ID NO: 15 (NB5-V1): (X)0-20(X)NELRVAPEE(X)0-20 SEQ ID NO: 16 (NB5-V2): (G/A)0-20Y(X)ELRVAREE(G/A)0-20 SEQ ID NO: 17 (NB5-V3): (G/A)0-20YN(X)LRVAPEE(G/A)0-20 SEQ ID NO: 18 (NB5-V4): (G/A)0-20YNE(X)RVAPEE(G/A)0-20 SEQ ID NO: 19 (NB5-V5): (G/A)0-20YNEL(X)VAPEE(G/A)0-20 SEQ ID NO: 20 (NB5-V6): (G/A)0-20YNELR(X)APEE(G/A)0-20 SEQ ID NO: 21 (NB5-V7): (G/A)0-20YNELRV(X)PEE(G/A)0-20 SEQ ID NO: 22 (NB5-V8): (G/A)0-20YNELRVA(X)EE(G/A)0-20 SEQ ID NO: 23 (NB5-V9): (G/A)0-20YNELRVAP(X)E(G/A)0-20 SEQ ID NO: 24 (NB5-V10): (G/A)0-20YNELRVAPE(X)(G/A)0-20 SEQ ID NO: 25 (B5-NV2): (X)0-20WHHTFYNELR(X)0-20 SEQ ID NO: 26 (B5-NV2): (G/A)0-20W(X)HTFYNELR(G/A)0-20 SEQ ID NO: 27 (B5-NV3): (G/A)0-20WH(X)TFYNELR(G/A)0-20 SEQ ID NO: 28 (B5-NV4): (G/A)0-20WHH(X)FYNELR(G/A)0-20 SEQ ID NO: 29 (B5-NV5): (G/A)0-20WHHT(X)YNELR(G/A)0-20 SEQ ID NO: 30 (B5-NV6): (G/A)0-20WHHTF(X)NELR(G/A)0-20 SEQ ID NO: 31 (B5-NV7): (G/A)0-20WHHTFY(X)ELR(G/A)0-20 SEQ ID NO: 32 (B5-NV8): (G/A)0-20WHHTFYN(X)LR(G/A)0-20 SEQ ID NO: 33 (B5-NV9): (G/A)0-20WHHTFYNE(X)R(G/A)0-20 SEQ ID NO: 34 (B5-NV10): (G/A)0-20WHHTFYNEL(X)(G/A)0-20 SEQ ID NO: 35 (B5-N1): (G/A)0-20VTNWDDMEKI(G/A)0-20 SEQ ID NO: 36 (B5-N2): (G/A)0-20TNWDDMEKIW(G/A)0-20 SEQ ID NO: 37 (B5-N3): (G/A)0-20NWDDMEKIWH(G/A)0-20 SEQ ID NO: 38 (B5-N4): (G/A)0-20WDDMEKIWHH(G/A)0-20 SEQ ID NO: 39 (B5-N5): (G/A)0-20DDMEKIWHHT(G/A)0-20 SEQ ID NO: 40 (B5-N6): (G/A)0-20DMEKIWHHTF(G/A)0-20 SEQ ID NO: 41 (B5-N7): (G/A)0-20MEKIWHHTFY(G/A)0-20 SEQ ID NO: 42 (B5-N8): (G/A)0-20EKIWHHTFYN(G/A)0-20 SEQ ID NO: 43 (B5-N9): (G/A)0-20KIWHHTFYNE(G/A)0-20 SEQ ID NO: 44 (B5-N10): (G/A)0-20IWHHTFYNEL(G/A)0-20 SEQ ID NO: 45 (B5-N11): (G/A)0-20WHHTFYNELR(G/A)0-20 SEQ ID NO: 46 (B5-N12): (G/A)0-20HHTFYNELRV(G/A)0-20 SEQ ID NO: 47 (B5-N13): (G/A)0-20HTFYNELRVA(G/A)0-20 SEQ ID NO: 48 (B5-N14): (G/A)0-20TFYNELRVAP(G/A)0-20 SEQ ID NO: 49 (B5-N15): (G/A)0-20FYNELRVAPE(G/A)0-20 SEQ ID NO: 50 (B5-N16): (G/A)0-20YNELRVAPEE(G/A)0-20 SEQ ID NO: 51 (B5-N17): (G/A)0-20NELRVAPEEH(G/A)0-20 SEQ ID NO: 52 (B5-N18): (G/A)0-20ELRVAPEEHP(G/A)0-20 SEQ ID NO: 53 (B5-N19): (G/A)0-20LRVAPEEHPV(G/A)0-20 SEQ ID NO: 54 (B5-N20): (G/A)0-20RVAPEEHPVL(G/A)0-20 SEQ ID NO: 55 (B5-N21): (G/A)0-20VAPEEHPVLL(G/A)0-20 SEQ ID NO: 56 (B5-N22): (G/A)0-20APEEHPVLLT(G/A)0-20 SEQ ID NO: 57 (B5-N23): (G/A)0-20PEEHPVLLTE(G/A)0-20 SEQ ID NO: 58 (B5-N24): (G/A)0-20EEHPVLLTEA(G/A)0-20 SEQ ID NO: 59 (B5-N25): (G/A)0-20EHPVLLTEAP(G/A)0-20 SEQ ID NO: 60 (B5-N26): (G/A)0-20HPVLLTEAPL(G/A)0-20 SEQ ID NO: 61 (B5-N27): (G/A)0-20PVLLTEAPLN(G/A)0-20 SEQ ID NO: 62 (B5-N28): (G/A)0-20VLLTEAPLNP(G/A)0-20 SEQ ID NO: 63 (B5-N29): (G/A)0-20LLTEAPLNPK(G/A)0-20 SEQ ID NO: 64 (B5-N30): (G/A)0-20LTEAPLNPKA(G/A)0-20 SEQ ID NO: 65 (B5-N31): (G/A)0-20TEAPLNPKANG/A)0-20 SEQ ID NO: 66 (B5-M2): (G/A)0-20EHGIVTNWDDMEKIWHHTFY(G/A)0-20 SEQ ID NO: 67 (B5-M3): (G/A)0-20HGIVTNWDDMEKIWHHTFYN(G/A)0-20 SEQ ID NO: 68 (B5-M4): (G/A)0-20GIVTNWDDMEKIWHHTFYNE(G/A)0-20 SEQ ID NO: 69 (B5-M5): (G/A)0-20IVTNWDDMEKIWHHTFYNEL(G/A)0-20 SEQ ID NO: 70 (B5-M6): (G/A)0-20NTNWDDMEKIWHHTFYNELR(G/A)0-20 SEQ ID NO: 71 (B5-M7): (G/A)0-20TNWDDMEKIWHHTFYNELRV(G/A)0-20 SEQ ID NO: 72 (B5-M8): (G/A)0-20NWDDMEKIWHHTFYNELRVA(G/A)0-20 SEQ ID NO: 73 (B5-M9): (G/A)0-20WDDMEKIWHHTFYNELRVAP(G/A)0-20 SEQ ID NO: 74 (B5-M10): (G/A)0-20DDMEKIWHHTFYNELRVAPE(G/A)0-20 SEQ ID NO: 75 (B5) (G/A)0-20DMEKIWHHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 76 (B5-P1): (G/A)0-20MEKIWHHTFYNELRVAPEEH(G/A)0-20 SEQ ID NO: 77 (B5-P2): (G/A)0-20EKIWHHTFYNELRVAPEEHP(G/A)0-20 SEQ ID NO: 78 (B5-P3): (G/A)0-20KIWHHTFYNELRVAPEEHPV(G/A)0-20 SEQ ID NO: 79 (B5-P4): (G/A)0-20IWHHTFYNELRVAPEEHPVL(G/A)0-20 SEQ ID NO: 80 (B5-P5): (G/A)0-20WHHTFYNELRVAPEEHPVLL(G/A)0-20 SEQ ID NO: 81 (B5-P6): (G/A)0-20HHTFYNELRVAPEEHPVLLT(G/A)0-20 SEQ ID NO: 82 (B5-P7): (G/A)0-20HTFYNELRVAPEEHPVLLTE(G/A)0-20 SEQ ID NO: 83 (B5-P8): (G/A)0-20TFYNELRVAPEEHPVLLTEA(G/A)0-20 SEQ ID NO: 84 (B5-P9): (G/A)0-20FYNELRVAPEEHPVLLTEAP(G/A)0-20 SEQ ID NO: 85 (B5-P10): (G/A)0-20YNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 86 (B5-V1): (G/A)0-20(X)MEKIWHHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 87 (B5-V2): (G/A)0-20D(X)EKIWHHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 88 (B5-V3): (G/A)0-20DM(X)KIWHHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 89 (B5-V4): (G/A)0-20DME(X)IWHHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 90 (B5-V5): (G/A)0-20DMEK(X)WHHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 91 (B5-V6): (G/A)0-20DMEKI(X)HHTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 92 (B5-V7): (G/A)0-20DMEKIW(X)HTFYNELRVAPEE(G/A)0-20 SEQ ID NO: 93 (B5-V8): (G/A)0-20DMEKIWH(X)TFYNELRVAPEE(G/A)0-20 SEQ ID NO: 94 (B5-V9): (G/A)0-20DMEKIWHH(X)FYNELRVAPEE(G/A)0-20 SEQ ID NO: 95 (B5-V10): (G/A)0-20DMEKIWHHT(X)YNELRVAPEE(G/A)0-20 SEQ ID NO: 96 (B5-V11): (G/A)0-20DMEKIWHHTF(X)NELRVAPEE(G/A)0-20 SEQ ID NO: 97 (B5-V12): (G/A)0-20DMEKIWHHTFY(X)ELRVAPEE(G/A)0-20 SEQ ID NO: 98 (B5-V13): (G/A)0-20DMEKIWHHTFYN(X)LRVAPEE(G/A)0-20 SEQ ID NO: 99 (B5-X1): (G/A)0-20(X)EHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 100 (B5-X2): (G/A)0-20I(X)HGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 101 (B5-X3): (G/A)0-20IE(X)GIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 102 (B5-X4): (G/A)0-20IEH(X)IVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 103 (B5-X5): (G/A)0-20IEHG(X)VTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 104 (B5-X6): (G/A)0-20IEHGI(X)TNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 105 (B5-X7): (G/A)0-20IEHGIV(X)NWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 106 (B5-X8): (G/A)0-20IEHGIVT(X)WDDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 107 (B5-X9): (G/A)0-20IEHGIVTN(X)DDMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 108 (B5-X10): (G/A)0-20IEHGIVTNW(X)DMEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 109 (B5-X11): (G/A)0-20IEHGIVTNWD(X)MEKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 110 (B5-X12): (G/A)0-20IEHGIVTNWDD(X)EKIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 111 (B5-X13): (G/A)0-20IEHGIVTNWDDM(X)KIWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 112 (B5-X14): (G/A)0-20IEHGIVTNWDDME(X)IWHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 113 (B5-X15): (G/A)0-20IEHGIVTNWDDMEK(X)WHHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 114 (B5-X16): (G/A)0-20IEHGIVTNWDDMEKI(X)HHTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 115 (B5-X17): (G/A)0-20IEHGIVTNWDDMEKIW(X)HTFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 116 (B5-X18): (G/A)0-20IEHGIVTNWDDMEKIWH(X)TFYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 117 (B5-X19): (G/A)0-20IEHGIVTNWDDMEKIWHH(X)FYNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 118 (B5-X20): (G/A)0-20IEHGIVTNWDDMEKIWHHT(X)YNELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 119 (B5-X21): (G/A)0-20IEHGIVTNWDDMEKIWHHTF(X)NELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 120 (B5-X22): (G/A)0-20IEHGIVTNWDDMEKIWHHTFY(X)ELRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 121 (B5-X23): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYN(X)LRVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 122 (B5-X24): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNE(X)RVAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 123 (B5-X25): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNEL(X)VAPEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 124 (B5-X26): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELR(X)APEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 125 (B5-X27): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRV(X)PEEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 126 (B5-X28): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVA(X)EEHPVLLTEAPL(G/A)0-20 SEQ ID NO: 127 (B5-X29): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAP(X)EHPVLLTEAPL(G/A)0-20 SEQ ID NO: 128 (B5-X30): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPE(X)HPVLLTEAPL(G/A)0-20 SEQ ID NO: 129 (B5-X31): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEE(X)PVLLTEAPL(G/A)0-20 SEQ ID NO: 130 (B5-X32): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEH(X)VLLTEAPL(G/A)0-20 SEQ ID NO: 131 (B5-X33): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHP(X)LLTEAPL(G/A)0-20 SEQ ID NO: 132 (B5-X34): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPV(X)LTEAPL(G/A)0-20 SEQ ID NO: 133 (B5-X35): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVL(X)TEAPL(G/A)0-20 SEQ ID NO: 134 (B5-X36): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVIL(X)EAPL(G/A)0-20 SEQ ID NO: 135 (B5-X37): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVILT(X)APL(G/A)0-20 SEQ ID NO: 136 (B5-X38): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVILTE(X)PL(G/A)0-20 SEQ ID NO: 137 (B5-X39): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVILTEA(X)L(G/A)0-20 SEQ ID NO: 138 (B5-X40): (G/A)0-20IEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVILTEAP(X)(G/A)0-20 SEQ ID NO: 139 (NB7-V1): (X)0-20(X)IMFETENTP(X)0-20 SEQ ID NO: 140 (NB7-V2): (G/A)0-20Q(X)MFETENTP(G/A)0-20 SEQ ID NO: 141 (NB7-V3): (G/A)0-20QI(X)FETFNTP(G/A)0-20 SEQ ID NO: 142 (NB7-V4): (G/A)0-20QIM(X)ETFNTP(G/A)0-20 SEQ ID NO: 143 (NB7-V5): (G/A)0-20QIMF(X)TFNTP(G/A)0-20 SEQ ID NO: 144 (NB7-V6): (G/A)0-20QIMFE(X)FNTP(G/A)0-20 SEQ ID NO: 145 (NB7-V7): (G/A)0-20QIMFET(X)NTP(G/A)0-20 SEQ ID NO: 146 (NB7-V8): (G/A)0-20QIMFETF(X)TP(G/A)0-20 SEQ ID NO: 147 (NB7-V9): (G/A)0-20QIMFETFN(X)P(G/A)0-20 SEQ ID NO: 148 (NB7-V10): (G/A)0-20QIMFETFNT(X)(G/A)0-20 SEQ ID NO: 149 (N7-NX1): (X)0-20TFN(X0)PAMYVA(X)0-20 SEQ ID NO: 150 (N7-NX1): (G/A)0-20(X)FN(X0)PAMYVA(G/A)0-20 SEQ ID NO: 151 (N7-NX2): (G/A)0-20T(X)N(X0)PAMYVA(G/A)0-20 SEQ ID NO: 152 (N7-NX3): (G/A)0-20TF(X)(X0)PAMYVA(G/A)0-20 SEQ ID NO: 153 (N7-NX4): (G/A)0-20TFN(X0)(X)AMYVA(G/A)0-20 SEQ ID NO: 154 (N7-NX5): (G/A)0-20TFN(X0)P(X)MYVA(G/A)0-20 SEQ ID NO: 155 (N7-NX6): (G/A)0-20TFN(X0)PA(X)YVA(G/A)0-20 SEQ ID NO: 156 (N7-NX7): (G/A)0-20TFN(X0)PAM(X)VA(G/A)0-20 SEQ ID NO: 157 (N7-NX8): (G/A)0-20TFN(X0)PAMY(X)A(G/A)0-20 SEQ ID NO: 158 (N7-NX9): (G/A)0-20TFN(X0)PAMYV(X)(G/A)0-20 SEQ ID NO: 159 (N7-T1): (G/A)0-20TEAPLNPKAN(G/A)0-20 SEQ ID NO: 160 (N7-T2): (G/A)0-20EAPLNPKANR(G/A)0-20 SEQ ID NO: 161 (N7-T3): (G/A)0-20APLNPKANRE(G/A)0-20 SEQ ID NO: 162 (N7-T4): (G/A)0-20PLNPKANREK(G/A)0-20 SEQ ID NO: 163 (N7-T5): (G/A)0-20LNPKANREKM(G/A)0-20 SEQ ID NO: 164 (N7-T6): (G/A)0-20NPKANREKMT(G/A)0-20 SEQ ID NO: 165 (N7-T7): (G/A)0-20PKANREKMTQ(G/A)0-20 SEQ ID NO: 166 (N7-T8): (G/A)0-20KANREKMTQI(G/A)0-20 SEQ ID NO: 167 (N7-T9): (G/A)0-20ANREKMTQIM(G/A)0-20 SEQ ID NO: 168 (N7-T10): (G/A)0-20NREKMTQIMF(G/A)0-20 SEQ ID NO: 169 (N7-T11): (G/A)0-20REKMTQIMFE(G/A)0-20 SEQ ID NO: 170 (N7-T12): (G/A)0-20EKMTQIMFET(G/A)0-20 SEQ ID NO: 171 (N7-T13): (G/A)0-20KMTQIMFETF(G/A)0-20 SEQ ID NO: 172 (N7-T14): (G/A)0-20MTQIMFETFN(G/A)0-20 SEQ ID NO: 173 (N7-T15): (G/A)0-20TQIMFETFN(X0)(G/A)0-20 SEQ ID NO: 174 (N7-T16): (G/A)0-20QIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 175 (N7-T17): (G/A)0-20IMFETFN(X0)PA(G/A)0-20 SEQ ID NO: 176 (N7-T18): (G/A)0-20MFETFN(X0)PAM(G/A)0-20 SEQ ID NO: 177 (N7-T19): (G/A)0-20FETFN(X0)PAMY(G/A)0-20 SEQ ID NO: 178 (N7-T20): (G/A)0-20ETFN(X0)PAMYV(G/A)0-20 SEQ ID NO: 179 (N7-T21): (G/A)0-20TFN(X0)PAMYVA(G/A)0-20 SEQ ID NO: 180 (N7-T22): (G/A)0-20FN(X0)PAMYVAI(G/A)0-20 SEQ ID NO: 181 (N7-T23): (G/A)0-20N(X0)PAMYVAIQ(G/A)0-20 SEQ ID NO: 182 (N7-T24): (G/A)0-20(X0)PAMYVAIQA(G/A)0-20 SEQ ID NO: 183 (N7-T25): (G/A)0-20PAMYVAIQAV(G/A)0-20 SEQ ID NO: 184 (N7-T26): (G/A)0-20AMYVAIQAVL(G/A)0-20 SEQ ID NO: 185 (N7-T27): (G/A)0-20MYVAIQAVLS(G/A)0-20 SEQ ID NO: 186 (N7-T28): (G/A)0-20YVAIQAVLSL(G/A)0-20 SEQ ID NO: 187 (N7-T29): (G/A)0-20VAIQAVLSLY(G/A)0-20 SEQ ID NO: 188 (N7-T30): (G/A)0-20AIQAVLSLYA(G/A)0-20 SEQ ID NO: 189 (N7-T31): (G/A)0-20IQAVLSLYAS(G/A)0-20 SEQ ID NO: 190 (N7-T32): (G/A)0-20QAVLSLYASG(G/A)0-20 SEQ ID NO: 191 (N7-M1): (G/A)0-20TEAPLNPKANREKMTQIMFE(G/A)0-20 SEQ ID NO: 192 (N7-M2): (G/A)0-20DEAPLNPKANREKMTQIMFET(G/A)0-20 SEQ ID NO: 193 (N7-M3): (G/A)0-20DAPLNPKANREKMTQIMFETF(G/A)0-20 SEQ ID NO: 194 (N7-M4): (G/A)0-20PLNPKANREKMTQIMFETFN(G/A)0-20 SEQ ID NO: 195 (N7-M5): (G/A)0-20LNPKANREKMTQIMFETFN(X0)(G/A)0-20 SEQ ID NO: 196 (N7-M6): (G/A)0-20NPKANREKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 197 (N7-M7): (G/A)0-20PKANREKMTQIMFETFN(X0)PA(G/A)0-20 SEQ ID NO: 198 (N7-M8): (G/A)0-20KANREKMTQIMFETFN(X0)PAM(G/A)0-20 SEQ ID NO: 199 (N7-M9): (G/A)0-20ANREKMTQIMFETFN(X0)PAMY(G/A)0-20 SEQ ID NO: 200 (N7-M10): (G/A)0-20NREKMTQIMFETFN(X0)PAMYV(G/A)0-20 SEQ ID NO: 201 (N7-M11): (G/A)0-20REKMTQIMFETFN(X0)PAMYVAG/A)0-20 SEQ ID NO: 202 (N7-M12): (G/A)0-20EKMTQIMFETFN(X0)PAMYVAI(G/A)0-20 SEQ ID NO: 203 (N7-M13): (G/A)0-20KMTQIMFETFN(X0)PAMYVAIQ(G/A)0-20 SEQ ID NO: 204 (N7-M14): (G/A)0-20MTQIMFETFN(X0)PAMYVAIQA(G/A)0-20 SEQ ID NO: 205 (N7-M15): (G/A)0-20TQIMFETFN(X0)PAMYVAIQAV(G/A)0-20 SEQ ID NO: 206 (N7): (G/A)0-20QIMFETFN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 207 (N7-P1): (G/A)0-20IMFETEN(X0)PAMYVAIQAVLS(G/A)0-20 SEQ ID NO: 208 (N7-P2): (G/A)0-20MFETFN(X0)PAMYVAIQAVLSL(G/A)0-20 SEQ ID NO: 209 (N7-P3): (G/A)0-20FETFN(X0)PAMYVAIQAVLSLY(G/A)0-20 SEQ ID NO: 210 (N7-P4): (G/A)0-20ETEN(X0)PAMYVAIQAVLSLYA(G/A)0-20 SEQ ID NO: 211 (N7-P5): (G/A)0-20TFN(X0)PAMYVAIQAVLSLYAS(G/A)0-20 SEQ ID NO: 212 (N7-V1): (G/A)0-20(X)QIMFETFN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 213 (N7-V2): (G/A)0-200Q(X)IMFETFN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 214 (N7-V3): (G/A)0-20QI(X)MFETFN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 215 (N7-V4): (G/A)0-200QIM(X)FETFN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 216 (N7-V5): (G/A)0-20QIMF(X)ETFN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 217 (N7-V6): (G/A)0-20QIMFE(X)TEN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 218 (N7-V7): (G/A)0-20QIMFET(X)FN(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 219 (N7-V8): (G/A)0-20QIMFETF(X)N(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 220 (N7-V9): (G/A)0-20QIMFETFN(X)(X0)PAMYVAIQAVL(G/A)0-20 SEQ ID NO: 221 (N7-V10): (G/A)0-20QIMFETFN(X0)P(X)AMYVAIQAVL(G/A)0-20 SEQ ID NO: 222 (N7-V11): (G/A)0-20QIMFETFN(X0)PA(X)MYVAIQAVL(G/A)0-20 SEQ ID NO: 223 (N7-V12): (G/A)0-20QIMFETFN(X0)PAM(X)YVAIQAVL(G/A)0-20 SEQ ID NO: 224 (N7-V13): (G/A)0-20QIMFETFN(X0)PAMY(X)VAIQAVL(G/A)0-20 SEQ ID NO: 225 (N7-V14): (G/A)0-20QIMFETFN(X0)PAMYV(X)AIQAVL(G/A)0-20 SEQ ID NO: 226 (N7-V15): (G/A)0-20QIMFETFN(X0)PAMYVA(X)IQAVL(G/A)0-20 SEQ ID NO: 227 (N7-V16): (G/A)0-20QIMFETFN(X0)PAMYVAI(X)QAVL(G/A)0-20 SEQ ID NO: 228 (N7-V17): (G/A)0-20QIMFETFN(X0)PAMYVAIQ(X)AVL(G/A)0-20 SEQ ID NO: 229 (N7-V18): (G/A)0-20QIMFETFN(X0)PAMYVAIQA(X)VL(G/A)0-20 SEQ ID NO: 230 (N7-V19): (G/A)0-20QIMFETFN(X0)PAMYVAIQAV(X)L(G/A)0-20 SEQ ID NO: 231 (N7-V20): (G/A)0-20QIMFETFNX0)PAMYVAIQAVL(X)(G/A)0-20 SEQ ID NO: 232 (N7-X1): (G/A)0-20(X)PKANREKMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 233 (N7-X2): (G/A)0-20N(X)KANREKMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 234 (N7-X3): (G/A)0-20NP(X)ANREKMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 235 (N7-X4): (G/A)0-20NPX(X)NREKMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 236 (N7-X5): (G/A)0-20NPKA(X)REKMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 237 (N7-X6): (G/A)0-20NPKAN(X)EKMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 238 (N7-X7): (G/A)0-20NPKANR(X)KMTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 239 (N7-X8): (G/A)0-20NPKANRE(X)MTQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 240 (N7-X9): (G/A)0-20NPKANREK(X)TQIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 241 (N7-X10): (G/A)0-20NPKANREKM(X)QIMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 242 (N7-X11): (G/A)0-20NPKANREKMT(X)IMFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 243 (N7-X12): (G/A)0-20NPKANREKMTQ(X)MFETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 244 (N7-X13): (G/A)0-20NPKANREKMTQI(X)FETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 245 (N7-X14): (G/A)0-20NPKANREKMTQIM(X)ETFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 246 (N7-X15): (G/A)0-20NPKANREKMTQIMF(X)TFN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 247 (N7-X16): (G/A)0-20NPKANREKMTQIMFE(X)FN(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 248 (N7-X17): (G/A)0-20NPKANREKMTQIMFET(X)N(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 249 (N7-X18): (G/A)0-20NPKANREKMTQIMFETF(X)(X0)PAMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 250 (N7-X19): (G/A)0-20NPKANREKMTQIMFETFN(X)(X0)AMYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 251 (N7-X20): (G/A)0-20NPKANREKMTQIMFETFN(X)P(X0)MYVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 252 (N7-X21): (G/A)0-20NPKANREKMTQIMFETFN(X)PA(X0)YVAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 253 (N7-X22): (G/A)0-20NPKANREKMTQIMFETFN(X)PAM(X0)VAIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 254 (N7-X23): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMY(X0)AIQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 255 (N7-X24): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYV(X0)IQAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 256 (N7-X25): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVA(X0)QAVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 257 (N7-X26): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAI(X0)AVLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 258 (N7-X27): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQ(X0)VLSLYASGRTTGI(G/A)0-20 SEQ ID NO: 259 (N7-X28): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQA(X0)LSLYASGRTTGI(G/A)0-20 SEQ ID NO: 260 (N7-X29): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAV(X0)SLYASGRTTGI(G/A)0-20 SEQ ID NO: 261 (N7-X30): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVL(X0)LYASGRTTGI(G/A)0-20 SEQ ID NO: 262 (N7-X31): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLS(X0)YASGRTTGI(G/A)0-20 SEQ ID NO: 263 (N7-X32): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSL(X0)ASGRTTGI(G/A)0-20 SEQ ID NO: 264 (N7-X33): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLY(X0)SGRTTGI(G/A)0-20 SEQ ID NO: 265 (N7-X34): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYA(X0)GRTTGI(G/A)0-20 SEQ ID NO: 266 (N7-X35): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYAS(X0)RTTGI(G/A)0-20 SEQ ID NO: 267 (N7-X36): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYASG(X0)TTGI(G/A)0-20 SEQ ID NO: 268 (N7-X37): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYASGR(X0)TGI(G/A)0-20 SEQ ID NO: 269 (N7-X38): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYASGRT(X0)GI(G/A)0-20 SEQ ID NO: 270 (N7-X39): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYASGRTT(X0)I(G/A)0-20 SEQ ID NO: 271 (N7-X40): (G/A)0-20NPKANREKMTQIMFETFN(X)PAMYVAIQAVLSLYASGRTTG(X0)(G/A)0-20 SEQ ID NO: 272 (B6-V1): (G/A)0-20(X)PKANREKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 273 (B6-V1): (G/A)0-20N(X)KANREKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 274 (B6-V1): (G/A)0-20NP(X)ANREKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 275 (B6-V1): (G/A)0-20NPK(X)NREKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 276 (B6-V1): (G/A)0-20NPKA(X)REKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 277 (B6-V1): (G/A)0-20NPKAN(X)EKMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 278 (B6-V1): (G/A)0-20NPKANR(X)KMTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 279 (B6-V1): (G/A)0-20NPKANRE(X)MTQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 280 (B6-V1): (G/A)0-20NPKANREK(X)TQIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 281 (B6-V1): (G/A)0-20NPKANREKM(X)QIMFETFN(X0)P(G/A)0-20 SEQ ID NO: 282 (B6-V1): (G/A)0-20NPKANREKMT(X)IMFETFN(X0)P(G/A)0-20 SEQ ID NO: 283 (B6-V1): (G/A)0-20NPKANREKMTQ(X)MFETFN(X0)P(G/A)0-20 SEQ ID NO: 284 (B6-V1): (G/A)0-20NPKANREKMTQI(X)FETFN(X0)P(G/A)0-20 SEQ ID NO: 285 (B6-V1): (G/A)0-20NPKANREKMTQIM(X)ETFN(X0)P(G/A)0-20 SEQ ID NO: 286 (B6-V1): (G/A)0-20NPKANREKMTQIMF(X)TFN(X0)P(G/A)0-20 SEQ ID NO: 287 (B6-V1): (G/A)0-20NPKANREKMTQIMFE(X)FN(X0)P(G/A)0-20 SEQ ID NO: 288 (B6-V1): (G/A)0-20NPKANREKMTQIMFET(X)N(X0)P(G/A)0-20 SEQ ID NO: 289 (B6-V1): (G/A)0-20NPKANREKMTQIMFETF(X)(X0)P(G/A)0-20 SEQ ID NO: 290 (B6-V1): (G/A)0-20NPKANREKMTQIMFETFN(X0)(X)(G/A)0-20 SEQ ID NO: 291 (NB9-core): (X)0-20(X)PHAILRLDL(X)0-20 SEQ ID NO: 292 (NB9-core): (G/A)0-20L(X)HAILRLDL(G/A)0-20 SEQ ID NO: 293 (NB9-core): (G/A)0-20LP(X)AILRLDL(G/A)0-20 SEQ ID NO: 294 (NB9-core): (G/A)0-20LPH(X)ILRLDL(G/A)0-20 SEQ ID NO: 295 (NB9-core): (G/A)0-20LPHA(X)LRLDL(G/A)0-20 SEQ ID NO: 296 (NB9-core): (G/A)0-20LPHAI(X)RLDL(G/A)0-20 SEQ ID NO: 297 (NB9-core): (G/A)0-20LPHAIL(X)LDL(G/A)0-20 SEQ ID NO: 298 (NB9-core): (G/A)0-20LPHAILRL(X)L(G/A)0-20 SEQ ID NO: 299 (NB9-core): (G/A)0-20LPHAILRLD(X)(G/A)0-20 SEQ ID NO: 300 (N9-NV1): (X)0-20(X)YALPHAI(X0)R(X)0-20 SEQ ID NO: 301 (N9-NV2): (G/A)0-20G(X)ALPHAI(X0)R(G/A)0-20 SEQ ID NO: 302 (N9-NV3): (G/A)0-20GY(X)LPHAI(X0)R(G/A)0-20 SEQ ID NO: 303 (N9-NV4): (G/A)0-20GYA(X)PHAI(X0)R(G/A)0-20 SEQ ID NO: 304 (N9-NV5): (G/A)0-20GYAL(X)HAI(X0)R(G/A)0-20 SEQ ID NO: 305 (N9-NV6): (G/A)0-20GYALP(X)AI(X0)R(G/A)0-20 SEQ ID NO: 306 (N9-NV7): (G/A)0-20GYALPH(X)I(X0)R(G/A)0-20 SEQ ID NO: 307 (N9-NV8): (G/A)0-20GYALPHA(X)(X0)R(G/A)0-20 SEQ ID NO: 308 (N9-NV9): (G/A)0-20GYALPHAI(X0)(X)(G/A)0-20 SEQ ID NO: 309 (N9-N5): (G/A)0-20GDGVTH(X0)VPI(G/A)0-20 SEQ ID NO: 310 (N9-N6): (G/A)0-20DGVTH(X0)VPIY(G/A)0-20 SEQ ID NO: 311 (N9-N7): (G/A)0-20GVTH(X0)VPIYE(G/A)0-20 SEQ ID NO: 312 (N9-N8): (G/A)0-20VTH(X0)VPIYEG(G/A)0-20 SEQ ID NO: 313 (N9-N9): (G/A)0-20TH(X0)VPIYEGY(G/A)0-20 SEQ ID NO: 314 (N9-N10): (G/A)0-20H(X0)VPIYEGYA(G/A)0-20 SEQ ID NO: 315 (N9-N11): (G/A)0-20(X0)VPIYEGYAL(G/A)0-20 SEQ ID NO: 316 (N9-N12): (G/A)0-20(X0)PIYEGYALP(G/A)0-20 SEQ ID NO: 317 (N9-N13): (G/A)0-20(X0)IYEGYALPH(G/A)0-20 SEQ ID NO: 318 (N9-N14): (G/A)0-20(X0)YEGYALPHA(G/A)0-20 SEQ ID NO: 319 (N9-N15): (G/A)0-20(X0)EGYALPHAI(G/A)0-20 SEQ ID NO: 320 (N9-N16): (G/A)0-20EGYALPHAI(X0)(G/A)0-20 SEQ ID NO: 321 (N9-N17): (G/A)0-20GYALPHAI(X0)R(G/A)0-20 SEQ ID NO: 322 (N9-N18): (G/A)0-20YALPHAI(X0)RL(G/A)0-20 SEQ ID NO: 323 (N9-N19): (G/A)0-20ALPHAI(X0)RLD(G/A)0-20 SEQ ID NO: 324 (N9-N20): (G/A)0-20LPHAI(X0)RLDL(G/A)0-20 SEQ ID NO: 325 (N9-N21): (G/A)0-20PHAI(X0)RLDLA(G/A)0-20 SEQ ID NO: 326 (N9-N22): (G/A)0-20HAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 327 (N9-N23): (G/A)0-20AI(X0)RLDLAGR(G/A)0-20 SEQ ID NO: 328 (N9-N24): (G/A)0-20I(X0)RLDLAGRD(G/A)0-20 SEQ ID NO: 329 (N9-N25): (G/A)0-20(X0)RLDLAGRDL(G/A)0-20 SEQ ID NO: 330 (N9-N26): (G/A)0-20LDLAGRDLTD(G/A)0-20 SEQ ID NO: 331 (N9-N27): (G/A)0-20DLAGRDLTDY(G/A)0-20 SEQ ID NO: 332 (N9-N28): (G/A)0-20LAGRDLTDYL(G/A)0-20 SEQ ID NO: 333 (N9-N29): (G/A)0-20AGRDLTDYLM(G/A)0-20 SEQ ID NO: 334 (N9-N30): (G/A)0-20GRDLTDYLMK(G/A)0-20 SEQ ID NO: 335 (N9-N31): (G/A)0-20RDLTDYLMKI(G/A)0-20 SEQ ID NO: 336 (N9-N32): (G/A)0-20DLTDYLMKIL(G/A)0-20 SEQ ID NO: 337 (N9-N32): (G/A)0-20LTDYLMKILT(G/A)0-20 SEQ ID NO: 338 (N9-N32): (G/A)0-20TDYLMKILTE(G/A)0-20 SEQ ID NO: 339 (N9-N32): (G/A)0-200DYLMKILTER(G/A)0-20 SEQ ID NO: 340 (B9-T28): (G/A)0-20YLMKILTERG(G/A)0-20 SEQ ID NO: 341 (B9-T29): (G/A)0-20LMKILTERGY(G/A)0-20 SEQ ID NO: 342 (B9-T30): (G/A)0-20MKILTERGYS(G/A)0-20 SEQ ID NO: 343 (B9-T31): (G/A)0-20KILTERGYSF(G/A)0-20 SEQ ID NO: 344 (N9-V1): (G/A)0-20(X)VPIYEGYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 345 (N9-V2): (G/A)0-20(X)PIYEGYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 346 (N9-V3): (G/A)0-20V(X)IYEGYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 347 (N9-V4): (G/A)0-20VP(X)YEGYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 348 (N9-V5): (G/A)0-20VPI(X)EGYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 349 (N9-V6): (G/A)0-20VRIY(X)GYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 350 (N9-V7): (G/A)0-20VPIYE(X)YALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 351 (N9-V8): (G/A)0-20VPIYEG(X)ALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 352 (N9-V9): (G/A)0-20VPIYEGY(X)LPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 353 (N9-V10): (G/A)0-20VPIYEGYA(X)PHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 354 (N9-V11): (G/A)0-20VPIYEGYAL(X)HAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 355 (N9-V12): (G/A)0-20VPIYEGYALP(X)AI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 356 (N9-V13): (G/A)0-20VPIYEGYALPH(X)I(X0)RLDLAG(G/A)0-20 SEQ ID NO: 357 (N9-V14): (G/A)0-20VPIYEGYALPHA(X)(X0)RLDLAG(G/A)0-20 SEQ ID NO: 358 (N9-V15): (G/A)0-20VPIYEGYALPHAI(X0)(X)LDLAG(G/A)0-20 SEQ ID NO: 359 (N9-V16): (G/A)0-20VPIYEGYALPHAI(X0)R(X)DLAG(G/A)0-20 SEQ ID NO: 360 (N9-V17): (G/A)0-20VPIYEGYALPHAI(X0)RL(X)LAG(G/A)0-20 SEQ ID NO: 361 (N9-V18): (G/A)0-20VPIYEGYALPHAI(X0)RLD(X)AG(G/A)0-20 SEQ ID NO: 362 (N9-V19): (G/A)0-20VPIYEGYALPHAI(X0)RLDL(X)G(G/A)0-20 SEQ ID NO: 363 (N9-V20): (G/A)0-20VPIYEGYALPHAI(X0)RLDLA(X)(G/A)0-20 SEQ ID NO: 364 (B9-V1): (G/A)0-20(X)PHAI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 365 (B9-V2): (G/A)0-20L(X)HAI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 366 (B9-V3): (G/A)0-20LP(X)AI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 367 (B9-V4): (G/A)0-20LPH(X)I(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 368 (B9-V5): (G/A)0-20LPHA(X)(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 369 (B9-V6): (G/A)0-20LPHAI(X0)(X)LDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 370 (B9-V7): (G/A)0-20LPHAI(X0)R(X)DLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 371 (B9-V8): (G/A)0-20LPHAI(X0)RL(X)LAGRDLTDYLM(G/A)0-20 SEQ ID NO: 372 (B9-V9): (G/A)0-20LPHAI(X0)RLD(X)AGRDLTDYLM(G/A)0-20 SEQ ID NO: 373 (B9-V10): (G/A)0-20LPHAI(X0)RLDL(X)GRDLTDYLM(G/A)0-20 SEQ ID NO: 374 (B9-V11): (G/A)0-20LPHAI(X0)RLDLA(X)RDLTDYLM(G/A)0-20 SEQ ID NO: 375 (B9-V12): (G/A)0-20LPHAI(X0)RLDLAG(X)DLTDYLM(G/A)0-20 SEQ ID NO: 376 (B9-V13): (G/A)0-20LPHAI(X0)RLDLAGR(X)LTDYLM(G/A)0-20 SEQ ID NO: 377 (B9-V14): (G/A)0-20LPHAI(X0)RLDLAGRD(X)TDYLM(G/A)0-20 SEQ ID NO: 378 (B9-V15): (G/A)0-20LPHAI(X0)RLDLAGRDL(X)DYLM(G/A)0-20 SEQ ID NO: 379 (B9-V16): (G/A)0-20LPHAI(X0)RLDLAGRDLT(X)YLM(G/A)0-20 SEQ ID NO: 380 (B9-V17): (G/A)0-20LPHAI(X0)RLDLAGRDLTD(X)LM(G/A)0-20 SEQ ID NO: 381 (B9-V18): (G/A)0-20LPHAI(X0)RLDLAGRDLTDY(X)MG/A)0-20 SEQ ID NO: 382 (B9-V19): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYL(X)(G/A)0-20 SEQ ID NO: 383 N9-M1): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYAL(G/A)0-20 SEQ ID NO: 384 (N9-M2): (G/A)0-20(X0)DSGDGVTH(X0)VPIYEGYALP(G/A)0-20 SEQ ID NO: 385 (N9-M3): (G/A)0-20DSGDGVTH(X0)VPIYEGYALPH(G/A)0-20 SEQ ID NO: 386 (N9-M4): (G/A)0-20SGDGVTH(X0)VPIYEGYALPHA(G/A)0-20 SEQ ID NO: 387 (N9-M5): (G/A)0-20GDGVTH(X0)VPIYEGYALPHAI(G/A)0-20 SEQ ID NO: 388 (N9-M6): (G/A)0-20DGVTH(X0)VPIYEGYALPHAI(X0)(G/A)0-20 SEQ ID NO: 389 (N9-M7): (G/A)0-20GVTH(X0)VPIYEGYALPHAI(X0)R(G/A)0-20 SEQ ID NO: 390 (N9-M8): (G/A)0-20VTH(X0)VPIYEGYALPHAI(X0)RL(G/A)0-20 SEQ ID NO: 391 (N9-M9): (G/A)0-20TH(X0)VPIYEGYALPHAI(X0)RLD(G/A)0-20 SEQ ID NO: 392 (N9): (G/A)0-20H(X0)VPIYEGYALPHAI(X0)RLDL(G/A)0-20 SEQ ID NO: 393 (N9-P1): (G/A)0-20(X0)VPIYEGYALPHAI(X0)RLDLA(G/A)0-20 SEQ ID NO: 394 (N9-P2): (G/A)0-20VPIYEGYALPHAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 395 (N9-P3): (G/A)0-20PIYEGYALPHAI(X0)RLDLAGR(G/A)0-20 SEQ ID NO: 396 (N9-P4): (G/A)0-20IYEGYALPHAI(X0)RLDLAGRD(G/A)0-20 SEQ ID NO: 397 (N9-P5): (G/A)0-20YEGYALPHAI(X0)RLDLAGRDL(G/A)0-20 SEQ ID NO: 398 (N9-P6): (G/A)0-20EGYALPHAI(X0)RLDLAGRDLT(G/A)0-20 SEQ ID NO: 399 (N9-P7): (G/A)0-20GYALPHAI(X0)RLDLAGRDLTD(G/A)0-20 SEQ ID NO: 400 (N9-P8): (G/A)0-20YALPHAI(X0)RLDLAGRDLTDY(G/A)0-20 SEQ ID NO: 401 (N9-P9): (G/A)0-20ALPHAI(X0)RLDLAGRDLTDYL(G/A)0-20 SEQ ID NO: 402 (N9-P10): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 403 (N9-P11): (G/A)0-20PHAI(X0)RLDLAGRDLTDYLMK(G/A)0-20 SEQ ID NO: 404 (N9-P12): (G/A)0-20HAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 405 (N9-P13): (G/A)0-20AI(X0)RLDLAGRDLTDYLMKIL(G/A)0-20 SEQ ID NO: 406 (B9-P04): (G/A)0-20I(X0)RLDLAGRDLTDYLMKILT(G/A)0-20 SEQ ID NO: 407 (B9-P05): (G/A)0-20(X0)RLDLAGRDLTDYLMKILTE(G/A)0-20 SEQ ID NO: 408 (B9-P06): (G/A)0-20(X0)LDLAGRDLTDYLMKILTER(G/A)0-20 SEQ ID NO: 409 (B9-P07): (G/A)0-20(X0)DLAGRDLTDYLMKILTERG(G/A)0-20 SEQ ID NO: 410 (B9-P08): (G/A)0-20(X0)LAGRDLTDYLMKILTERGY(G/A)0-20 SEQ ID NO: 411 (B9-P09): (G/A)0-20(X0)AGRDLTDYLMKILTERGYS(G/A)0-20 SEQ ID NO: 412 (B9-P10): (G/A)0-20(X0)GRDLTDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 413 (B9-NV01): (G/A)0-20(X)PHAI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 414 (B9-NV02): (G/A)0-20L(X)HAI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 415 (B9-NV03): (G/A)0-20LP(X)AI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 416 (B9-NV04): (G/A)0-20LPH(X)I(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 417 (B9-NV05): (G/A)0-20LPHA(X)(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 418 (B9-NV06): (G/A)0-20LPHA(X)(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 419 (B9-NV07): (G/A)0-20LPHAI(X0)(X)LDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 420 (B9-NV08): (G/A)0-20LPHAI(X0)R(X)DLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 421 (B9-NV09): (G/A)0-20LPHAI(X0)RL(X)LAGRDLTDYLM(G/A)0-20 SEQ ID NO: 422 (B9-NV10): (G/A)0-20LPHAI(X0)RLD(X)AGRDLTDYLM(G/A)0-20 SEQ ID NO: 423 (B9-NV11): (G/A)0-20LPHAI(X0)RLDL(X)GRDLTDYLM(G/A)0-20 SEQ ID NO: 424 (B9-NV12): (G/A)0-20LPHAI(X0)RLDLA(X)RDLTDYLM(G/A)0-20 SEQ ID NO: 425 (B9-NV13): (G/A)0-20LPHAI(X0)RLDLAG(X)DLTDYLM(G/A)0-20 SEQ ID NO: 426 (B9-NV14): (G/A)0-20LPHAI(X0)RLDLAGR(X)LTDYLM(G/A)0-20 SEQ ID NO: 427 (B9-NV15): (G/A)0-20LPHAI(X0)RLDLAGRD(X)TDYLM(G/A)0-20 SEQ ID NO: 428 (B9-NV16): (G/A)0-20LPHAI(X0)RLDLAGRDL(X)DYLM(G/A)0-20 SEQ ID NO: 429 (B9-NV17): (G/A)0-20LPHAI(X0)RLDLAGRDLT(X)YLM(G/A)0-20 SEQ ID NO: 430 (B9-NV18): (G/A)0-20LPHAI(X0)RLDLAGRDLTD(X)LM(G/A)0-20 SEQ ID NO: 431 (B9-NV19): (G/A)0-20LPHAI(X0)RLDLAGRDLTDY(X)M(G/A)0-20 SEQ ID NO: 432 (B9-NV20): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYL(X)(G/A)0-20 SEQ ID NO: 433 (N9-X1): (G/A)0-20(X)(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)LDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 434 (N9-X2): (G/A)0-20V(X0)(X)SGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 435 (N9-X3): (G/A)0-20V(X0)D(X)GDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 436 (N9-X4): (G/A)0-20V(X0)DS(X)DGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 437 (N9-X5): (G/A)0-20V(X0)DSG(X)GVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 438 (N9-X6): (G/A)0-20V(X0)DSGD(X)VTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 439 (N9-X7): (G/A)0-20V(X0)DSGDG(X)TH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 440 (N9-X8): (G/A)0-20V(X0)DSGDGV(X)H(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 441 (N9-X9): (G/A)0-20V(X0)DSGDGVT(X)(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 442 (N9-X10): (G/A)0-20V(X0)DSGDGVTH(X0)(X)PIYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 443 (N9-X11): (G/A)0-20V(X0)DSGDGVTH(X0)V(X)IYEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 444 (N9-X12): (G/A)0-20V(X0)DSGDGVTH(X0)VP(X)YEGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 445 (N9-X13): (G/A)0-20V(X0)DSGDGVTH(X0)VPI(X)EGYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 446 (N9-X14): (G/A)0-20V(X0)DSGDGVTH(X0)VPIY(X)GYALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 447 (N9-X15): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYE(X)YALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 448 (N9-X16): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEG(X)ALPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 449 (N9-X17): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGY(X)LPHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 450 (N9-X18): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYA(X)PHAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 451 (N9-X19): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYAL(X)HAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 452 (N9-X20): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALP(X)AI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 453 (N9-X21): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPH(X)I(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 454 (N9-X22): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHA(X)(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 455 (N9-X23): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)(X)LDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 456 (N9-X24): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)R(X)DLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 457 (N9-X25): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RL(X)LAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 458 (N9-X26): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLD(X)AGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 459 (N9-X27): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDL(X)GRDLTDYLMKI(G/A)0-20 SEQ ID NO: 460 (N9-X28): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLA(X)RDLTDYLMKI(G/A)0-20 SEQ ID NO: 461 (N9-X29): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAG(X)DLTDYLMKI(G/A)0-20 SEQ ID NO: 462 (N9-X30): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGR(X)LTDYLMKI(G/A)0-20 SEQ ID NO: 463 (N9-X31): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRD(X)TDYLMKI(G/A)0-20 SEQ ID NO: 464 (N9-X32): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDL(X)DYLMKI(G/A)0-20 SEQ ID NO: 465 (N9-X33): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLT(X)YLMKI(G/A)0-20 SEQ ID NO: 466 (N9-X34): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTD(X)LMKI(G/A)0-20 SEQ ID NO: 467 (N9-X35): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDY(X)MKI(G/A)0-20 SEQ ID NO: 468 (N9-X36): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYL(X)KI(G/A)0-20 SEQ ID NO: 469 (N9-X37): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLM(X)I(G/A)0-20 SEQ ID NO: 470 (N9-X38): (G/A)0-20V(X0)DSGDGVTH(X0)VPIYEGYALPHAI(X0)RLDLAGRDLTDYLMK(X)(G/A)0-20 SEQ ID NO: 471 (NB10-core): (X)0-20AGRDLTDYLM(X)0-20 SEQ ID NO: 472 (NB10-core): (G/A)0-20(X)GRDLTDYLM(G/A)0-20 SEQ ID NO: 473 (NB10-core): (G/A)0-20A(X)RDLTDYLM(G/A)0-20 SEQ ID NO: 474 (NB10-core): (G/A)0-20AG(X)DLTDYLM(G/A)0-20 SEQ ID NO: 475 (NB10-core): (G/A)0-20AGR(X)LTDYLM(G/A)0-20 SEQ ID NO: 476 (NB10-core): (G/A)0-20AGRD(X)TDYLM(G/A)0-20 SEQ ID NO: 477 (NB10-core): (G/A)0-20AGRDL(X)DYLM(G/A)0-20 SEQ ID NO: 478 (NB10-core): (G/A)0-20AGRDLT(X)YLM(G/A)0-20 SEQ ID NO: 479 (NB10-core): (G/A)0-20AGRDLTD(X)LM(G/A)0-20 SEQ ID NO: 480 (NB10-core): (G/A)0-20AGRDLTDY(X)M(G/A)0-20 SEQ ID NO: 481 (NB10-core): (G/A)0-20AGRDLTDYL(X)(G/A)0-20 SEQ ID NO: 482 (N10-NV1): (G/A)0-20(X)DYLMKILTE(G/A)0-20 SEQ ID NO: 483 (N10-NV2): (G/A)0-20T(X)YLMKILTE(G/A)0-20 SEQ ID NO: 484 (N10-NV3): (G/A)0-20TD(X)LMKILTE(G/A)0-20 SEQ ID NO: 485 (N10-NV4): (G/A)0-20DTDY(X)MKILTE(G/A)0-20 SEQ ID NO: 486 (N10-NV5): (G/A)0-20TDYL(X)KILTE(G/A)0-20 SEQ ID NO: 487 (N10-NV6): (G/A)0-20TDYLM(X)ILTE(G/A)0-20 SEQ ID NO: 488 (N10-NV7): (G/A)0-20TDYLMK(X)LTE(G/A)0-20 SEQ ID NO: 489 (N10-NV8): (G/A)0-20TDYLMKI(X)TE(G/A)0-20 SEQ ID NO: 490 (N10-NV9): (G/A)0-20TDYLMKIL(X)E(G/A)0-20 SEQ ID NO: 491 (N10-NV10): (G/A)0-20TDYLMKILT(X)(G/A)0-20 SEQ ID NO: 492 (N10-N1): (G/A)0-20LPHAI(X0)RLDL(G/A)0-20 SEQ ID NO: 493 (N10-N2): (G/A)0-20PHAI(X0)RLDLA(G/A)0-20 SEQ ID NO: 494 (N10-N3): (G/A)0-20HAI(X0)RLDLAG(G/A)0-20 SEQ ID NO: 495 (N10-N4): (G/A)0-20AI(X0)RLDLAGR(G/A)0-20 SEQ ID NO: 496 (N10-N5): (G/A)0-20I(X0)RLDLAGRD(G/A)0-20 SEQ ID NO: 497 (N10-N6): (G/A)0-20(X0)RLDLAGRDL(G/A)0-20 SEQ ID NO: 498 (N10-N7): (G/A)0-20(X0)LDLAGRDLT(G/A)0-20 SEQ ID NO: 499 (N10-N8): (G/A)0-20(X0)DLAGRDLTD(G/A)0-20 SEQ ID NO: 500 (N10-N9): (G/A)0-20(X0)LAGRDLTDY(G/A)0-20 SEQ ID NO: 501 (N10-N10): (G/A)0-20(X0)AGRDLTDYL(G/A)0-20 SEQ ID NO: 502 (N10-N11): (G/A)0-20(X0)GRDLTDYLM(G/A)0-20 SEQ ID NO: 503 (N10-N12): (G/A)0-20(X0)RDLTDYLMK(G/A)0-20 SEQ ID NO: 504 (N10-N13): (G/A)0-20(X0)DLTDYLMKI(G/A)0-20 SEQ ID NO: 505 (N10-N14): (G/A)0-20(X0)LTDYLMKIL(G/A)0-20 SEQ ID NO: 506 (N10-N15): (G/A)0-20(X0)TDYLMKILT(G/A)0-20 SEQ ID NO: 507 (N10-N16): (G/A)0-20(X0)DYLMKILTE(G/A)0-20 SEQ ID NO: 508 (N10-N17): (G/A)0-20(X0)YLMKILTER(G/A)0-20 SEQ ID NO: 509 (N10-N18): (G/A)0-20(X0)LMKILTERG(G/A)0-20 SEQ ID NO: 510 (N10-N19): (G/A)0-20(X0)MKILTERGY(G/A)0-20 SEQ ID NO: 511 (N10-N20): (G/A)0-20(X0)KILTERGYS(G/A)0-20 SEQ ID NO: 512 (N10-N21): (G/A)0-20(X0)ILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 513 (N10-N22): (G/A)0-20ILTERGYSF(X0)(G/A)0-20 SEQ ID NO: 514 (N10-N23): (G/A)0-20LTERGYSF(X0)T(G/A)0-20 SEQ ID NO: 515 (N10-N24): (G/A)0-20TERGYSF(X0)TT(G/A)0-20 SEQ ID NO: 516 (N10-N25): (G/A)0-20ERGYSF(X0)TTA(G/A)0-20 SEQ ID NO: 517 (N10-N26): (G/A)0-20RGYSF(X0)TTAE(G/A)0-20 SEQ ID NO: 518 (N10-N27): (G/A)0-20GYSF(X0)TTAER(G/A)0-20 SEQ ID NO: 519 (N10-N28): (G/A)0-20YSF(X0)TTAERE(G/A)0-20 SEQ ID NO: 520 (N10-N29): (G/A)0-20SF(X0)TTAEREI(G/A)0-20 SEQ ID NO: 521 (N10-N30): (G/A)0-20F(X0)TTAEREIV(G/A)0-20 SEQ ID NO: 522 (N10-N31): (G/A)0-20(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 523 (N10-V1): (G/A)0-20(X)GRDLTDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 524 (N10-V2): (G/A)0-20A(X)RDLTDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 525 (N10-V3): (G/A)0-20AG(X)DLTDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 526 (N10-V4): (G/A)0-20AGR(X)LTDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 527 (N10-V5): (G/A)0-20AGRD(X)TDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 528 (N10-V6): (G/A)0-20AGRDL(X)DYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 529 (N10-V7): (G/A)0-20AGRDLT(X)YLMKILTERGYSF(G/A)0-20 SEQ ID NO: 530 (N10-V8): (G/A)0-20AGRDLTD(X)LMKILTERGYSF(G/A)0-20 SEQ ID NO: 531 (N10-V9): (G/A)0-20AGRDLTDY(X)MKILTERGYSF(G/A)0-20 SEQ ID NO: 532 (N10-V10): (G/A)0-20AGRDLTDYL(X)KILTERGYSF(G/A)0-20 SEQ ID NO: 533 (N10-V11): (G/A)0-20AGRDLTDYLM(X)ILTERGYSF(G/A)0-20 SEQ ID NO: 534 (N10-V12): (G/A)0-20AGRDLTDYLMK(X)LTERGYSF(G/A)0-20 SEQ ID NO: 535 (N10-V13): (G/A)0-20AGRDLTDYLMKI(X)TERGYSF(G/A)0-20 SEQ ID NO: 536 (N10-V14): (G/A)0-20AGRDLTDYLMKIL(X)ERGYSF(G/A)0-20 SEQ ID NO: 537 (N10-V15): (G/A)0-20AGRDLTDYLMKILT(X)RGYSF(G/A)0-20 SEQ ID NO: 538 (N10-V16): (G/A)0-20AGRDLTDYLMKILTE(X)GYSF(G/A)0-20 SEQ ID NO: 539 (N10-V17): (G/A)0-20AGRDLTDYLMKILTER(X)YSF(G/A)0-20 SEQ ID NO: 540 (N10-V18): (G/A)0-20AGRDLTDYLMKILTERG(X)SF(G/A)0-20 SEQ ID NO: 541 (N10-V19): (G/A)0-20AGRDLTDYLMKILTERGY(X)F(G/A)0-20 SEQ ID NO: 542 (N10-V20): (G/A)0-20AGRDLTDYLMKILTERGYS(X)(G/A)0-20 SEQ ID NO: 543 (N10-M1): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLM(G/A)0-20 SEQ ID NO: 544 (N10-M2): (G/A)0-20PHAI(X0)RLDLAGRDLTDYLMK(G/A)0-20 SEQ ID NO: 545 (N10-M3): (G/A)0-20HAI(X0)RLDLAGRDLTDYLMKI(G/A)0-20 SEQ ID NO: 546 (N10-M4): (G/A)0-20AI(X0)RLDLAGRDLTDYLMKIL(G/A)0-20 SEQ ID NO: 547 (N10-M5): (G/A)0-20I(X0)RLDLAGRDLTDYLMKILT(G/A)0-20 SEQ ID NO: 548 (N10-M6): (G/A)0-20(X0)RLDLAGRDLTDYLMKILTE(G/A)0-20 SEQ ID NO: 549 (N10-M7): (G/A)0-20RLDLAGRDLTDYLMKILTER(G/A)0-20 SEQ ID NO: 550 (N10-M8): (G/A)0-20LDLAGRDLTDYLMKILTERG(G/A)0-20 SEQ ID NO: 551 (N10-M9): (G/A)0-20DLAGRDLTDYLMKILTERGY(G/A)0-20 SEQ ID NO: 552 (N10-M10): (G/A)0-20LAGRDLTDYLMKILTERGYS(G/A)0-20 SEQ ID NO: 553 (N10): (G/A)0-20AGRDLTDYLMKILTERGYSF(G/A)0-20 SEQ ID NO: 554 (N10-P1): (G/A)0-20GRDLTDYLMKILTERGYSF(X0)(G/A)0-20 SEQ ID NO: 555 (N10-P2): (G/A)0-20RDLTDYLMKILTERGYSF(X0)T(G/A)0-20 SEQ ID NO: 556 (N10-P3): (G/A)0-20DLTDYLMKILTERGYSF(X0)TT(G/A)0-20 SEQ ID NO: 557 (N10-P4): (G/A)0-20LTDYLMKILTERGYSF(X0)TTA(G/A)0-20 SEQ ID NO: 558 (N10-P5): (G/A)0-20TDYLMKILTERGYSF(X0)TTAE(G/A)0-20 SEQ ID NO: 559 (N10-P6): (G/A)0-20DYLMKILTERGYSF(X0)TTAER(G/A)0-20 SEQ ID NO: 560 (N10-P7): (G/A)0-20YLMKILTERGYSF(X0)TTAERE(G/A)0-20 SEQ ID NO: 561 (N10-P8): (G/A)0-20LMKILTERGYSF(X0)TTAEREI(G/A)0-20 SEQ ID NO: 562 (N10-P9): (G/A)0-20MKILTERGYSF(X0)TTAEREIV(G/A)0-20 SEQ ID NO: 563 (N10-P10): (G/A)0-20KILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 564 (N10-X1): (G/A)0-20(X)PHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 565 (N10-X2): (G/A)0-20L(X)HAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 566 (N10-X3): (G/A)0-20LP(X)AI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 567 (N10-X4): (G/A)0-20LPH(X)I(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 568 (N10-X5): (G/A)0-20LPHA(X)(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 569 (N10-X6): (G/A)0-20LPHAI(X0)(X)LDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 570 (N10-X7): (G/A)0-20LPHAI(X0)R(X)DLAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 571 (N10-X8): (G/A)0-20LPHAI(X0)RL(X)LAGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 572 (N10-X9): (G/A)0-20LPHAI(X0)RLD(X)AGRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 573 (N10-X10): (G/A)0-20LPHAI(X0)RLDL(X)GRDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 574 (N10-X11): (G/A)0-20LPHAI(X0)RLDLA(X)RDLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 575 (N10-X12): (G/A)0-20LPHAI(X0)RLDLAG(X)DLTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 576 (N10-X13): (G/A)0-20LPHAI(X0)RLDLAGR(X)LTDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 577 (N10-X14): (G/A)0-20LPHAI(X0)RLDLAGRD(X)TDYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 578 (N10-X15): (G/A)0-20LPHAI(X0)RLDLAGRDL(X)DYLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 579 (N10-X16): (G/A)0-20LPHAI(X0)RLDLAGRDLT(X)YLMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 580 (N10-X17): (G/A)0-20LPHAI(X0)RLDLAGRDLTD(X)LMKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 581 (N10-X18): (G/A)0-20LPHAI(X0)RLDLAGRDLTDY(X)MKILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 582 (N10-X19): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYL(X)KILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 583 (N10-X20): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLM(X)ILTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 584 (N10-X21): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMK(X)LTERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 585 (N10-X22): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKI(X)TERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 586 (N10-X23): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKIL(X)ERGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 587 (N10-X24): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILT(X)RGYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 588 (N10-X25): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTE(X)GYSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 589 (N10-X26): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTER(X)YSF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 590 (N10-X27): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERG(X)SF(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 591 (N10-X28): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGY(X)F(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 592 (N10-X29): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYS(X)(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 593 (N10-X30): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)(X)TAEREIVR(G/A)0-20 SEQ ID NO: 594 (N10-X31): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)T(X)AEREIVR(G/A)0-20 SEQ ID NO: 595 (N10-X32): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TT(X)EREIVR(G/A)0-20 SEQ ID NO: 596 (N10-X33): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTA(X)REIVR(G/A)0-20 SEQ ID NO: 597 (N10-X34): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAE(X)EIVR(G/A)0-20 SEQ ID NO: 598 (N10-X35): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAER(X)IVR(G/A)0-20 SEQ ID NO: 599 (N10-X36): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAERE(X)VR(G/A)0-20 SEQ ID NO: 600 (N10-X37): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREI(X)R(G/A)0-20 SEQ ID NO: 601 (N10-X38): (G/A)0-20LPHAI(X0)RLDLAGRDLTDYLMKILTERGYSF(X0)TTAEREIV(X)(G/A)0-20 SEQ ID NO: 602 (B11-core): (X)0-20LCYVALDFEQ(X)0-20 SEQ ID NO: 603 (B11-NV01): (G/A)0-20(X)CYVALDFE(X0)(G/A)0-20 SEQ ID NO: 604 (B11-NV02): (G/A)0-20L(X)YVALDFE(X0)(G/A)0-20 SEQ ID NO: 605 (B11-NV03): (G/A)0-20LC(X)VALDFE(X0)(G/A)0-20 SEQ ID NO: 606 (B11-NV04): (G/A)0-20LCY(X)ALDFE(X0)(G/A)0-20 SEQ ID NO: 607 (B11-NV05): (G/A)0-20LCYV(X)LDFE(X0)(G/A)0-20 SEQ ID NO: 608 (B11-NV06): (G/A)0-20LCYVA(X)DFE(X0)(G/A)0-20 SEQ ID NO: 609 (B11-NV07): (G/A)0-20LCYVAL(X)FE(X0)(G/A)0-20 SEQ ID NO: 610 (B11-NV08): (G/A)0-20LCYVALD(X)E(X0)(G/A)0-20 SEQ ID NO: 611 (B11-NV09): (G/A)0-20LCYVALDF(X)(X0)(G/A)0-20 SEQ ID NO: 612 (B11-T01): (G/A)0-20F(X0)TTAEREIV(G/A)0-20 SEQ ID NO: 613 (B11-T02): (G/A)0-20(X0)TTAEREIVR(G/A)0-20 SEQ ID NO: 614 (B11-T03): (G/A)0-20(X0)TAEREIVRD(G/A)0-20 SEQ ID NO: 615 (B11-T04): (G/A)0-20(X0)AEREIVRDI(G/A)0-20 SEQ ID NO: 616 (B11-T05): (G/A)0-20(X0)EREIVRDIK(G/A)0-20 SEQ ID NO: 617 (B11-T06): (G/A)0-20(X0)REIVRDIKE(G/A)0-20 SEQ ID NO: 618 (B11-T07): (G/A)0-20(X0)EIVRDIKEK(G/A)0-20 SEQ ID NO: 619 (B11-T08): (G/A)0-20(X0)IVRDIKEKL(G/A)0-20 SEQ ID NO: 620 (B11-T09): (G/A)0-20(X0)VRDIKEKLC(G/A)0-20 SEQ ID NO: 621 (B11-T10): (G/A)0-20(X0)RDIKEKLCY(G/A)0-20 SEQ ID NO: 622 (B11-T11): (G/A)0-20(X0)DIKEKLCYV(G/A)0-20 SEQ ID NO: 623 (B11-T12): (G/A)0-20(X0)IKEKLCYVA(G/A)0-20 SEQ ID NO: 624 (B11-T13): (G/A)0-20(X0)KEKLCYVAL(G/A)0-20 SEQ ID NO: 625 (B11-T14): (G/A)0-20(X0)EKLCYVALD(G/A)0-20 SEQ ID NO: 626 (B11-T15): (G/A)0-20(X0)KLCYVALDF(G/A)0-20 SEQ ID NO: 627 (B11-T16): (G/A)0-20(X0)LCYVALDFE(G/A)0-20 SEQ ID NO: 628 (B11-T17): (G/A)0-20LCYVALDFE(X0)(G/A)0-20 SEQ ID NO: 629 (B11-T18): (G/A)0-20CYVALDFE(X0)E(G/A)0-20 SEQ ID NO: 630 (B11-T19): (G/A)0-20YVALDFE(X0)EM(G/A)0-20 SEQ ID NO: 631 (B11-T20): (G/A)0-20VALDFE(X0)EMA(G/A)0-20 SEQ ID NO: 632 (B11-T21): (G/A)0-20ALDFE(X0)EMAT(G/A)0-20 SEQ ID NO: 633 (B11-T22): (G/A)0-20LDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 634 (B11-T23): (G/A)0-20DFE(X0)EMATAA(G/A)0-20 SEQ ID NO: 635 (B11-T24): (G/A)0-20FE(X0)EMATAAS(G/A)0-20 SEQ ID NO: 636 (B11-T25): (G/A)0-20E(X0)EMATAASS(G/A)0-20 SEQ ID NO: 637 (B11-T26): (G/A)0-20(X0)EMATAASSS(G/A)0-20 SEQ ID NO: 638 (B11-T27): (G/A)0-20(X0)MATAASSSS(G/A)0-20 SEQ ID NO: 639 (B11-T28): (G/A)0-20(X0)ATAASSSSL(G/A)0-20 SEQ ID NO: 640 (B11-T29): (G/A)0-20(X0)TAASSSSLE(G/A)0-20 SEQ ID NO: 641 (B11-T30): (G/A)0-20(X0)AASSSSLEK(G/A)0-20 SEQ ID NO: 642 (B11-T31): (G/A)0-20(X0)ASSSSLEKS(G/A)0-20 SEQ ID NO: 643 (B11-T32): (G/A)0-20(X0)SSSSLEKSY(G/A)0-20 SEQ ID NO: 644 (B11-M01): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYV(G/A)0-20 SEQ ID NO: 645 (B11-M02): (G/A)0-20(X0)TTAEREIVRDIKEKLCYVA(G/A)0-20 SEQ ID NO: 646 (B11-M03): (G/A)0-20(X0)TAEREIVRDIKEKLCYVAL(G/A)0-20 SEQ ID NO: 647 (B11-M04): (G/A)0-20(X0)AEREIVRDIKEKLCYVALD(G/A)0-20 SEQ ID NO: 648 (B11-M05): (G/A)0-20(X0)EREIVRDIKEKLCYVALDF(G/A)0-20 SEQ ID NO: 649 (B11-M06): (G/A)0-20(X0)REIVRDIKEKLCYVALDFE(G/A)0-20 SEQ ID NO: 650 (B11-M07): (G/A)0-20EIVRDIKEKLCYVALDFE(X0)(G/A)0-20 SEQ ID NO: 651 (B11-M08): (G/A)0-20IVRDIKEKLCYVALDFE(X0)EM(G/A)0-20 SEQ ID NO: 652 (B11-M09): (G/A)0-20VRDIKEKLCYVALDFE(X0)EMA(G/A)0-20 SEQ ID NO: 653 (B11-M10): (G/A)0-20RDIKEKLCYVALDFE(X0)EMAT(G/A)0-20 SEQ ID NO: 654 (B11): (G/A)0-20DIKEKLCYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 655 (B11-P01): (G/A)0-20IKEKLCYVALDFE(X0)EMATAA(G/A)0-20 SEQ ID NO: 656 (B11-P02): (G/A)0-20KEKLCYVALDFE(X0)EMATAAS(G/A)0-20 SEQ ID NO: 657 (B11-P03): (G/A)0-20EKLCYVALDFE(X0)EMATAASS(G/A)0-20 SEQ ID NO: 658 (B11-PO4): (G/A)0-20KLCYVALDFE(X0)EMATAASSS(G/A)0-20 SEQ ID NO: 659 (B11-P05): (G/A)0-20LCYVALDFE(X0)EMATAASSSS(G/A)0-20 SEQ ID NO: 660 (B11-P06): (G/A)0-20CYVALDFE(X0)EMATAASSSSL(G/A)0-20 SEQ ID NO: 661 (B11-P07): (G/A)0-20YVALDFE(X0)EMATAASSSSLE(G/A)0-20 SEQ ID NO: 662 (B11-P08): (G/A)0-20VALDFE(X0)EMATAASSSSLEK(G/A)0-20 SEQ ID NO: 663 (B11-P09): (G/A)0-20ALDFE(X0)EMATAASSSSLEKS(G/A)0-20 SEQ ID NO: 664 (B11-P10): (G/A)0-20LDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 665 (B11-P11): (G/A)0-20DFE(X0)EMATAASSSSLEKSYE(G/A)0-20 SEQ ID NO: 666 (B11-V01): (G/A)0-20(X)IKEKLCYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 667 (B11-V02): (G/A)0-20D(X)KEKLCYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 668 (B11-V03): (G/A)0-20DI(X)EKLCYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 669 (B11-VO4): (G/A)0-20DIK(X)KLCYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 670 (B11-V05): (G/A)0-20DIKE(X)LCYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 671 (B11-V06): (G/A)0-20DIKEK(X)CYVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 672 (B11-V07): (G/A)0-20DIKEKL(X)YVALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 673 (B11-V08): (G/A)0-20DIKEKLC(X)VALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 674 (B11-V09): (G/A)0-20DIKEKLCY(X)ALDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 675 (B11-V10): (G/A)0-20DIKEKLCYV(X)LDFE(X0)EMATA(G/A)0-20 SEQ ID NO: 676 (B11-V11): (G/A)0-20DIKEKLCYVA(X)DFE(X0)EMATA(G/A)0-20 SEQ ID NO: 677 (B11-V12): (G/A)0-20DIKEKLCYVAL(X)FE(X0)EMATA(G/A)0-20 SEQ ID NO: 678 (B11-V13): (G/A)0-20DIKEKLCYVALD(X)E(X0)EMATA(G/A)0-20 SEQ ID NO: 679 (B11-V14): (G/A)0-20DIKEKLCYVALDF(X)(X0)EMATA(G/A)0-20 SEQ ID NO: 680 (B11-V15): (G/A)0-20DIKEKLCYVALDFE(X0)(X)MATA(G/A)0-20 SEQ ID NO: 681 (B11-V16): (G/A)0-20DIKEKLCYVALDFE(X0)E(X)ATA(G/A)0-20 SEQ ID NO: 682 (B11-V17): (G/A)0-20DIKEKLCYVALDFE(X0)EM(X)TA(G/A)0-20 SEQ ID NO: 683 (B11-V18): (G/A)0-20DIKEKLCYVALDFE(X0)EMA(X)A(G/A)0-20 SEQ ID NO: 684 (B11-V19): (G/A)0-20DIKEKLCYVALDFE(X0)EMAT(X)(G/A)0-20 SEQ ID NO: 685 (B11-X01): (G/A)0-20(X)(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 686 (B11-X02): (G/A)0-20F(X0)(X)TAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 687 (B11-X03): (G/A)0-20F(X0)T(X)AEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 688 (B11-X04): (G/A)0-20F(X0)TT(X)EREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 689 (B11-X05): (G/A)0-20F(X0)TTA(X)REIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 690 (B11-X06): (G/A)0-20F(X0)TTAE(X)EIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 691 (B11-X07): (G/A)0-20F(X0)TTAER(X)IVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 692 (B11-X08): (G/A)0-20F(X0)TTAERE(X)VRDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 693 (B11-X09): (G/A)0-20F(X0)TTAEREI(X)RDIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 694 (B11-X10): (G/A)0-20F(X0)TTAEREIV(X)DIKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 695 (B11-X11): (G/A)0-20F(X0)TTAEREIVR(X)IKEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 696 (B11-X12): (G/A)0-20F(X0)TTAEREIVRD(X)KEKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 697 (B11-X13): (G/A)0-20F(X0)TTAEREIVRDI(X)EKLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 698 (B11-X14): (G/A)0-20F(X0)TTAEREIVRDIK(X)KLCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 699 (B11-X15): (G/A)0-20F(X0)TTAEREIVRDIKE(X)LCYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 700 (B11-X16): (G/A)0-20F(X0)TTAEREIVRDIKEK(X)CYVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 701 (B11-X17): (G/A)0-20F(X0)TTAEREIVRDIKEKL(X)YVALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 702 (B11-X18): (G/A)0-20F(X0)TTAEREIVRDIKEKLC(X)VALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 703 (B11-X19): (G/A)0-20F(X0)TTAEREIVRDIKEKLCY(X)ALDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 704 (B11-X20): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYV(X)LDFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 705 (B11-X21): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVA(X)DFE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 706 (B11-X22): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVAL(X)FE(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 707 (B11-X23): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALD(X)E(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 708 (B11-X24): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDF(X)(X0)EMATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 709 (B11-X25): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)(X)MATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 710 (B11-X26): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)E(X)ATAASSSSLEKSY(G/A)0-20 SEQ ID NO: 711 (B11-X27): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EM(X)TAASSSSLEKSY(G/A)0-20 SEQ ID NO: 712 (B11-X28): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMA(X)AASSSSLEKSY(G/A)0-20 SEQ ID NO: 713 (B11-X29): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMAT(X)ASSSSLEKSY(G/A)0-20 SEQ ID NO: 714 (B11-X30): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATA(X)SSSSLEKSY(G/A)0-20 SEQ ID NO: 715 (B11-X31): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAS(X)SSSLEKSY(G/A)0-20 SEQ ID NO: 716 (B11-X32): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATASS(X)SSLEKSY(G/A)0-20 SEQ ID NO: 717 (B11-X33): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATASSS(X)SLEKSY(G/A)0-20 SEQ ID NO: 718 (B11-X34): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATASSSS(X)LEKSY(G/A)0-20 SEQ ID NO: 719 (B11-X35): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSS(X)EKSY(G/A)0-20 SEQ ID NO: 720 (B11-X36): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSL(X)KSY(G/A)0-20 SEQ ID NO: 721 (B11-X37): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLE(X)SY(G/A)0-20 SEQ ID NO: 722 (B11-X38): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEK(X)Y(G/A)0-20 SEQ ID NO: 723 (B11-X39): (G/A)0-20F(X0)TTAEREIVRDIKEKLCYVALDFE(X0)EMATAASSSSLEKS(X)(G/A)0-20 SEQ ID NO: 724 (B17-core): (X)0-20KYSVWIGGSI(X)0-20 SEQ ID NO: 725 (B17-TV01): (G/A)0-20(X)YSVWIGGSI(G/A)0-20 SEQ ID NO: 726 (B17-TV02): (G/A)0-20K(X)SVWIGGSI(G/A)0-20 SEQ ID NO: 727 (B17-TV03): (G/A)0-20KY(x)vwIGGsI(G/A)0-20 SEQ ID NO: 728 (B17-TV04): (G/A)0-20KYS(X)WIGGSI(G/A)0-20 SEQ ID NO: 729 (B17-TV05): (G/A)0-20KYSV(X)IGGSI(G/A)0-20 SEQ ID NO: 730 (B17-TV06): (G/A)0-20KYSVW(X)GGSI(G/A)0-20 SEQ ID NO: 731 (B17-TV07): (G/A)0-20KYSVWI(X)GSI(G/A)0-20 SEQ ID NO: 732 (B17-TV08): (G/A)0-20KYSVWIG(X)SI(G/A)0-20 SEQ ID NO: 733 (B17-TV09): (G/A)0-20KYSVWIGG(X)I(G/A)0-20 SEQ ID NO: 734 (B17-TV10): (G/A)0-20KYSVwIGGS(X)(G/A)0-20 SEQ ID NO: 735 (B17-T01): (G/A)0-20(X0)PSTMKIKII(G/A)0-20 SEQ ID NO: 736 (B17-T02): (G/A)0-200(X0)STMKIKIIA(G/A)0-20 SEQ ID NO: 737 (B17-T03): (G/A)0-20(X0)TMKIKIIAP(G/A)0-20 SEQ ID NO: 738 (B17-T04): (G/A)0-20(X0)MKIKIIAPP(G/A)0-20 SEQ ID NO: 739 (B17-T05): (G/A)0-20(X0)KIKIIAPPE(G/A)0-20 SEQ ID NO: 740 (B17-T06): (G/A)0-20(X0)IKIIAPPER(G/A)0-20 SEQ ID NO: 741 (B17-T07): (G/A)0-20(X0)KIIAPPERK(G/A)0-20 SEQ ID NO: 742 (B17-T08): (G/A)0-20(X0)IIAPPERKY(G/A)0-20 SEQ ID NO: 743 (B17-T09): (G/A)0-20(X0)IAPPERKYS(G/A)0-20 SEQ ID NO: 744 (B17-T10): (G/A)0-20(X0)APPERKYSV(G/A)0-20 SEQ ID NO: 745 (B17-T11): (G/A)0-20(X0)PPERKYSVW(G/A)0-20 SEQ ID NO: 746 (B17-T12): (G/A)0-20(X0)PERKYSVWI(G/A)0-20 SEQ ID NO: 747 (B17-T13): (G/A)0-20(X0)ERKYSVWIG(G/A)0-20 SEQ ID NO: 748 (B17-T14): (G/A)0-20(X0)RKYSVWIGG(G/A)0-20 SEQ ID NO: 749 (B17-T15): (G/A)0-20(X0)KYSVWIGGS(G/A)0-20 SEQ ID NO: 750 (B17-T16): (G/A)0-20(X0)YSVWIGGSI(G/A)0-20 SEQ ID NO: 751 (B17-T17): (G/A)0-20(X0)SVWIGGSIL(G/A)0-20 SEQ ID NO: 752 (B17-T18): (G/A)0-20(X0)VWIGGSILA(WA)0-20 SEQ ID NO: 753 (B17-T19): (G/A)0-20(X0)WIGGSILAS(G/A)0-20 SEQ ID NO: 754 (B17-T20): (G/A)0-20(X0)IGGSILASL(G/A)0-20 SEQ ID NO: 755 (B17-T21): (G/A)0-20(X0)GGSILASLS(G/A)0-20 SEQ ID NO: 756 (B17-T22): (G/A)0-20(X0)GSILASLST(G/A)0-20 SEQ ID NO: 757 (B17-T23): (G/A)0-20(X0)SILASLSTF(G/A)0-20 SEQ ID NO: 758 (B17-T24): (G/A)0-20(X0)ILASLSTFQ(G/A)0-20 SEQ ID NO: 759 (B17-T25): (G/A)0-20(X0)LASLSTFQQ(G/A)0-20 SEQ ID NO: 760 (B17-T26): (G/A)0-20(X0)ASLSTFQQM(G/A)0-20 SEQ ID NO: 761 (B17-T27): (G/A)0-20(X0)SLSTFQQMW(G/A)0-20 SEQ ID NO: 762 (B17-T28): (G/A)0-20(X0)LSTFQQMWI(G/A)0-20 SEQ ID NO: 763 (B17-T29): (G/A)0-20LSTFQQMWI(X0)(G/A)0-20 SEQ ID NO: 764 (B17-T30): (G/A)0-20STFQQMWI(X0)K(G/A)0-20 SEQ ID NO: 765 (B17-T31): (G/A)0-20TFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 766 (B17-M01): (G/A)0-20APSTMKIKIIAPPERKYSVW(G/A)0-20 SEQ ID NO: 767 (B17-M02): (G/A)0-20PSTMKIKIIAPPERKYSVWI(G/A)0-20 SEQ ID NO: 768 (B17-M03): (G/A)0-20STMKIKIIAPPERKYSVWIG(G/A)0-20 SEQ ID NO: 769 (B17-M04): (G/A)0-20TMKIKIIAPPERKYSVWIGG(G/A)0-20 SEQ ID NO: 770 (B17-M05): (G/A)0-20MKIKIIAPPERKYSVWIGGS(G/A)0-20 SEQ ID NO: 771 (B17-M06): (G/A)0-20KIKIIAPPERKYSVWIGGSI(G/A)0-20 SEQ ID NO: 772 (B17-M07): (G/A)0-20IKIIAPPERKYSVWIGGSIL(G/A)0-20 SEQ ID NO: 773 (B17-M08): (G/A)0-20KIIAPPERKYSVWIGGSILA(G/A)0-20 SEQ ID NO: 774 (B17-M09): (G/A)0-20IIAPPERKYSVWIGGSILAS(G/A)0-20 SEQ ID NO: 775 (B17-M10): (G/A)0-20IAPPERKYSVWIGGSILASL(G/A)0-20 SEQ ID NO: 776 (B17): (G/A)0-20APPERKYSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 777 (B17-P01): (G/A)0-20PPERKYSVWIGGSILASLST(G/A)0-20 SEQ ID NO: 778 (B17-P02): (G/A)0-20PERKYSVWIGGSILASLSTF(G/A)0-20 SEQ ID NO: 779 (B17-P03): (G/A)0-20ERKYSVWIGGSILASLSTFQ(G/A)0-20 SEQ ID NO: 780 (B17-PO4): (G/A)0-20RKYSVWIGGSILASLSTFQQ(G/A)0-20 SEQ ID NO: 781 (B17-P05): (G/A)0-20KYSVWIGGSILASLSTFQQM(G/A)0-20 SEQ ID NO: 782 (B17-P06): (G/A)0-20YSVWIGGSILASLSTFQQMW(G/A)0-20 SEQ ID NO: 783 (B17-P07): (G/A)0-20SVWIGGSILASLSTFQQMWI(G/A)0-20 SEQ ID NO: 784 (B17-P08): (G/A)0-20VWIGGSILASLSTFQQMWI(X0)(G/A)0-20 SEQ ID NO: 785 (B17-P09): (G/A)0-20WIGGSILASLSTFQQMWI(X0)K(G/A)0-20 SEQ ID NO: 786 (B17-P10): (G/A)0-20IGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 787 (B17-V01): (G/A)0-20(X)PPERKYSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 788 (B17-V02): (G/A)0-20A(X)PERKYSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 789 (B17-V03): (G/A)0-20AP(X)ERKYSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 790 (B17-VO4): (G/A)0-20APP(X)RKYSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 791 (B17-V05): (G/A)0-20APPE(X)KYSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 792 (B17-V06): (G/A)0-20APPER(X)YSVWIGGSILASLS(G/A)0-20 SEQ ID NO: 793 (B17-V07): (G/A)0-20APPERK(X)SVWIGGSILASLS(G/A)0-20 SEQ ID NO: 794 (B17-V08): (G/A)0-20APPERKY(X)VWIGGSILASLS(G/A)0-20 SEQ ID NO: 795 (B17-V09): (G/A)0-20APPERKYS(X)WIGGSILASLS(G/A)0-20 SEQ ID NO: 796 (B17-V10): (G/A)0-20APPERKYSV(X)IGGSILASLS(G/A)0-20 SEQ ID NO: 797 (B17-V11): (G/A)0-20APPERKYSVWX)GGSILASLS(G/A)0-20 SEQ ID NO: 798 (B17-V12): (G/A)0-20APPERKYSVWI(X)GSILASLS(G/A)0-20 SEQ ID NO: 799 (B17-V13): (G/A)0-20APPERKYSVWIG(X)SILASLS(G/A)0-20 SEQ ID NO: 800 (B17-V14): (G/A)0-20APPERKYSVWIGG(X)ILASLS(G/A)0-20 SEQ ID NO: 801 (B17-V15): (G/A)0-20APPERKYSVWIGGS(X)LASLS(G/A)0-20 SEQ ID NO: 802 (B17-V16): (G/A)0-20APPERKYSVWIGGSI(X)ASLS(G/A)0-20 SEQ ID NO: 803 (B17-V17): (G/A)0-20APPERKYSVWIGGSIL(X)SLS(G/A)0-20 SEQ ID NO: 804 (B17-V18): (G/A)0-20APPERKYSVWIGGSILA(X)LS(G/A)0-20 SEQ ID NO: 805 (B17-V19): (G/A)0-20APPERKYSVWIGGSILAS(X)S(G/A)0-20 SEQ ID NO: 806 (B17-V20): (G/A)0-20APPERKYSVWIGGSILASL(X)(G/A)0-20 SEQ ID NO: 807 (B17-X01): (G/A)0-20(X)PSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 808 (B17-X02): (G/A)0-20A(X)STMKIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 809 (B17-X03): (G/A)0-20AP(X)TMKIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 810 (B17-X04): (G/A)0-20APS(X)MKIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 811 (B17-X05): (G/A)0-20APST(X)KIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 812 (B17-X06): (G/A)0-20APSTM(X)IKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 813 (B17-X07): (G/A)0-20APSTMK(X)KIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 814 (B17-X08): (G/A)0-20APSTMKI(X)IIAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 815 (B17-X09): (G/A)0-20APSTMKIK(X)IAPPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 816 (B17-X10): (G/A)0-20APSTMKIKI(X)APPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 817 (B17-X11): (G/A)0-20APSTMKIKII(X)PPERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 818 (B17-X12): (G/A)0-20APSTMKIKIIA(X)PERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 819 (B17-X13): (G/A)0-20APSTMKIKIIAP(X)ERKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 820 (B17-X15): (G/A)0-20APSTMKIKIIAPP(X)RKYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 821 (B17-X16): (G/A)0-20APSTMKIKIIAPPE(X)KYSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 822 (B17-X17): (G/A)0-20APSTMKIKIIAPPER(X)YSVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 823 (B17-X18): (G/A)0-20APSTMKIKIIAPPERK(X)SVWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 824 (B17-X19): (G/A)0-20APSTMKIKIIAPPERKY(X)VWIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 825 (B17-X20): (G/A)0-20APSTMKIKIIAPPERKYS(X)WIGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 826 (B17-X21): (G/A)0-20APSTMKIKIIAPPERKYSV(X)IGGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 827 (B17-X22): (G/A)0-20APSTMKIKIIAPPERKYSVW(X)GGSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 828 (B17-X23): (G/A)0-20APSTMKIKIIAPPERKYSVWI(X)GSILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 829 (B17-X24): (G/A)0-20APSTMKIKIIAPPERKYSVWIG(X)SILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 830 (B17-X25): (G/A)0-20APSTMKIKIIAPPERKYSVWIGG(X)ILASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 831 (B17-X26): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGS(X)LASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 832 (B17-X27): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSI(X)ASLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 833 (B17-X28): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSIL(X)SLSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 834 (B17-X29): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILA(X)LSTFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 835 (B17-X30): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILAS(X)STFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 836 (B17-X31): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASL(X)TFQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 837 (B17-X32): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLS(X)FQQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 838 (B17-X33): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLST(X)QQMWI(X0)KQ(G/A)0-20 SEQ ID NO: 839 (B17-X34): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTF(X)QMWI(X0)KQ(G/A)0-20 SEQ ID NO: 840 (B17-X35): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTFQ(X)MWI(X0)KQ(G/A)0-20 SEQ ID NO: 841 (B17-X36): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTFQQ(X)WI(X0)KQ(G/A)0-20 SEQ ID NO: 842 (B17-X37): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTFQQM(X)I(X0)KQ(G/A)0-20 SEQ ID NO: 843 (B17-X38): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMW(X)(X0)KQ(G/A)0-20 SEQ ID NO: 844 (B17-X39): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)(X)Q(G/A)0-20 SEQ ID NO: 845 (B17-X40): (G/A)0-20APSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWI(X0)K(X)(G/A)0-20 - In another embodiment, a peptide according to formula SEQ ID No:1 to SEQ ID No:845 is a cyclic peptide. A cyclic peptide can be made by covalently crosslinking amino acid residues together via a disulfide bond (e.g., thiol group of cysteine) or a side chain of amino acid residues (e.g., Lye, Arg, Ser, Tyr). Furthermore, a functionalized linker (e.g., polyethylene glycol or PEG) can be introduced to generate a cyclic peptide.
- Although the sequences enumerated here comprise 40 AA, 20 AA, and 10 AA, it is to be understood that peptides of the invention may include any length from 5 to 40 AA.
- Numerous permutations and variations of the present invention are readily apparent to a person of ordinary skill in the art in view of this disclosure. Therefore it is to be understood that the invention may be practiced otherwise than as specifically described herein.
-
TABLE 1 Actin alignment As one can see below from the actin protein sequences of human, mouse, rabbit, and fly, the actin sequence is highly conserved. SEQ ID NO: 846: Human ACTAl: Human ACTA1 (alpha skeletal muscle actin) SEQ ID NO: 847: Human ACTAC1: Human ACTC1 (alpha cardiac muscle actin) SEQ ID NO: 848: Human ACTAB: Human ACTB ( cytoplasmic 1 actin)SEQ ID NO: 849: Human ACTABG1: Human ACTG1 ( cytoplasmic 2 actin)SEQ ID NO: 850: Mouse ACTB: Mus musculus Actin, beta SEQ ID NO: 851: Rabbit ACTB: Orycytolagus cuniculus ACTB ( cytoplasmic 1 actinSEQ ID NO: 852: Fly ACTB: Drosophila actin Actin5C, (Isoform B) 10 20 30 40 50 SEQ ID NO: 846: MCDEDETTALVC DNGSGLVKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK SEQ ID NO: 847: MCDDEETTALVC DNGSGLVKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK SEQ ID NO: 848: MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK SEQ ID NO: 849: MEEEIAALVI DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK SEQ ID NO: 850: MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK SEQ ID NO: 851: MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK SEQ ID NO: 852: MCDEEVAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK 60 70 80 90 100 SEQ ID NO: 846: DSYVGDEAQS KRGILTLKYP IEHGIITNWD DMEKIWHHTF YNELRVAPEE SEQ ID NO: 847: DSYVGDEAQS KRGILTLKYP IEHGIITNWD DMEKIWHHTF YNELRVAPEE SEQ ID NO: 848: DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE SEQ ID NO: 849: DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE SEQ ID NO: 850: DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE SEQ ID NO: 851: DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE SEQ ID NO: 852: DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE 110 120 130 140 150 SEQ ID NO: 846: HPTLLTEAPL NPKANREKMT QIMFETFNVP AMYVAIQAVL SLYASGRTTG SEQ ID NO: 847: HPTLLTEAPL NPKANREKMT QIMFETFNVP AMYVAIQAVL SLYASGRTTG SEQ ID NO: 848: HPVLLTEAPL NPKANREKMT QIMFETFNIP AMYVAIQAVL SLYASGRTTG SEQ ID NO: 849: HPVLLTEAPL NPKANREKMT QIMFETFNIP AMYVAIQAVL SLYASGRTTG SEQ ID NO: 850: HPVLLTEAPL NPKANREKMT QIMFETFNIP AMYVAIQAVL SLYASGRTTG SEQ ID NO: 851: RPVLLTEAPL NPKANREKMT QIMFETFNIP AMYVAIQAVL SLYASGRTTG SEQ ID NO: 852: HPVLLTEAPL NPKANREKMT QIMFETFNIP AMYVAIQAVL SLYASGRTTG 160 170 180 190 200 SEQ ID NO: 846: IVLDSGDGVT HNVPIYEGYA LPHAIMRLDL AGRDLTDYLM KILTERGYSF SEQ ID NO: 847: IVLDSGDGVT HNVPIYEGYA LPHAIMRLDL AGRDLTDYLM KILTERGYSF SEQ ID NO: 848: IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF SEQ ID NO: 849: IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF SEQ ID NO: 850: IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF SEQ ID NO: 851: IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF SEQ ID NO: 852: IVLDSGDGVS HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF 210 220 230 240 250 SEQ ID NO: 846: VTTAEREIVR DIKEKLCYVA LDFENEMATA ASSSSLEKSY ELPDGQVITI SEQ ID NO: 847: VTTAEREIVR DIKEKLCYVA LDFENEMATA ASSSSLEKSY ELPDGQVITI SEQ ID NO: 848: ITTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI SEQ ID NO: 849: ITTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI SEQ ID NO: 850: ITTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI SEQ ID NO: 851: ITTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI SEQ ID NO: 852: ITTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI 260 270 280 290 300 SEQ ID NO: 846: GNERFRCPET LFQPSFIGME SAGIHETTYN SIMKCDIDIR KDLYANNVMS SEQ ID NO: 847: GNERFRCPET LFQPSFIGME SAGIHETTYN SIMKCDIDIR KDLYANNVLS SEQ ID NO: 848: GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS SEQ ID NO: 849: GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS SEQ ID NO: 850: GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS SEQ ID NO: 851: GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS SEQ ID NO: 852: GNERFRCPEA LFQPSFLGME ACGIHETTYN SIMKCDVDIR KDLYANTVLS 310 320 330 340 350 SEQ ID NO: 846: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS SEQ ID NO: 847: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS SEQ ID NO: 848: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS SEQ ID NO: 849: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS SEQ ID NO: 850: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS SEQ ID NO: 851: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS SEQ ID NO: 852: GGITMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS 360 370 SEQ ID NO: 846: TFQQMWITKQ EYDEAGPSIV HRKCF SEQ ID NO: 847: TFQQMWISKQ EYDEAGPSIV HRKCF SEQ ID NO: 848: TFQQMWISKQ EYDESGPSIV HRKCF - This application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety.
Claims (2)
1-21. (canceled)
22. An actin-based peptide, comprising
an actin core domain and a cell penetration domain, operably linked together by a a spacer domain,
wherein an N-terminus or C-terminus may have either the actin core domain or the cell penetration domain, and
wherein the actin core domain is N7 types selected from SEQ ID NOs: 2, 8, 9, 139-290.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/317,803 US20210261635A1 (en) | 2016-07-02 | 2021-05-11 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357991P | 2016-07-02 | 2016-07-02 | |
US15/446,240 US11028138B2 (en) | 2016-07-02 | 2017-03-01 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
US17/317,803 US20210261635A1 (en) | 2016-07-02 | 2021-05-11 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/446,240 Division US11028138B2 (en) | 2016-07-02 | 2017-03-01 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210261635A1 true US20210261635A1 (en) | 2021-08-26 |
Family
ID=60806167
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/446,240 Active US11028138B2 (en) | 2016-07-02 | 2017-03-01 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
US17/317,803 Abandoned US20210261635A1 (en) | 2016-07-02 | 2021-05-11 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/446,240 Active US11028138B2 (en) | 2016-07-02 | 2017-03-01 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
Country Status (3)
Country | Link |
---|---|
US (2) | US11028138B2 (en) |
CN (1) | CN109689867B (en) |
WO (1) | WO2018009457A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108089618B (en) | 2017-12-11 | 2019-06-18 | 北京空间机电研究所 | A kind of energy-saving temperature control loop circuit heat pipe device of space flight optical remote sensor |
CN110194793B (en) * | 2018-02-26 | 2020-12-01 | 中国科学院武汉病毒研究所 | Polypeptide for inhibiting actin recombination and application |
US20240108687A1 (en) * | 2021-02-13 | 2024-04-04 | Virongy L.L.C. | Compositions and methods for using combinations of actin-based peptides to modulate cellular bioactivity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053322A1 (en) * | 1997-05-23 | 1998-11-26 | The Institute Of Cancer Research: Royal Cancer Hospital | Binding complexes |
US20050112118A1 (en) * | 1999-12-02 | 2005-05-26 | Myriad Genetics, Incorporated | Compositions and methods for treating inflammatory disorders |
WO2010115141A2 (en) * | 2009-04-02 | 2010-10-07 | New York University | System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions |
WO2014205518A1 (en) * | 2013-06-26 | 2014-12-31 | Phylogica Limited | Method of monitoring cellular trafficking of peptides |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087398A (en) * | 1996-03-01 | 2000-07-11 | South Alabama Medical Science Foundation | Sickle cell anemia treatment |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
US20090325189A1 (en) * | 2006-09-18 | 2009-12-31 | Cell Signaling Technology , Inc | Tyrosine phosphorylation sites |
EP2071336A1 (en) | 2007-12-13 | 2009-06-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma |
CN102448484A (en) * | 2009-04-01 | 2012-05-09 | 医学研究,基础设施和卫生服务基金的特拉维夫医疗中心 | A method of regulating proliferation and differentiation of keratinocyes |
CN102481280A (en) * | 2009-05-21 | 2012-05-30 | 儿童医疗研究院 | Use Of Dynamin Ring Stabilizers |
MX353482B (en) * | 2011-04-29 | 2018-01-16 | Celgene Corp | METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR. |
CN104364259A (en) * | 2012-03-26 | 2015-02-18 | 普罗努塔利亚公司 | Nutritive fragments, proteins and methods |
KR101721028B1 (en) * | 2014-02-12 | 2017-03-29 | 연세대학교 산학협력단 | Compsition for promotion of wound healing |
-
2017
- 2017-03-01 US US15/446,240 patent/US11028138B2/en active Active
- 2017-06-30 WO PCT/US2017/040415 patent/WO2018009457A1/en active Application Filing
- 2017-06-30 CN CN201780054188.XA patent/CN109689867B/en active Active
-
2021
- 2021-05-11 US US17/317,803 patent/US20210261635A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053322A1 (en) * | 1997-05-23 | 1998-11-26 | The Institute Of Cancer Research: Royal Cancer Hospital | Binding complexes |
US7018791B1 (en) * | 1997-05-23 | 2006-03-28 | Institute Of Cancer Research: Royal Cancer Hospital | Binding complexes |
US20050112118A1 (en) * | 1999-12-02 | 2005-05-26 | Myriad Genetics, Incorporated | Compositions and methods for treating inflammatory disorders |
WO2010115141A2 (en) * | 2009-04-02 | 2010-10-07 | New York University | System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions |
WO2014205518A1 (en) * | 2013-06-26 | 2014-12-31 | Phylogica Limited | Method of monitoring cellular trafficking of peptides |
US20160146786A1 (en) * | 2013-06-26 | 2016-05-26 | Phylogica Limited | Method of monitoring cellular trafficking of peptides |
Also Published As
Publication number | Publication date |
---|---|
US11028138B2 (en) | 2021-06-08 |
CN109689867B (en) | 2024-06-14 |
WO2018009457A1 (en) | 2018-01-11 |
US20180002390A1 (en) | 2018-01-04 |
CN109689867A (en) | 2019-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210261635A1 (en) | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens | |
Kane et al. | Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2 | |
Martin-Serrano et al. | Host factors involved in retroviral budding and release | |
Ono | Relationships between plasma membrane microdomains and HIV‐1 assembly | |
Spear et al. | Viral exploitation of actin: force-generation and scaffolding functions in viral infection | |
Goldberg | Actin-based motility of intracellular microbial pathogens | |
Miller et al. | Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein | |
Buffalo et al. | How HIV Nef proteins hijack membrane traffic to promote infection | |
Langel | Handbook of cell-penetrating peptides | |
Bauer et al. | New aspects of the molecular constituents of tissue barriers | |
Edwards et al. | Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence | |
Humphries et al. | The non-canonical roles of clathrin and actin in pathogen internalization, egress and spread | |
Sternweis et al. | Regulation of Rho guanine nucleotide exchange factors by G proteins | |
Liao et al. | Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein | |
KR20040044435A (en) | Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses | |
ES2605445T3 (en) | Protein-protein interactions in the human immunodeficiency virus | |
Shaw et al. | Binding of bacterial secondary messenger molecule c di-GMP is a STING operation | |
US20240108687A1 (en) | Compositions and methods for using combinations of actin-based peptides to modulate cellular bioactivity | |
US20170275650A1 (en) | Endosomal escape domains for delivery of macromolecules into cells | |
US20210206811A1 (en) | Cell-Penetrating Peptides and Methods of Use Thereof | |
Muthumani et al. | Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr) | |
Steiner | Antiviral function of Mx proteins: role of cellular factors and subcellular localization | |
Wang et al. | Infectious bronchitis virus attaches to lipid rafts and enters cells via clathrin mediated endocytosis | |
Chan | GBF1 recruitment to membranes: domains and interacting proteins | |
Oostendorp et al. | Synthetic hexapeptides derived from the transmembrane envelope proteins of retroviruses suppress N-formylpeptide–induced monocyte polarization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |